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ABSTRACT
Endothelial cells from different tissues differ widely in the expression of 
junctional proteins like occludin and transporters like the transferrin receptor. The 
mechanism(s) responsible for the differential expression of these proteins is not 
known. In this project we have studied how the occludin promoter interacts with 
nuclear transcription factors (TFs) from brain and non-brain endothelium. EMSA 
data indicates the TFs Spl, Sp3 and YY1 are responsible for the specific binding 
to the occludin promoter in hCMEC/D3 cells, a transformed brain endothelial cell 
line. Using ChIP assays, we confirmed the interaction between these three 
transcription factors and DNA as these complexes were active in live cultured 
cells from transformed and primary brain endothelium. We investigated the 
expression and localisation of Spl, Sp3 and YY1 in these cells and compared with 
lung endothelial cells and report the specific association of the TFs Sp3 and YY1 
in brain endothelium which is absent in non brain endothelium. In addition, we 
have compared the activity of the occludin promoter in hCMEC/D3 cell to that in 
primary human dermal and lung endothelial cells by transfection with reporter 
vectors under the control of the full length and fragments of the occludin 
promoter. Our work identifies a group of transcription factors present in brain 
endothelium which may regulate the expression of the tight junction protein 
occludin. We propose a model whereby the TF Sp3 is necessary for the 
transcription of the occludin promoter in brain endothelium and YY1 negatively 
regulates promoter activity in non-brain endothelium by controlling access of Sp3 
to the initiation sites on the occludin promoter.
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1 Introduction
1.1 Endothelium
Endothelial cells which line the inside layer of blood vessels and the lymphatic 
system form the endothelium. This layer of cells constitutes all physiological 
communication between the circulation and the proximal tissue. Functions of the 
endothelium include maintenance of homeostasis, exchange of nutrients, 
trafficking of cells during an inflammatory response, regulation of vessel 
permeability, control of vasomotor tone and angiogenesis (Jaffe 1985; Nawroth, 
Kisiel et al. 1985; Simionescu and Simionescu 1986).
Structural differences in endothelium are associated with corresponding variations 
in capillary permeability (Fig 1.1) (Risau 1995). Throughout much of the body, 
the endothelial lining is continuous and capillaries with continuous endothelium 
are found in the lungs, muscle and central nervous system. In the brain the 
specialised blood brain barrier is the most restrictive of all continuous endothelia 
in the body and limits paracellular and transcellular traffic to and from the brain. 
Nutrients and molecules either diffuse through plasma membranes or via specific 
membrane transporters (Rubin and Staddon 1999).
However, the blood brain barrier is absent in the choroid plexuses and in the 
following organs: the pineal gland, subfornical organ, organum vasculosum of the 
lamina terminalis, paraventricular organ, median eminence, neurohypophysis, 
subcommissural organ and the area postrema. These structures are located around 
the third and fourth cerebral ventricles and commonly referred to as the
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circumventricular organs (CVOs) (Joly, Osorio et al. 2007). CVOs possess a 
specialised type of endothelium that is continuous but is characterised by circular 
transcellular gaps referred to as fenestrae. Presence of fenestrae enables important 
communication between the brain and the blood because fenestrated capillaries 
are relatively more permeable to unrestricted passage of high-molecular weight 
and polar substances.
Fenestrated capillaries resemble continuous endothelium in having an 
uninterrupted basement membrane but are characterised by regional thinning 
leading to the presence of circular transcellular gaps referred to as fenestrations 
(Stan 2007). The diameter of the fenestrae ranges from 60-80 nm and are readily 
permeable to hydrophilic molecules of low molecular weight and hence their 
location in tissues with high rates of fluid exchange such as the sinusoids of the 
liver, small intestine, glomeruli of the kidney, and in most endocrine glands. In 
the kidney and choroid plexus, signalling from the epithelial layer which is always 
in close proximity to the endothelium is believed to be important in the 
differentiation and maintenance of the fenestrae. High constitutive expression of 
VEGF which is known to induce permeability is highly expressed in epithelial 
layers and therefore could induce the phenotype of the fenestrated endothelium 
(Risau 1998).
Discontinuous endothelium found in liver, spleen and bone marrow has wide 
intercellular spaces, approximately 80-200 nm in width, and with no basement 
membrane. This allows for almost unrestricted transport of molecules from 
interstitium to the capillary lumen (Aird 2007).
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Freeze-fracture electron microscopy analyses have elucidated the differences 
between continuous and discontinuous endothelia. Tight junctional structures in 
the latter do not form a continuous barrier but as the term suggests a discontinuous 
series of stranded clusters. In addition, the spatial distribution of tight junction 
components within the endothelial cell membrane is different. Components of the 
tight junction are associated with either the internal (P-face) or external (E-face) 
membrane leaflets (Lane, Reese et al. 1992). Tight and leaky junctions are 
characterised by components with associations at the P-face and E-face 
respectively (Schneeberger and Lynch 2004). In the endothelial cells of the blood 
brain barrier, it has been found using immunogold labelling and freeze fracture 
technique that 57% of the particles are within the internal P-face and about 44% 
of the particles associate with the external leaflet (Kniesel, Risau et al. 1996) . 
This distribution contributes to the integrity of the blood brain barrier. In 
pathology, increased permeability is associated with a shift of components and 
enzymatic activities from the P-face to the E-face (Wolburg, Neuhaus et al. 1994). 
The molecular mechanisms involved in the gain and loss of P-face association of 
tight junctions are unknown.
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Figure 1-1 Structural Features of Adult Microvascular Endothelial 
Phenotypes
a  Continuous b Fenestrated c Discontinous
(Cleaver and Melton 2003)
(a) Continuous capillaries have no openings in their walls and are lined 
continuously with the endothelial cell body.
(b) Fenestrated capillaries have small openings, called fenestrae, which are 
covered by a small, nonmembranous, permeable diaphragm, and allow the rapid 
passage of macromolecules. The basement membrane of endothelial cells is 
continuous over the fenestrae.
(c) Discontinuous capillaries, also called sinusoids, have a large lumen, many 
fenestrations with no diaphragm and a discontinuous or absent basal lamina 
(Cleaver and Melton 2003).
Intercellular Lumen Fenestrae Intercellular cleft
cleft
Basement JNucieus 
membrane ° f  endothelial 
cell
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1.2 Blood Brain Barrier (BBB)
The blood-brain barrier (BBB) is formed by a complex network of endothelial 
cells, astroglia, pericytes, perivascular macrophages, and a basal lamina (Fig 1.3). 
It was first reported in 1885 by the German pathologist Ehrlich (Ehrlich 1885) 
and subsequent electron microscopy studies showed that intravenous administered 
electron dense particles, such as horseradish peroxidase, are prevented from 
entering the brain by the capillary endothelial cells (Reese and Kamovsky 1967).
Brain endothelial cells differ from endothelial cells in the periphery by forming 
continuous tight junctions (TJ) and lack fenestrations except in the 
circumventricular organs. TJs severely restrict passage of water-soluble 
compounds, including polar drugs and are the structural basis for the paracellular 
impermeability and high electrical resistance (Reese and Kamovsky 1967; Rubin 
and Staddon 1999). In comparison with transendothelial electrical resistance 
(TEER) values of 2-20 fXcm2 in peripheral capillaries, brain capillaries exhibit 
TEER values exceeding 1,000 flcm 2. In addition, the presence of very few 
endocytic vesicles (Sage, Wilson et al. 1998) limits transcellular transport and 
expression of specific transport systems and carrier molecules restrict entry to 
only required nutrients (Wolburg and Lippoldt 2002; Begley 2004). CNS 
endothelium is also characterised by the presence of increased mitochondrial 
content which contributes to about 8-11% of the endothelial cell volume in 
contrast to 2-5% in non-CNS endothelial cells (Oldendorf, Comford et al. 1977).
Structurally, the basic unit of the blood brain barrier is composed of endothelial 
cells which completely surround the lumen of a capillary. Pericytes associate with
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the endothelial cells at the abluminal surface and the cells are embedded in a 
common basement membrane which is about 30 to 40 nm thick and composed of 
extracellular matrix proteins including laminins (8 and 10), collagen type IV, 
heparan sulphate proteoglycans and fibronectin (Farkas and Luiten 2001). The 
basement membrane provides both mechanical support and a barrier function. The 
astrocyte end feet ensheathe the capillary and the plasma membranes of the foot 
processes are closely connected to the basement membrane.
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Figure 1-2 Representation of the Blood Brain Barrier Unit
Tight v 
junction Axonal ending
Microglial
cell
Pericyte
A strocyte^  
foot processes
' Endothelium
Extracellular matrix
The cerebral endothelial cells form tight junctions at their margins where they 
meet. Pericytes are distributed discontinuously along the length of the cerebral 
capillaries and partially surround the endothelium. Foot processes from astrocytes 
form a network fully surrounding the capillaries. Axons from neurons are also 
present close to the endothelial cells and contain vasoactive neurotransmitters and 
peptides. Microglia and perivascular macrophages are derived from systemic 
circulating monocytes and form the resident immuno competent cells of the brain 
(Begley 2004).
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1.2.1 Development of the Blood Brain Barrier
In rodents, brain capillaries differentiate to blood brain barrier endothelium during 
late embryonic and early postnatal development. The increase in vessel 
impermeability to protein correlates with a conformational change of the TJs. 
There is an increasing association of tight junctional particles with the P-face 
membrane leaflet from embryonic day 13 to postnatal day 125 (Robertson, Du 
Bois et al. 1985). It should be remembered that tight junction components in the 
periphery are usually associated with the E-face in vivo.
1.2.1.1 Role of Astrocytes
Astrocytes, whose processes form end-feet that surround brain microvessels 
(Janzer and Raff 1987; Abbott, Ronnback et al. 2006) have been shown to play 
important roles in conferring BBB properties to the endothelial cells. The 
development of complex tight junctions, specialized enzyme systems, expression 
and asymmetrical localization of transporters in the endothelial cells has been 
attributed to astrocytic signalling (DeBault and Cancilla 1980; Boado, Wang et al. 
1994; Dehouck, Dehouck et al. 1994; Roux, Durieu-Trautmann et al. 1994; 
Wolburg, Neuhaus et al. 1994; Hayashi, Nomura et al. 1997; Rist, Romero et al. 
1997). The astrocytic end feet display a high density of purinergic P2Y receptors, 
K+ channels and the water-channel protein aquaporin-4, indicating a possible role 
in the regulation of water permeability in the brain (Simard, Arcuino et al. 2003).
Transplanted astrocytes in vivo (Janzer and Raff 1987), and astrocytes in vitro 
(Hayashi, Nomura et al. 1997) induce BBB properties in adjacent non-neural 
endothelial cells from different species. Evidence supports the importance of
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astrocytes in mediating expression and localisation of markers including p- 
glycoprotein, GLUT1 and y-glutamyl transpeptidase (y-GTP) (Abbott, Ronnback 
et al. 2006). The parenchymal basement membrane, one of the two basement 
membranes associated with the blood brain barrier, is produced by astrocytes. 
Two components namely agrin (Barber and Lieth 1997) and j82 laminin (Hunter, 
Llinas et al. 1992) in this membrane are important in the terminal development of 
the blood brain barrier.
In addition, astrocytes secrete growth factors like transforming growth factor-p 
(TGF-p), angiopoetin 1 (ANG1), glial derived neurotrophic factor (GDNF) and 
basic fibroblast growth factor (bFGF) which influence development of the barrier 
phenotype. In 2003, Lee and colleagues identified a single gene SSeCKS which is 
upregulated in astrocytes in response to oxygen tension. Ectopic overexpression in 
rat cerebral cortex astrocytes led to downregulation of VEGF and increased 
expression of ANG1. VEGF is a known mediator of increased permeability and 
ANG1 mediates angiogenesis and vessel maturation (Ferrara, Gerber et al. 2003). 
Supernatants from SSeCKS expressing cells also upregulated the expression of 
ZOl and claudin 1, constituents of the TJs of the blood brain barrier. Hence it is 
clear that the gene product of SSeCKS is instrumental in the development and 
maturation of the blood brain barrier (Lee, Kim et al. 2003).
Bidirectional astrocyte-endothelial calcium signalling has been demonstrated in 
co-cultures employing astrocytes and endothelial cells (Braet, Paemeleire et al. 
2001) and in brain slices (Zonta, Angulo et al. 2003). The calcium oscillations 
seen in astrocytes have been shown to be important for vasodilation induced by
22
neuronal activity (Zonta, Angulo et al. 2003). Hence it appears that the complex 
interactions between cerebral endothelial cells, astrocytes and neurons regulate 
circulation in the CNS.
However the first known markers of brain endothelial cells and the accumulation 
of p-glycoprotein appear even before astrocytes is present (Qin and Sato 1995). So 
it seems unlikely that all the properties are acquired simultaneously. It also 
appears that astrocytes are important in maintaining the barrier properties in the 
adult although short term loss of astrocytic end feet does not affect the function of 
the blood brain barrier (Krum and Rosenstein 1993). Some of the BBB-inducing 
properties of astrocytes are mimicked by corticosteroids (Romero, Radewicz et al. 
2003).
1.2.1.2 Role of Pericytes
Pericytes are present in the basement membrane formed by the capillary 
endothelial cells and astrocytes (Fig. 1.3) and play important role in conferring 
BBB properties to the cerebral endothelial cells (Lai and Kuo 2005). Pericytes 
possess long cytoplasmic extensions and along with gap junctions are involved in 
maintaining contact with endothelial cells. During embryonic development, the 
ligand PDGF-B required for angiogenesis is expressed by capillary endothelial 
cells, but its receptor PDGFR/3 is expressed on pericytes (Betsholtz, Lindblom et 
al. 2004). Pericytes induce endothelial differentiation and growth arrest (Sims 
2000; Gerhardt and Betsholtz 2003). Pericytes in the brain can function as 
macrophages and also exhibit phagocytic activity (Thomas 1999). They have also 
been shown to protect the integrity of the blood brain barrier in hypoxia in vitro
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(Hayashi, Nakao et al. 2004).
1.2.1.3 Role of Neurons
It is possible that non-astrocytic factors are also important as different kinds of 
nerve endings are also associated with brain capillaries (Kobayashi, Magnoni et 
al. 1985; Petty and Lo 2002). In the developed brain, groups have demonstrated 
roles for noradrenergic (Cohen, Molinatti et al. 1997), serotonergic (Cohen, 
Bonvento et al. 1996) and GABAnergic (Vaucher, Tong et al. 2000) neurons in 
the activation of endothelial cells. Inhibition of noradrenergic contacts to the CNS 
vasculature increases susceptibility of the BBB to hypertension (Ben-Menachem, 
Johansson et al. 1982). Neurons have been shown to be as effective as astrocytes 
in inducing barrier properties in vitro. In 2000, Savettieri and colleagues 
investigated the role of neurons in the induction of occludin, a TJ protein and 
showed the expression and localisation of occludin is dependent on presence of 
neurons in the culture (Savettieri, Di Liegro et al. 2000). It can be said that 
neurons are critical in maintaining the phenotype of the established blood brain 
barrier but their importance in its formation is yet to be clearly demonstrated. The 
same group also has also shown extracellular matrix protein collagen IV 
influences occludin mRNA expression but not the protein levels (Savettieri, Di 
Liegro et al. 2000).
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1.2.1.4 Molecular Characteristics of the Blood Brain Barrier
1.2.1.5 T ran sp o rt Systems
The continuous tight junctions between the cerebral endothelial cells abrogate 
access to polar substances unless they are transferred by specific transport 
pathways. At the BBB, various membrane transporters on the luminal and 
abluminal membranes o f the capillary endothelium function to regulate the entry 
of essential molecules into the brain, as well as effluxing harmful substances and 
waste products from the brain into the blood (Fig. 1-4) (Abbott and Romero 
1996). Transport systems (Fig. 1-4) at the BBB include carrier-mediated transport 
(CMT, Table 1.1), active efflux transport (AET, Table 1.2) and receptor-mediated 
transport (RMT) (Begley 2004).
Figure 1-3 Three Classes of BBB Transport Systems
Carrier-med ated Active-effli-x Receptor-mediated
transport transport transport
Blood Bood Blood
Brain Brain Bram
(Pardridge 2002)
CMT systems (Table 1.1, Fig. 1-4) CMT systems are expressed on both the
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luminal and abluminal membranes of the capillary endothelium, so that transport 
in either the blood-to-brain or brain-to-blood direction can be mediated (e.g. 
amino acid transporters).
AET systems (Table 1.2, Fig. 1-4) are responsible for the transport of substrates 
usually from the brain to blood (e.g. P-glycoprotein).
The RMT systems (Fig. 1-4) are responsible for the transport of endogenous 
molecules. The transferrin receptor depicted as system 1 in panel C, is a 
bidirectional system that transports transferrin in either the blood-to-brain or 
brain-to-blood direction. The blood-brain barrier Fc receptor which is depicted as 
system 2 in panel C selectively transports immunoglobulin G molecules in the 
brain-to-blood direction only. The type I scavenger receptor which is depicted as 
system 3 in panel C, can only mediate the uptake of circulating ligand, such as 
acetylated low-density lipoprotein, into the brain capillary endothelial 
compartment, without transcytosis or release into brain. (Pardridge 2002)
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Table 1-1 CMT at the Blood Brain Barrier
Molecule
Nucleosides/nucleic acid transport 
transport
System ASC/B0+ ......
System B°+
Choline transport 
GLUT1 
i LAT/4F2hc (system L)
CAT1 (system y4)
j j
System A 
i MCT1 "  ■ ' .............
Transport
Nucleosides/nucleic acid
L-Aia/L-Ser/L-Cys & others
Basic AAs
Choline
D-Glucose, Ascorbic acid 
Large neutral AA’s 
Cationic AA’s 
Anionic AA’s 
Small neutral AA’s 
: L-Lactate/monocarboxylates
Table 1-2 AET at the Blood Brain Barrier
. Gene [ Protein i Function
ABCB1 (MDR1) P-glycoprotein multidrug resistance
f  ABCCl ( ^ ^ 1 )  '
i
i MDRl-related protein i drug resistance
ABCC2 (MRP2) cMOAT organic anion efflux
r  ABCC3 ( h ® IMRP3.......... ! drug resistance
ABCC4 (MRP4) MRP4 nucleoside transport
ABCC5 (MRP5) ! MRP5 ..... r “ .............. ! nucleoside transport
i f
ABCG2 (BCRP) breast cancer resistance
.. i i,
drug resistance
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1.2.2 The Blood Brain Barrier in Disease
The blood brain barrier is metabolically active and hence it is possible to modulate 
the gene expression of endothelial cells and subsequent changes in function and 
permeability across the barrier. Transient opening of the barrier occurs at times to 
allow for passage of other blood borne substances into the brain. Cytokines such 
as tumour necrosis factor-a (TNF-a), interleukins IL -la  and IL-6, histamine, 
glutamate, free radicals, nitric oxide, purine nucleotides are known to increase the 
permeability of the barrier.
Breakdown of the BBB is associated with a variety of CNS disorders and results 
in aggravation of the condition. In multiple sclerosis, the barrier function is 
compromised along with the loss of laminin (Oki, Takahashi et al. 2004) in the 
basement membrane and the tight junction proteins claudin -1 and -3 (Minagar, 
Ostanin et al. 2003). Post mortem CNS tissue from HIV-1 patients with 
encephalitis displayed decreased immune reactivity for occludin (Dallasta, Pisarov 
et al. 1999).
Endothelial cells comprising blood vessels in malignant gliomas, metastatic and 
benign tumours fail to form TJs or form leaky TJs. Occludin and claudin-5 are 
down regulated in human gliomas and are absent in metastatic tumour vessel TJs 
(Liebner, Fischmann et al. 2000; Papadopoulos, Saadoun et al. 2001; Rascher, 
Fischmann et al. 2002). Two reasons for the poor quality or absence of TJs can be 
attributed to decreased astrocyte numbers in the tumours and increased secretion 
of angiogenic factors (Janzer and Raff 1987; Bates, Lodwick et al. 1999).
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In bacterial meningitis, free radicals and presence of interleukins IL-6 and IL-1 p 
generated in response to lipopolysaccharide increase permeability (Gaillard, de 
Boer et al. 2003). Exposure to stress or hypoxia results in the increased levels of 
cAMP and Glutl and a subsequent increase in terminal resistance and 
upregulation of Pgp activity (Kis, Deli et al. 2001).
BBB in Alzheimer’s disease is characterised by increase in GLUT1 expression 
(Kalaria 1999), altered agrin levels (Berzin, Zipser et al. 2000) and accumulation 
of amyloid-p due to decreased clearance (Lee and Bendayan 2004). Microglia and 
astrocytes are closely associated with neuronal plaques and activated by the 
accumulated /5-amyloid protein to release cytokines, reactive oxygen species etc 
(Giulian, Haverkamp et al. 1995). /5-amyloid stimulates NFkB a transcription 
factor that has been implicated in altering the barrier function. The transcription 
factor activates transcription of TNF-a; IL-1, IL-6 and monocyte chemoattractant 
protein (MCP)-l all known potentiators of increased permeability of the blood 
brain barrier (Akama, Albanese et al. 1998; Brown and Davis 2005).
Restoration of the BBB is thus one strategy during therapy of CNS diseases. One 
of the agents used to reduce inflammation is dexamethasone, a corticosteroid that 
is commonly used to treat oedema (Kaal and Vecht 2004). Some of the potential 
ideas for therapy include employing modulators that can increase activity of the 
enzymatic machinery and/or affect gene expression in the endothelial or 
surrounding cells resulting in restoration of barrier function and hence integrity. 
Their success depends on the knowledge of the structural and functional aspects 
of the blood brain barrier.
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1.2.3 In vitro Models of the Blood Brain Barrier
Over the past two decades, many groups have devised in vitro models of the blood 
brain barrier in order to facilitate understanding of the unique properties and 
regulation of endothelial cells. Some of the in vitro models are discussed below.
1.2.3.1 Isolated Brain Capillaries
(Siakotos and Rouser 1969) described the isolation of capillaries from 
homogenised post-mortem human brain tissue by filtration. This model was the 
first system used to demonstrate receptor mediated transport of insulin and 
transferrin in capillary endothelial cells. However, isolated capillaries cannot be 
used to measure transendothelial transport across the BBB.
1.2.3.2 Primary Cultures of Endothelial Cells
Primary endothelial cells maintain morphology, biochemistry and function in in 
vitro growth conditions. Detailed methodology of obtaining viable endothelial 
cells from donor tissue has been described in the General Materials and Methods 
section. However, there are several constraints including availability and quality 
of human post mortem donor tissue; slight variation in phenotypic properties 
between different donor tissue; mouse, bovine or porcine based primary 
endothelial cell cultures cannot be compared with human cell cultures because of 
well recognised differences in gene expression (e.g. p-glycoprotein). 
Establishment of immortalised cell cultures has answered some of the problems of 
primary cultures. Endothelial cell lines used in the field are tabled below.
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Table 1-3 Immortalized Brain Capillary Endothelial Cell Lines Reported in 
the Literature
Cell line > Species ? Nature of Reference
m I transformation
SV-HCEC Human SV40 T antigen (Muruganandam, Herx et al.
1997)
| hCMEC/D3 ; Human < r SV40 T antigen + ; j (Weksler, Subileau et al. 2005)
S..' ! IhTERT ;
HBEC-51 Human SV40T antigen (Xiao, Yang et al. 1996)
I BB19 i Human i E6E7 gene (Prudhomme, Sherman et al.
! 11996)
MBEC Mouse E6E7 gene (Tatsuta, Naito et al. 1992)
S5C j Mouse | Adenovirus E l A ;s (Sobue, Yamamoto et ai. 1999)
I !  S ,  i  . ’  I ,  ,  ^
TM-BBB4 Mouse SV40 T antigen (Asaba, Hosoya et al. 2000)
f RBE4 [Rat I Adenovirus El A ; (Couraud, Greenwood et al.
i  ;  ;  :2003)
GPNT Rat SV40T antigen (Regina, Romero et al. 1999)
• CR3 j Rat \ SV40 T antigen < [ (Lechardeur, Schwartz et al.
t : ; :1995)
GP8.3 Rat SV40 T antigen (Greenwood, Pryce et al. 1996)
i RBEC1 Rat | SV40 T antigen | (Kido, Tamai et al. 2000)
RCE-T1 Rat Rous Sarcoma (Mooradian and Diglio 1991)
virus
t-BBEC-117 Bovine ! SV40 T antigen | (Sobue, Yamamoto et al. 1999)
SV-BEC Bovine SV40T antigen (Durieu-Trautmann, Foignant-
Chaverot et al. 1991)
I BBEC-SV ..i i Bovine SV40 T antigen ; (Stins, Prasadarao et al. 1997)
PBMEC Porcine SV40T antigen (Teifel and Friedl 1996)
Adapted from (Gumbleton and Audus 2001)
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1.3 Tight Junctions
Cell junctions can be classified into occluding, anchoring and communicating 
junctions. The occluding junctions commonly referred to as the tight junctions 
(TJs) represent the connections between adjacent cells and represent the apical 
most type of junctional complexes in vertebrate epithelium (Wolburg and 
Lippoldt 2002). They are also observed in endothelial cells and mesothelial cells, 
as well as several other types of cells including Schwann cells, Sertoli cells and 
oligodendrocytes. By transmission electron microscopy, tight junctions appear as 
a series of very close membrane appositions of adjacent cells. On ffeeze-fracture, 
these contact sites principally correspond to continuous networks of tight junction 
strands and complementary grooves in the protoplasmic and extracellular faces, 
respectively (Vorbrodt and Dobrogowska 2003).
TJs are crucial in limiting paracellular transport and in maintaining polarity of 
cells. In addition TJs function as specialized micro domains in the plasma 
membrane and coordinate vesicle protein docking and actin organization. 
Components of the TJs especially the cytoplasmic components are important 
signalling proteins regulating differentiation and proliferation. These multiple 
functions of TJs are important in segregating the epithelial and endothelial cellular 
layers and in establishing distinct tissue compartments within the body to 
ultimately maintain homeostasis.
Disturbance of the functions of TJs is considered to cause or contribute to the 
pathology of diseases, such as inflammatory bowel disease (IBD), infections and
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cancers, as well as vasogenic oedema and blood-borne metastases. In turn, the 
barrier function of tight junctions also restricts drug delivery to underlying tissues 
and therefore how to overcome the paracellular barrier is critical for treatment of 
diseases.
Table 1-4 Recruitment of Proteins into TJs During Development
Protein : j Stage at 
I which first 
I detected
1 Assembly 
[ into TJ
j Model [ Reference
Claudin 1 Not 32-cell stage Mouse Fleming et al.
determined (Epithelium) 2001
Claudin 5 1 Embryonic | Embryonic | Chick IKojima et al.
1 Day 5 [day 10 [(Retinal 
i pigment 
[epithelium)
12002
i  I • ' • • •
Occludin Throughout Early 32-cell Mouse Sheth et al.
all embryonic stage (Epithelium) 2000
stages
Z O - lV ; j throughout I Punctate [Mouse | Sheth et al.
! all embryonic j staining 8-cell ) (Epithelium) ; 1997
■: | stages | embryos 1
Z0-1 a  + Beginning of Early 32-cell Mouse Sheth et al.
the blastocyst stage (Epithelium) 1997
stage
(GONZALEZ-MARISCAL, BETANZOS, NAVA, JARAMILLO, 2003)
33
Figure 1-4 Molecular Constituents of Tight Junctions
Claudins
> Plasma membranes of 
^ adjacent cells
Simplekin
Cytosol
Paracellular Space
aE -ca ten in
Actin
TJs are composed of a set of transmembrane proteins- occludin, claudin 5 and 
junctional adhesion molecule-JAM. Adaptor molecules, ZO-1, -2 and -3 bind the 
cytoplasmic tail of occludin and actin, AF-6, ZAK-(Z01 associated kinase) and 
alpha-catenin. The function of simplekin, cingulin and 7H6 which also localise to 
the junctions is not yet known. Many of the cytoplasmic junctional components 
are signalling proteins or exhibit sequence similarities with tumour suppressors, 
and so might function in transducing signals to and from the cell interior.
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1.3.1 Molecular Constituents of TJs
1.3.1.1 Occludin
Discovered by (Furuse, Hirase et al. 1993), occludin is an approximately 65-kD 
type II transmembrane protein composed of four transmembrane domains, two 
extracellular loops, and a large C-terminal cytosolic domain. When observed by 
freeze fracture electron microscopy, occludin is concentrated directly within the 
tight junction fibrils (Fujimoto 1995).
1.3.1.1.1 Structure and Interactions
Occludin protein can be subdivided into five domains based on its structure. 
Referred as domains A-E, these regions include a carboxy terminal, amino 
terminus, two extra cellular loops and a cytosolic loop (Fig 1.5)
Domain E (carboxy terminus) is localised to the cytoplasm and is composed of 
225 residues which are enriched for charged amino acids. Occludin mutants with 
truncations in domain E localise to the TJs but the barriers generated are leaky 
indicating that the this domain is necessary for correct TJ assembly and function 
(Chen, Merzdorf et al. 1997). Protein interaction studies have indicated this 
domain binds the ZO protein family. Within the 150-amino acid region that 
interacts with the ZO proteins, is a 27-amino acid stretch with hydrophobic 
residues clustered in a pattern that has identified to be consistent with a coiled-coil 
structure. In an elegant study (Nusrat, Chen et al. 2000), the authors have shown 
that this region is responsible for most of the interactions of the full length 
occludin protein.
These include associations with members of the TJ and proteins associated with 
the plasma membrane. The following proteins c-Yes, the regulatory (p85) subunit 
of PI3K, PKC-£, and the gap junction component, connexin 26 have been shown 
to interact with this domain. There are however differences in the interactions 
within the proteins; PI3K interacts with both interfacial surfaces of the domain in 
contrast to PKC-£ and c-Yes which interact solely with the hydrophobic surface. 
Connexin-26 interacts with the hydrophilic surface of the coiled-coil (Nusrat, 
Chen et al. 2000).
The N-terminus referred to as domain A is comprised of 65 amino acids and is 
directly involved in barrier function. Occludin constructs lacking this domain 
when over expressed localise to the TJ and also interact with ZO-1 but this 
localisation and subsequent interaction with other TJ proteins is not functional as 
the barriers formed are leaky (Bamforth, Kniesel et al. 1999). Domains A and E 
are enriched in serine and threonine residues. Since occludin at the TJ is hyper 
phosphorylated, it is likely these residues are potential targets for phosphorylation 
and hence are important in function (Feldman, Mullin et al. 2005).
The two extracellular domains, B and D, are rich in tyrosine and glycine residues 
(Feldman, Mullin et al. 2005) and are separated by a short (10 aa) cytosolic loop. 
Occludin constructs lacking domain D, or both the domains when ectopically 
expressed in epithelial cells, were restricted to the basolateral cell surface 
indicating the domains are important in the targeting of the protein to the TJ 
(Medina, Rahner et al. 2000). There are two conserved protein domains, the 
MARVEL and the Occludin-ELL domain. The MARVEL domain is a membrane-
36
associating domain often found in lipid-associating proteins and may contribute to 
the machinery of membrane apposition events. The occludin-ELL domain is a 
conserved region of approximately 100 residues between occludin and the RNA 
polymerase II elongation factor ELL.
Figure 1-5 Structural Representation of Occludin
Occludin
254 aa 
COOH10 aa
■y 45 aa
Membrane
(Feldman, Mullin et al. 2005)
Occludin has four transmembrane regions; two extracellular domains and the 
amino and carboxyl terminal ends are oriented towards the intracellular region. 
Both extracellular loops of occludin are of approximately the same size, lack 
charged residues and are very rich in tyrosine (Y). More than half of the first loop 
residues are tyrosines and glycines (G). (Feldman, Mullin et al. 2005).
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1.3.1.1.2 Splice Variants
In 2002 (Mankertz, Waller et al. 2002), identified four differentially spliced 
occludin-specific mRNA transcripts (Fig 1.6). Two splice variants, occludin types 
II and III, lack the fourth transmembrane domain and do not co-localize with ZO-
1. An occludin isoform lacking the TM4 domain was discovered by RT-PCR 
analysis of human tissues, embryos and cells using primers spanning the TM4 and 
adjacent C-terminal region (Ghassemifar, Sheth et al. 2002). It is possible that this 
isoform might modulate intercellular adhesion.
Occludin IB variant contains a 193 bp insertion that results in a longer form of the 
protein with a unique domain A comprising of 56 amino acids. The localization of 
occludin IB on ectopic expression in MDCK cells is similar to that of the full 
length occludin (Muresan, Paul et al. 2000). Occludin IB has been observed in 
T84 human colon carcinoma cells and in a range of epithelial tissues 
(Ghassemifar, Sheth et al. 2002). Co-expression of occludin and occludin IB has 
also been seen in various murine tissues. It appears that occludin IB expressed in 
the gut is conserved between mouse and human. The presence of occludin IB in 
epithelium and conservation across species implies that occludin IB is potentially 
a significant player in the modulation of TJ barrier properties in vascular 
endothelium (Muresan, Paul et al. 2000).
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Figure 1-6 Structural Comparison of the Occludin mRNA Variants
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(Mankertz, Waller et al. 2002)
Primary nucleic acid sequences from occludin-specific cDNAs (types I, II, III, and 
IV) were compared to the published occludin sequence (GenBank accession 
number U49184). The sequence boundaries are determined by the location of the 
oligonucleotides used for amplification. Translation start and stop codons are 
marked by broken lines, regions of homology are indicated by filled boxes, and 
deletions are represented by thin lines (Mankertz, Waller et al. 2002).
1.3.1.1.3 Expression
Occludin is expressed in a broad range of epithelial cells in addition to the blood 
brain barrier and blood vessel endothelium. It is clear that expression of occludin 
correlates with barrier function.
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Blood Brain Barrier: Occludin is localized at the TJs of cerebral endothelial cells. 
(Hirase, Staddon et al. 1997) first reported that occludin protein was strongly 
expressed and distributed continuously at the interface of brain endothelial cells. 
Occludin expression has been shown to be relatively lower in TJs of endothelial 
cells in non-neural tissue. Occludin levels at the TJs of brain endothelial cells 
increase with development. The levels of occludin protein in brain and non-neural 
tissue are mirrored at the mRNA level (reviewed in Wolburg and Lippoldt 2002).
Blood Retinal Barrier: Occludin is also highly expressed in the capillaries of the 
retina, which represents the blood-retinal barrier (BRB). Occludin is strongly 
expressed between adjacent endothelial cells in all retinal blood vessels. In 
contrast, low levels of occludin were detectable in choroid vessels, which do not 
exhibit blood-barrier properties (Morcos, Hosie et al. 2001).
Epithelium:
Occludin expression is seen in stratified (Langbein, Grund et al. 2002) as well as 
simple epithelium (Brandner, Kief et al. 2002) where it contributes to barrier 
function. Occludin has been found localised to focal strands between granular 
cells in the outer most zones of the epidermis in rodents (Moroi, Saitou et al. 
1998). Occludin mRNA expression has also been reported in human neo-natal and 
adult keratinocytes (Tebbe, Mankertz et al. 2002). Immunostaining analyses for 
the protein shows its presence in the intercellular space of the granular layer. It 
appears that occludin contributes to formation of TJs between keratinocytes in the 
epidermis (Brandner, Kief et al. 2002). Increase in occludin protein expression in 
regenerating epidermis suggests that it may function during epidermal wound
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healing (Malminen, Koivukangas et al. 2003).
Its expression has been reported in bladder epithelium of mouse, rat and rabbit 
where it localises to the TJ and contributes to the high resistance of the 
uroepithelial-associated TJ complex (Acharya, Beckel et al. 2004).
Studies investigating occludin expression in liver epithelium demonstarted that its 
localisation alters during cell division which differs from other peripheral proteins 
like ZOl and Z02 (Kojima, Kokai et al. 2001) (Fallon, Brecher et al. 1995). 
Occludin and another integral TJ protein claudin 1 are strongly expressed in the 
mid body between daughter cells. This was one of the first studies wherein a 
difference in the regulation of integral versus periperhal TJ proteins was seen in 
cell division. (Kojima, Kokai et al. 2001).
Occludin is expressed in the acinar cells of the salivary gland (Hashimoto, Ochiai 
et al. 2000). The protein localizes to the abluminal side in adjacent acinar cells. 
Since salivary fluid secretion is dependent on paracellular routes as well as 
transcellular routes, occludin regulates the salivary fluid secretion by means of its 
presence at the tight junction.
Occludin is a component of corneal epithelium (Ban, Dota et al. 2003). Studies on 
the canine kidney have shown weak and irregular to strong, continuous 
immunostaining for occludin. For e.g. the protein was highly expressed in the 
ascending and descending loop of Henle and in the cells of the distal tubule and 
was weak in the cells of the proximal tubule. There is a strong correlation between 
the TER and the level of occludin expression thereby implying this protein is
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required for the function of the renal TJ (Kwon, Myers et al. 1998).
Occludin is concentrated at the TJs in the Sertoli cells of the murine testis (Moroi, 
Saitou et al. 1998) where it is highly phosphorylated and its concentration 
increases with maturity. (Kevil, Okayama et al. 1998) observed that occludin in 
endothelial monolayers was more concentrated in arterial junctions than in venous 
junctions both in vivo and in vitro.
1.3.1.1.4 Occludin Knock-out Mouse
The occludin knockout mouse showed growth retardation, brain calcification, 
thinning of bone, male sterility, chronic inflammation and hyperplasia of gastric 
epithelium (Saitou, Furuse et al. 2000). However, TJ formation in gut epithelial 
cells and function was not affected (Saitou, Fujimoto et al. 1998). Similarly, TJs 
of embryoid bodies originating from occludin-deficient embryonic stem cells were 
similar to their wild-type counterparts (Saitou, Fujimoto et al. 1998).
1.3.1.1.5 Functions
There is considerable evidence for the importance of occludin in TJs. Over 
expression of chicken occludin in cultured MDCK cells increases the number of 
TJ strands, and in increase in transepithelial resistance (TER). Introduction of C- 
terminally truncated occludin into MDCK cells or Xenopus embryo cells resulted 
in the increased paracellular leakage of tracers of low molecular mass. The TER 
of cultured Xenopus epithelial cells is reduced by addition into the culture 
medium of a synthetic peptide corresponding to the second extracellular loop of 
occludin. Occludin confers adhesive property to transfected fibroblasts which can
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be blocked by peptides to any of the two extracellular loops (Anderson and Van 
Itallie 1995; McCarthy, Skare et al. 1996). But nevertheless, occludin is not 
absolutely required for the formation of TJs. Well-developed TJ structures 
between adjacent epithelial cells developed from embryonic stem cells lacking 
occludin.
1.3.1.1.6 Regulation of Occludin Protein
Cytokines
Interferon-y (IFN-y) an inflammatory cytokine released by activated T cells and 
natural killer cells leads to decreased expression of ZOl, redistribution of 
occludin and Z02 and also the disruption and disorganization of actin in vitro. In 
combination with TNF-a, it induces a loss of claudin 5 and occludin. Both 
cytokines act to increase paracellular permeability and have been shown to 
regulate the barrier in gut epithelium (Schmitz, Fromm et al. 1999).
Treatment with TGF-pl results in loss of cell-cell contact, rearrangement in actin 
cytoskeleton and impairment of endothelial permeability (Barrios-Rodiles, Brown 
et al. 2005). Other cytokines such as interleukin (IL)-l, IL-4, IL-13, TGF-p, 
insulin-like growth factor (IGF)-I and -II, and vascular endothelial growth factor 
(VEGF) have been documented to decrease the barrier properties of endothelial 
cells (Walsh, Hopkins et al. 2000).
MAP and PI3 Kinase Signalling
MAP signalling pathway modulates blood brain barrier function by regulating the 
expression or phosphorylation status of TJ proteins (Yuan 2002). Activation of the
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PI3 kinase, and PKB pathway by reactive oxygen species leads to the down 
regulation of occludin in brain endothelial cells (Schreibelt, Kooij et al. 2007). In 
human umbilical vein endothelial cell, alcohol induced toxicity, activation of 
ERK1/2, JNK and p38 signalling results in phosphorylation of Ser residues in 
occludin resulting in its degradation (Kevil, Oshima et al. 2000). HIV-1 Tat 
protein activates ERK1/2 leading to relocalisation of occludin from cell surface to 
the cytosol in brain endothelial cells (Andras, Pu et al. 2003).
The cytokine, TGFpl activates the PI3K pathway and independently upregulates 
the expression of the transcriptional repressor snail (Ozdamar, Bose et al. 2005). 
During epithelial to mesenchyme transitions (EMT), expression of TJ and 
adherens junction proteins is down regulated. The ZnF transcription repressor, 
Snail has recently been implicated in EMT. Snail acts as a transcriptional 
repressor and binds DNA with the carboxy terminal zinc fingers. Snail binds the 
E-box motif, 5-CA (G/C) (G/C) TG, which is found in the E-cadherin promoter 
(Cano, Perez-Moreno et al. 2000) and in the occludin and claudin-3, -4, and -7 
promoters which contain one, six and eight, E-boxes, respectively. In a human 
epithelial carcinoma cell line, Snail over expression in epithelial cells lead to the 
complete repression of occludin, claudin-3, -4, and -7, and E-cadherin expression 
at both mRNA and protein levels, and this was accompanied by the disruption of 
both TJs and adherens junctions with subsequent induction of EMT (Ikenouchi, 
Matsuda et al. 2003).
The effects of PI3K signalling on TJ physiology depends on the stimulus as 
activation of the signalling cascade by different agents can induce opposite effects
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on the TJ proteins. In Caco2 cells, activation of the PI3K pathway by oxidative 
stress mediates the loss of occludin (Sheth, Basuroy et al. 2003). Glucocorticoids 
lead to the recruitment of PI3K subunit p85 and its association with ZOl and the 
C-terminal domain of occludin to positively affect the TJ barrier in brain 
endothelial cells (Forster, Silwedel et al. 2005). PI3K signalling can also act to 
inhibit GSK-3p mediated blocking of p-catenin and snail degradation. In addition, 
it positively upregulates Smad signalling which promotes the transcription of the 
transcription factor LEF1, which promotes EMT and down regulation of TJ 
proteins in epithelial cells (Bachelder, Yoon et al. 2005).
Phosphatases PP1, PP2A and PP2B
Ser/Thr phosphorylation of several TJ proteins promotes the barrier function of 
TJs and it is expected that Ser/Thr phosphatases exert opposite effects on the 
barrier function. Protein phosphatases PP2A and PP1 interact with the carboxyl 
terminal tail of occludin and dephosphorylate occludin on Ser residues leading to 
decrease in TER and increased paracellular permeability. PP2A also associates 
with aPKC£, leading to the inhibition of its activity and promoting its 
relocalisation to the cytosol. This subsequently leads to the disappearance of TJ 
proteins at cell-cell contacts. PP2B in turn appears to blocks the phosphorylation 
and thus activation of cPKCa, the kinase that promotes TJ disassembly in 
epithelial cells (Seth, Sheth et al. 2007).
Rho Signalling
Rho family of small GTPases includes the proteins, RhoA, Rac and Cdc42 
(Wennerberg and Der 2004). These proteins regulate apical and basal actin
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structures in response to extracellular cues (Nusrat, Giry et al. 1995). Many of the 
integral proteins present at the TJ are stabilised by virtue of direct or indirect 
interactions with actin (e.g., occludin, ZO family AF-6 and cingulin). 
Investigations into the effect of dominant active and negative mutants of the Rho 
family indicate all the members are involved in conserving the integrity of the 
barrier. A dominant-negative mutant or an inhibitor of RhoA prevented occludin 
phosphorylation (Hirase, Kawashima et al. 2001). RhoA signalling pathway has 
also been shown to promote the migration of small lung cancer cells through brain 
endothelium (Li, Zhao et al. 2006).
Other Modulators
The E3 ubiquitin ligase Itch was identified to be a binding partner for the amino 
terminus of occludin in a study by Traweger et al. 2002. Itch is a member of the 
HECT domain-containing ubiquitin protein ligases and is responsible for the 
ubiquitination of occludin and subsequent degradation in epithelial cells 
(Traweger, Fang et al. 2002)
1.3.1.2 Claudins
The association of tight junctional particles with the P or the E membrane leaflet 
is dependent on various claudins (Tsukita and Furuse 2000). Claudins were 
identified as major cell-adhesion molecules of TJs and belong to the 
PMP22/EMP/MP20/claudin mammalian superfamily. 20 different claudins have 
been identified in different tissues so far with molecular weights ranging from 20- 
27 kDa (Turksen and Troy 2004). Claudin 1 was the first member of the family to
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be identified as a TJ component (Furuse, Fujita et al. 1998).
1.3.1.2.1 Structure
The claudin family is characterised by four transmembrane helices, two 
extracellular domains, a short N-terminal sequence (2-6 residues), and a long C 
terminus tail (Fig 1.7). The N- and C-termini are localised to the cytoplasm. The 
first extracellular domain ranges from 49-52 residues and includes the conserved 
motif of the claudin family, a set of highly conserved amino acids, W-GLW-C-C. 
The second extracellular domain is comprised of 16-33 amino acids and is a 
known receptor for bacterial toxins. The C-terminus binds cytoplasmic proteins 
through a PDZ (PSD95 DlgA ZOl) motif. The cytoplasmic tails are the most 
diverse in sequence and vary in length from 21-63 residues. The membrane- 
proximal region of the C terminus is palmitoylated on conserved cysteines, and it 
is probable that most claudins can be phosphorylated on serines and/or threonines 
in the cytoplasmic tail. Claudins may form hexamers, as suggested by studies of 
claudin-4 and a distant relative, MP20. (Reviewed (Matter and Baida 2003).
Figure 1-7 Structural Representation of Claudins
Extracellular
W-
Intraccllular
VY
(Turksen and Troy 2004)
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13,1,2.2 Interactions
Multiple claudins interact in both homotypic and heterotypic fashion and confer 
selective permeability in different tissues (Fig 1.8). All claudins (except claudin- 
12) end in PDZ-binding motifs. This motif is responsible for associations with 
related PDZ domains in the cytoplasmic junction proteins ZO-1, -2, and -3; 
MUPP1, PATJ and possibly other proteins. However, blocking of the PDZ- 
binding sites does not restrict localisation. Claudins still localize to cell-cell 
contacts and form freeze-fracture strands, suggesting that they have an inherent 
ability to polymerize, independent of PDZ interactions. However, the strands 
formed by PDZ-blocked claudins are poorly organized and not restricted to the 
apical border (Tsukita and Furuse 2002).
13.1.23 Expression
Northern blotting analysis for claudin expression has shown that most tissues 
expressed more than two species of claudins. For example, kidney epithelium 
expresses claudins -4 and -8 (Acharya, Beckel et al. 2004); claudins -1,-2, and -3 
are present in the liver epithelium (Morita, Furuse et al. 1999). Therefore, it is 
likely that most TJ strands are heteropolymers of claudins (Fig 1.8), although 
specialized TJ strands in the myelin sheaths of oligodendrocytes and in the Sertoli 
cells in the testis appeared to be mainly composed of a single species of claudin, 
claudin-11 (Morita, Sasaki et al. 1999). Claudin 5 was originally described to be 
restricted to endothelial cells. However, the protein was also found in epithelium 
of the stomach and of the large and small intestine (Morita, Furuse et al. 1999).
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1.3.1.2.4 Claudins in the CNS
The only claudins detected in endothelial cells thus far are claudin-1 and claudin-5 
(Morita, Sasaki et al. 1999; Lippoldt, Liebner et al. 2000). A novel anti-claudin-3 
antibody recognized cerebral capillary endothelial cell TJs (Engelhardt and 
Wolburg). Additionally, claudin-11 localizes to TJs in myelin sheaths and 
claudins -1 ,-2  and -11 are present in the fenestrated endothelium of the choroid 
plexus (Wolburg, Wolburg-Buchholz et al. 2001). Claudins 2, 4, 5, 6, 8 and to a 
lesser extent -7 were observed in rat hippocampus and cortex (Lamas, Gonzalez- 
Mariscal et al. 2002).
1.3.1.2.5 Function
The claudin family members are essential for the formation of TJs in epithelial 
and endothelial cells and hence have important roles in the control of paracellular 
transport and in the maintenance of cell polarity. Multiple claudins interact in a 
homotypic as well as in a heterotypic fashion to confer selective permeability in 
different tissues.
In CldS'7' mice, the blood vessels showed normal morphology and distinctly 
formed TJs comprising claudin-12. However, the TJs were not fully functional as 
the BBB was severely affected against molecules less than ~800 D, but not larger 
molecules. Nevertheless, the mice died within 10 hours of birth (Nitta, Hata et al. 
2003).
In addition to barrier functions, claudins are involved in development. Mutations 
in claudin genes lead to various familial diseases such as neonatal sclerosing 
cholangitis (Claudin 1) (Hadj-Rabia, Baala et al. 2004), nonsyndromic
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recessive deafness (Claudin 14) (Wilcox, Burton et al. 2001), and familial 
hypomagnesaemia (Claudin 16) (Lai-Cheong, Arita et al. 2007).
Recent analyses also show the role of the claudin family in the progression of 
various cancers (Morin 2005). One of the hallmarks of metastasis is loss of tight 
junctions and hence loss of expression in TJ proteins is expected. However, 
expression of claudins -1, -3, -4, -5, -7, -10, -16 are not lost but altered in various 
cancers; claudins 3 and -4 are increased in ovarian, breast, prostate and pancreatic 
tumours (Morin 2005). Claudin 17 is elevated in stomach cancer but is decreased 
in breast cancer (Kramer, White et al. 2000).
Claudins -3 and -4 are being used as targets for therapy in malignancies over 
expressing these proteins. Clostridium perfringens enterotoxin (CPE) a natural 
ligand for Claudins-3 and -4 (Van Itallie, Betts et al. 2008) binds to the proteins 
resulting in rapid cytolysis of the cells (Katahira, Sugiyama et al. 1997).
1.3.1.3 Submembranous TJ Associated Proteins
The transmembrane components are tethered to the actin cytoskeleton and 
properly positioned at the tight junction by a group of cytoplasmic proteins 
including ZOl, -2, -3, AF6, MUPP1, PAR3, Cingulin, Simplekin and 7H6.
1.3.1.3.1 ZO (Zona Occludens) Proteins
ZO proteins are members of the Membrane Associated Guanylate Kinase 
(MAGuK) homologue family and are structurally composed of three PDZ 
domains, an SH3 domain and a non-catalytic guanylate kinase homology domain. 
In addition, they have an acidic and a basic domain, a proline rich C-terminus and
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a leucine zipper dimerization motif (Gonzalez-Mariscal, Betanzos et al. 2000). 
ZO family members interact with each other to form heterodimers via their PDZ 
domains. The PDZ domain of the ZO family mediates binding to the C-terminal 
regions of claudins 1-8 (Itoh, Furuse et al. 1999; Umeda, Ikenouchi et al. 2006). 
The GuK domain and the acidic domain mediate binding to occludin in vitro. 
Recombinant ZO-2 and -3 also interact with occludin in vitro (Wittchen, Haskins 
et al. 1999) (Fig. 1.10).
ZO proteins are anchored to the cytoskeleton by association of the proline rich C- 
terminus with F-Actin. The SH3 domain mediates binding to G proteins such as 
G a l2. ZOl also interacts with the Ras target, AF-6 (Yamamoto, Harada et al.
1997) and this binding can be disrupted by the over expression of activated Ras. 
ZO-1 binds to Cingulin (D'Atri, Nadalutti et al. 2002), JAM A (Ebnet, Suzuki et 
al. 2004) and the gap junction protein, Connexin 43 (Toyofuku, Yabuki et al.
1998) and also the adherens junction protein a-catenin (Gonzalez-Mariscal, 
Betanzos et al. 2000; Salama, Eddington et al. 2006).
ZO-1 expression is regulated at the post-transcriptional level by alternate splicing 
leading to the generation of two isoforms that can be differentiated by the 
presence or absence of the a  motif. The a  motif is an 80 amino acid domain 
within the C-terminus. The a + isoform is present in epithelial cells and the a  
isoform in cells of endothelial origin (Willott, Baida et al. 1992). Additional splice 
variants in the C-terminus gives rise to the p and y isoforms (Gonzalez-Mariscal, 
Islas et al. 1999).
ZOl has been shown to interact with ZONAB, a TF homologous to Y-box
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proteins (Baida and Matter 2000). The two proteins functionally interact in the 
nucleus to modulate the expression of the erbB-2 proto-oncogene, indicating a 
role for regulation of gene expression for TJ proteins (Baida, Garrett et al. 2003). 
Data supports the view that the two proteins also interact to promote paracellular 
impermeability either through occludin or affecting the gene expression of TJ 
proteins.
Figure 1-8 Structure of ZO Family Members
zo-1------------------------------- --------------------— — r 1745
Claudins ZO-2 JAM-1 ZONAB Occludin AF-6. Cingulin, Actin
ZO-2 ---------a— 1167
Claudins ZO-1 Occtudin Aclin
SAF-B
ZO-3  —  905
A A A AF-6
Claudins ZO-1 Occludin pi20catenin
(Gonzalez-Mariscal, Betanzos et al. 2003)
Domains are represented by labelled boxes. Intermolecular associations with other 
TJ and cytoskeletal proteins are indicated underneath the domains. (Gonzalez- 
Mariscal, Betanzos et al. 2003).
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1.4 Transcriptional control in eukaryotes
RNA polymerases I, II, and III allow for the transcription of rRNA, mRNA, and 
small RNAs in eukaryotes. Much of the regulation of transcription occurs at the 
promoter region where specific DNA sequences effect the recruitment of the 
polymerases and regulatory proteins (transcription factors) (Komberg 2007). 
However, gene expression can be controlled at the processing of the RNA 
transcript, transport of RNA to the cytoplasm, translation of mRNA, and mRNA 
and protein stability. General transcriptional machinery includes:
1. Basal transcription machinery: RNA polymerases and promoter region.
2. Long range regulatory elements and transcription factors (TFs)
3. Co activators and co repressors.
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Table 1-5 Regulatory Proteins in Transcription
B l B l M l l l l B l i H I B l B
General RNA Pol II
transcription
machinery TFIIB: TF for RNA Pol II B
TBP: TATA-binding protein
TAF: TBP-associated factor 
TFIIE: TF for RNA Pol HE 
TFIIF: TF for RNA Pol IIF
TFIIH: TF for RNA Pol II H
Mediator
Co activators Chromatin modification
l i i l B l i l l l l i f l l l i i i i l l l  l l l l l l l l l l l l l l l l l l l l i l l l B l l i l l l l i l B l i l l S S l l l l l l i l i l i l l l l  
repressors complexes:
HATs: Histone acetvltransferases
HDACs: Histone deacetylases
CBP: CREB-binding protein
HMTs: Histone methyltransferase
LSD1: Lysine-specific 
demethylasel
Function
Catalysis of RNA synthesis
Stabilization of TBP-DNA 
interactions, recruitment of 
RNA Pol II-TFIIF
Core promoter recognition, 
TFIIB recruitment
Core promoter recognition
TFIIH recruitment
Recruitment of RNA Pol II 
to promoter DNA-TBP- 
TFIIB complex
Promoter melting, helicase, 
RNA Pol II CTD kinase
Transduces regulatory 
information from activator 
and repressor proteins to 
RNA Pol II
Elongation
factors
FACT: Facilitates
transcription
chromatin
Elongator
TFIIS: TF for RNA Pol IIS
Acetyl ate histones 
Deacetylate histones 
HAT activity 
Methvlate histones 
Demethyl ates histones
Transcription-dependent 
nucleosome alterations
Exact function unknown
Facilitates RNA pol II 
passage through regions that 
cause transcriptional arrest
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1.4.1 Eukaryotic Promoters
The promoter of a gene is the cis-regulatory DNA region that can drive the 
transcription of its target gene in response to environmental signals. Eukaryotic 
promoters can be defined into three regions:
1. Core-promoter situated —80—100 bp surrounding the transcription start site.
2. Proximal-promoter present at -250-1000 bp upstream of the core- 
promoter. DNA motifs in this region can predict tissue-specific gene 
expression.
3. Distal-promoter located further upstream, normally excluding enhancer or 
other regulatory regions whose influences are position/orientation 
independent.
1.4.1.1 Upstream and Downstream Core Promoter Elements
Known core promoter elements include the TATA box, the initiator element (Inr), 
the TFIIB recognition element (BRE), the downstream promoter element (DPE), 
and the motif ten element (MTE). TATA box, Inr and BRE form the upstream 
promoter elements; DPE and MTE, the downstream promoter elements.
1.4.1.1.1 TATABox
The TATA Box is a T/A-rich sequence that is usually located 25-35 base pairs 
upstream of the transcription start site(s) and is essential for transcription 
initiation. However, TATA boxes are present in only 32% of 1031 potential core 
promoters and transcription from promoters lacking TATA boxes takes place
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through enhancer elements and or GC boxes. The consensus sequence of TATA 
Box is TATAWAWN (where N is any base and W denotes A-T base pair without 
regard to end-for-end orientation) and recruitment of the TFIID complex which 
includes the TBP and TBP associated factors, directs assembly of the pre­
initiation complex (PIC). TATATAAG has been identified as the optimal TBP 
recognition sequence.
One factor that is present at promoters used by all three RNA polymerases is the 
TATA-binding protein (TBP). TBP along with factors such as the TAFis, TAFus, 
and TAFms that bind to class I, II, and III promoters determine general and gene- 
specific regulation of gene expression. Among the eight factors that interact with 
TBP, TAFi, TAFus, TAFms, and PTF/SNAPc function in promoter selection and 
the other four factors namely, SAGA, Motl, NC2, and Nots function together with 
TAFus to regulate expression of protein-coding genes. All but one of these factors 
(PTF/SNAPc) is highly conserved among eukaryotes. In the case of genes 
transcribed by RNA polymerase II, TBP is responsible for promoter recognition 
and binds directly to DNA in the minor groove of an AT rich sequence (consensus 
TATA T/A A T/A X) (Matangkasombut, Auty et al. 2004; Sandelin, Caminci et 
al. 2007).
1.4.1,1.2 Initiator (Inr) Element
Functionally similar to the TATA box, the Inr element whose sequence is 
PyPyA+lN(T/A)PyPy is recognized by TAFI and TAF2 and can function 
independently of the TATA box. However, in TATA-containing promoters, it acts 
synergistically to increase the efficiency of transcription initiation (Gross and
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Oelgeschlager 2006).
1.4.1.1.3 Downstream Promoter Element (DPE)
The DPE is a distinct seven nucleotide element conserved from the fly to humans 
and is bound by the subunits TAF6 and TAF9 of the TFIID complex. The DPE 
consensus sequence is (A/G)G(A/T)(C/T)(G/A/C) and is located about +30 bp 
relative to the transcription start site. It functions in TATA-less promoters and 
requires the presence of an Inr element for activity (Kadonaga 2002)
1.4.1.1.4 Motif Ten Element (MTE)
MTE whose consensus sequence is C(G/A)A(A/G)C(G/C)(C/A/G)AACG(G/C) is 
located at positions +18 to +27 relative to the transcription start site and promotes 
transcriptional activity and binding of TFIID along with the Inr element. Although 
it can function independently of the TATA box or DPE, it exhibits strong 
synergism with both of these elements (Lim, Santoso et al. 2004; Juven-Gershon, 
Hsu et al. 2006).
1.4.1.2 Proximal Promoter Elements
1.4.1.2.1 CCAAT box
The CCAAT box was one of the first elements identified in eukaryotic promoters. 
The pentanucleotide sequence has been described in different, unrelated 
promoters in vertebrates, plant and yeast and the various transcription factors that 
interact with the sequence have also been described. In higher eukaryotes, the 
CCAAT box is present in reverse ATTGG orientation in 60% of the promoters
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and usually, genes lacking TATA boxes show a preference for the ATTGG box 
(Ramji and Foka 2002). The transcription factors, c/EBP, CTF/NF1, CDP, NF-Y 
(also known as CBF, CPI) have been described extensively to regulate 
transcription from this element. TFs NF1 and c/EBP are discussed in the next 
section.
The CCAAT displacement protein (CDP) is a homolog of the Drosophila 
homeodomain protein Cut (Neufeld, Skalnik et al. 1992). CDP/Cut proteins were 
found to function primarily as transcriptional repressors and some examples of the 
genes targets are H2B, NCAM, c-Myc, etc. Repression can occur through 
competition with activators for a binding site or through the two active repression 
domains identified within the C terminal domain (Nepveu 2001).
The NF-Y is a heteromeric protein that is composed of three subunits NF-YA, -  
YB and -YC and requires all the CCAAT nucleotides for binding and interaction. 
NF-Y sites are predominantly found in proximal promoters and in the absence of 
TATA-TBP interactions, NF-Y has been known to function in connecting the 
upstream activators with the general transcription machinery allowing for RNA 
polymerase to mediate its effects from the start site (Mantovani 1999).
GC box is discussed in detail in the Sp transcription factor section.
1.4.2 Long Range Regulatory Elements
Transcriptional control also involves additional regulatory DNA sequences 
namely enhancers and silencers, insulators, locus control regions (LCRs), and 
matrix attachment regions (MARs).
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1.4.2.1 Enhancers and Silencers
Usually situated 700-1000 bp or more from the transcription start site, these 
elements can be found downstream, upstream, or within an intron, and can 
function in either orientation relative to the promoter (Maston, Evans et al. 2006). 
A typical enhancer is around 500 bp in length and exhibits binding sites for 
several different transcription factors. Enhancer activation could result in 
chromatin reorganisation and access of the promoter to transcription factors 
(Bulger and Groudine 1999; Engel and Tanimoto 2000). Activation of the 
enhancer element could also lead to interaction of proteins separately bound at the 
promoter and enhancer regions resulting in the looping out of DNA and the 
formation of a promoter/enhancer holocomplex (Hatzis and Talianidis 2002). 
Similar elements that repress gene activity are called silencers (Pozzoli and Sironi 
2005).
1.4.2.2 Insulators
An insulator is a DNA sequence element, typically 300 bp to 2 kb in length that 
functions as a chromatin boundary marker, marking the border between regions of 
heterochromatin and euchromatin (Geyer and Clark 2002; Brasset and Vaury
2005). Another important function is to block enhancer blocking activity to 
prevent inappropriate cross-activation or repression of neighboring genes by 
blocking the action of enhancers and silencers (Brasset and Vaury 2005). It is 
believed that insulators tether the DNA to subnuclear sites, forming loops that 
separate the promoter of one gene from the enhancer of another.
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1.4.2.3 Locus Control Regions (LCRs)
LCRs are DNA sequences that organize and maintain a functional domain of 
active chromatin to enhance the transcription of downstream genes and operate in 
an orientation-dependent manner (Dean 2006). LCRs have been shown to be 
important in the transcription of the p-globins (Sawado, Halow et al. 2003), MHC 
II proteins (Mastemak, Peyraud et al. 2003), human growth hormone (Horan, 
Millar et al. 2003), serpins (Zhao, Friedman et al. 2007) and cytokines (Dean
2006).
1.4.2.4 Matrix Attachment Regions (MARs)
MARs are genomic DNA fragments that have the ability to bind to isolated 
nuclear matrices in vitro (Cockerill and Garrard 1986). Located near enhancers in 
5' and 3' flanking sequences, MARs sequences are scattered throughout the 
genome at 5-200 kb intervals and play important roles in modulating chromatin 
structure in interphase and metaphase (Laemmli, Kas et al. 1992; Bode, Stengert- 
Iber et al. 1996). The MARs recognition signature (MRS) comprises two 
individual sequence elements AATAAYAA (where Y = C or T) and 
AWWRTAANNWWGNNNC (where W = A or T, R = A or G, N = A, C, G or T) 
that are <200 bp apart (van Drunen, Sewalt et al. 1999). MARs recruit TFs and 
chromatin-remodelling enzymes resulting in the formation of chromatin loops 
(Mirkovitch, Mirault et al. 1984). Associations of MARs with other factors can be 
altered by interactions with components of enhancers and LCRs.
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Figure 1-9 Model Describing the Activation Process of a Eukaryotic Gene in 
Chromatin
Step 1
Step 2
Enhancer Promoter
HATHem
TFIID
HA1
Step 3
Step A HAT
TFIID
Key:
Sequonce-specifrc activator (R e m ) ATP-dependenl chromatin remodelling complex
Mediator (£}A  ^ Histone acety ltransferase
(Szutorisz and Dillon, et al 2005)
Step 1: The gene (black box) has a core promoter element (purple box) and is 
regulated by a distal enhancer (grey box). Step 2: The enhancer-bound activator 
recruits ATP-dependent chromatin-remodelling complexes (Rem) and histone- 
modifying factors (HATs) to the core promoter. Step 3: Mediator complexes 
(Med) establish the link between the enhancer-bound activator and the basal 
transcription machinery at the promoter. Step 4: The PIC remains inactive until a
direct contact (looping) occurs between the distal enhancer and the promoter 
resulting in Pol II recruitment and initiation of transcription (Szutorisz and Dillon, 
et al 2005)
1.4.3 Transcription Factors
Transcription factors are proteins that bind to the promoter or enhancer elements 
upstream of genes and function to either initiate or inhibit transcription. 
Transcription factors are composed of two essential functional regions: a DNA- 
binding domain and an activator domain. The DNA-binding domain consists of 
amino acids that recognize specific DNA bases near the start of transcription and 
the structure of the DNA-binding domain has been used to classify transcription 
factors. The activator domains are responsible for interacting with RNA 
polymerase and other regulatory proteins. This interaction often enhances the 
efficiency with which the basal transcriptional complex can be built and bind 
RNA polymerase II. Other mechanisms by which TFs can activate transcription 
are:
1. Induction of a conformational change or post-translational modification (such 
as phosphorylation) that stimulates the activity of the general transcription 
machinery.
2. Interaction with proteins that are involved in chromatin modifications so as to 
permit enhanced accessibility of the promoter region to transcription factors or 
coactivators.
There are several families of transcription factors and those that are relevant in the
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project are discussed below:
1.4.3.1 Zinc Finger Proteins (ZnFs)
Zinc finger proteins include the ubiquitous transcription factor Spl, Kruppel, GR, 
GAT A family, YY1 etc. The proteins have two or more a-helical domains which 
are linked by a centrally located zinc ion. In addition to their role in binding DNA, 
roles for ZnFs have been implicated in protein: protein (RING family) and 
protein: lipid interactions.
1.4.3.2 The Sp Family
G-rich elements such as GC (GGGGCGGGG) and GT/CACC boxes 
(GGTGTGGGG) are widely distributed cis-acting elements required for the 
appropriate expression of genes important in development as well as house­
keeping and viral genes. Spl was the first transcription factor that was shown to 
bind GC elements. However, other proteins related to Spl namely Sp2, Sp3, Sp4 
and members of the KLF family have been characterised to act through the GC 
elements (Philipsen and Suske 1999). Sp family members bind not only GC-box 
motifs but also GT (GGGTGTGC) and CTC (CTCCTCCTC) motifs although 
with different affinities. Sp/KLF family contains at least twenty identified 
members. The Sp proteins are identical in their zinc finger region and N-terminal 
motifs. The KLF family is more heterogeneous in comparison and includes 
factors, BTEB1, TIEG1 and TIEG2 which are closely related to the Sp family and 
the subfamily, XKLFs which includes the factors, BTEB2, GBF/ZF9, ZNF741 
and AP-2rep (Suske, Bruford et al. 2005).
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Family members bind the GC boxes with different affinities and hence have 
different transcriptional properties. Since cells can express multiple family 
members, there is a possibility of synergistic activation and repression within a 
network of Sp/KLF factors. The prototype family member, Spl can activate 
transcription by functioning as a basal promoter element and as an upstream 
activator simultaneously. In many genes lacking TATA boxes, a proximally 
positioned Spl site determines promoter activity and the start site of transcription 
(Emami, Burke et al. 1998).
1.4.3.2.1 Expression
Except for Sp4 whose expression is restricted to the brain, Spl, -2 and -3 are 
ubiquitously expressed (Table 1.4). Individual cells hence can express multiple 
members of the family (for e.g. Spl, Sp3 have been detected in vascular 
endothelial cells (Yet, McA'Nulty et al. 1998), which leads to the possibility that 
the members can modulate each others activity at the level of expression or at 
promoters or via direct interactions at the level of protein.
Table 1-6 Expression of Sp Family Members
TF Expression Function
Spl Ubiquitous Activator
- Sp2 Absent in Brain endothelium Activator
Sp3 Ubiquitous Activator/Repressor
Sp4 Brain, Epithelial tissues, Testis Activator/Repressor
1.4.3.2.2 Structure
Sp family members have similar domains and are characterized by a highly
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conserved C-terminal DNA-binding domain containing three zinc fingers (Fig 
1.11). Critical amino acids in the zinc fingers are conserved in Spl, Sp3 and Sp4 
but not in Sp2 and hence the former are more closely related to each other than to 
Sp2. Despite conservation in the DNA binding domain, the family members bind 
target motifs with different affinities (Suske 1999).
Figure 1-10 Structural Features of Sp Family TFs
-c 784
(Suske 1999)
Their length in amino acids is indicated on the right. Sp3 full length isoform is 
represented here. Red boxes indicate regions rich in glutamine and yellow boxes 
indicate serine/threonine rich regions. The black boxes represent the ZnFs and the 
region preceding the first zinc finger (+/-) is rich in charged amino acids. Known 
activation (AD) and inhibitory (ID) domains are indicated. (Suske 1999).
1.4.3.2.3 Structural Variants of Sp3
There are three distinct Sp3 isoforms: a full length 110-115 kDa Sp3 protein and 
two shorter isoforms approximately 80 and 78 kDa species. The lower weight 
species are generated by internal translational initiation within Sp3 mRNA and 
possess functional DNA binding domains and are nuclear localised. They bind the 
Sp target motif with similar affinities (Suske 1999) and function as potent
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inhibitors of Sp3 mediated transcription (Kennett, Udvadia et al. 1997).
1.4.3.2.4 Regulation of Gene Expression by Spl and Sp3
Spl functions primarily as an activator. Sp3 can function either as an activator or 
a repressor depending on the promoter context and ratio of Spl:Sp3 in a cell 
(Sjottem, Anderssen et al. 1996) . Furthermore, functions of Sp3 may depend on 
the number of functional Spl binding sites. Promoters containing a single binding 
site are activated, whereas those containing multiple Spl sites are not activated or 
respond weakly to Sp3 (Dennig, Beato et al. 1996). In addition, Sp3 protein is a 
target for phosphorylation. In the regulation of the VEGF promoter, ERK 
phosphorylates a key serine residue in the Sp3 protein and enhancing its activity 
in vitro (Pages 2007). Sp3 is also modified by acetylation (Braun, Koop et al. 
2001) and sumoylation (Ross, Best et al. 2002). These modifications are likely to 
determine the role of Sp3 in regulating transcriptional activity. Furthermore, 
unlike Spl, binding of Sp3 to GC- and GT-boxes is influenced by flanking 
nucleotides. Amino acid triplet KEE in the inhibitory domain of Sp3 is 
responsible for the poor activity (Plata, Duh et al. 1998) and mutation of these 
amino acids to alanine residues converted Sp3 to a strong activator.
1.4.3.3 YY (Yin Yang) 1
YY1 (NF-E1, UCRBP, and CF1) is multifunctional ZnF transcription factor 
belonging to the GLI-Kriippel class of ZnFs and can act as a transcriptional 
repressor, activator, or initiator element binding protein (Thomas and Seto 1999) 
YY1 plays an important role in embryonic development, cell cycle, oncogenesis, 
X-chromosome inactivation in differentiating and non-dividing cells of all types,
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chromatin remodelling, etc (Sui, Affar el et al. 2004; Gordon, Akopyan et al. 
2006; Kim, Hinz et al. 2006).
This transcription factor has been implicated in the regulation of a very large 
number of genes involved in many metabolic processes in the cell. YY1 may 
target histone deacetylases and histone acetyltransferases to a promoter thereby 
implicating histone modification as one of the functions. Chronic activation of 
YY1 is associated with increased cellular proliferation, resistance to apoptotic 
insults and metastatic potential. The number of promoters that have been reported 
to be regulated by YY1 is increasing and include human transferrin receptor, p53, 
viral LTRs, c-Myc, a-actin, IgH enhancer, p-casein, IFN-y, c-Fos, E6 and E7 of 
HPV, P6 of B 19-parvovirus etc (reviewed in Shi, Lee et al. 1997).
1.4.3.3.1 Related Proteins
In 2004, (Nguyen, Zhang et al. 2004) described the identification of a protein 
YY2 with significant structural similarity to the transcription factor YY1. YY2 is 
a transcriptional activator and it appears that it binds only a few YY1 target sites 
on promoters leading to the suggestion that accessory DNA motifs are needed to 
recruit YY2 to the DNA. Further investigations are needed to ascertain the 
function of YY2. (Wang, Liang et al. 2004) reported the identification of an YY1 
associated protein (YY1AP). YY1AP is ubiquitously expressed in human tissues 
and has been shown to enhance activation of YY1 and hence regulate expression 
from promoters responsive to YY1. The mechanism by which YY1AP synergises 
YY1 activity is not clear but it is possible the factor is recruited by YY1 itself and 
tethered to the DNA.
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1.4.3.3.2 Structure
The YY1 protein is characterised by four C2H2-type zinc-finger motifs. Regions 
comprising amino acids 298-397 in the c-terminus serves as an inhibitory domain. 
Sequences within the zinc finger motifs and a glycine rich region between amino 
acids 157 and 201 promote the activity of the inhibitory domain. The N-terminus 
region (AA 43-53) acts as a potent activation domain (Shi, Lee et al. 1997). The 
role of the 11 consecutive histidine residues (AA 70-80) is not known (Fig. 1.13)
Figure 1-11 Domain Structure of YY1
&
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(THOMAS AND SETO 1999)
1.4.4 Basic Leucine Zipper proteins
Basic leucine zipper (bZIP) family of proteins which includes c/EBP, API and 
yeast GCN4 are a class of enhancer-type transcription factors that play important 
roles during embryonic development and in the adult organism (Sanyal, 
Sandstrom et al. 2002; Nerlov 2007). The leucine zipper motif that characterizes 
these proteins is composed of leucine residues separated by 7 amino acid residues 
and repeating at least 3 times (LxxxxxxLxxxxxxL) (Landschulz, Johnson et al. 
1988). On binding to a promoter, adjacent basic regions undergo conformational 
change and also interact with the promoter. This domain is followed by a 
regulatory domain that can interact with the promoter to stimulate or repress
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transcription.
1.4.4.1 GATA1
GATA1, along with five other structurally related proteins, -2 to -6, regulates gene 
expression in many different cell types. The consensus DNA sequence is 
A/TGATAA/G which is bound through two highly conserved ZnF domains. The 
conserved ZnFs also function in interaction with other proteins such as PU.l and 
CBP/p300 both of which function as important co-factors enhancing activity 
GATA-1 activity. The main function of GATA1 is the transcriptional control of 
genes that are important in hematopoietic lineage. Mutations in the zinc fingers 
lead to severe dysfunction in the hematopoietic system (Morceau, Schnekenburger 
et al. 2004).
1.4.5 Other TFs
1.4.5.1 GR (Glucocorticoid Receptor)
GR regulates the transcription of genes carrying the specific GR binding 
sequence, the glucocorticoid response element (GRE). Some of the BBB-inducing 
properties of astrocytes are mimicked by corticosteroids (Romero, Radewicz et al. 
2003). GR has a single DNA-binding domain that and a ligand-binding domain 
which is receptive to ligands like cortisol. Inactive GR localises to the cytoplasm 
to a large multiprotein complex containing heat shock proteins (hsp90, hsp70). 
Activation by ligand induces conformational changes resulting in the exposure of 
the GR nuclear localization signal and subsequent nuclear translocation (Chandran 
and DeFranco 1999) where it interacts with specific DNA sequences, known as
69
glucocorticoid response elements (GREs), in target genes eliciting a specific 
transcriptional response. The GREs are normally palindromic, with two hexameric 
half sites separated by three nucleotides, the perfect palindromic GRE reading 
5’-AGAACAnnnTGTTCT-3’. GR acts by transactivation or inhibition of the 
transactivating function of other transcription factors (transrepression) such as 
API andNFicB (Schoneveld, Gaemers et al. 2004).
1.4.5.2 NF1
The CTF/NF-1(CCAAT/Nuclear Factor 1 TF) family was first described in the 
replication of Adenovirus DNA and it has been established that this family is 
important in the growth state of cells and oncogenesis. The binding motif is 
TTGGC (N5) GCGAA and the protein has been shown to bind to individual half 
sites-TTGGC and GCCAA though with reduced capacity. NF1 proteins have been 
identified as negative regulatory elements of a number of promoters including 
peripherin, eta-globin, Pit-1 and Glut4 genes (Dusserre and Mermod 1993).
1.4.5.3 c/EBP
The c/EBP (CCAAT/enhancer binding protein) family consisting of six members 
(c/EBP-a, -p , -y, -8 , -s , and CHOP-10/GADD153) is bZIP transcription factors 
which have been shown to bind to the dyad-symmetric sequence ATTGCGCAAT 
either as homodimers or heterodimers. Members of the C/EBP family have been 
implicated in regulating the differentiation of adipocytes, hepatocytes, and 
myelomonocytes (Nerlov 2007).
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1.4.6 Co activators and Co repressors
The coactivators and co repressors proteins effect transcriptional activity through 
protein-protein interactions without binding DNA directly. Genomic DNA is 
packaged efficiently around protein complexes called histone octamers which 
serves the purpose of packing DNA in the nucleus but at the same time, this 
highly compact state limits access of TFs and other regulatory proteins to their 
target sites.
One mechanism by which chromatin is made more accessible to regulatory 
proteins is by histone acetylation. Histones are positively charged proteins that 
interact tightly with the negatively charged DNA. Acetylation of histones reduces 
charge and loosens their interaction with DNA leading to an increase in binding of 
transcription factors. Several transcription factors in a variety of organisms have 
now been found to be histone acetyltransferases (reviewed in (Kuo and Allis 
1998; Roth, Denu et al. 2001). To counteract HATs are the histone 
deacetyltransferases (HDACs) which catalyse the removal of acetyl groups from 
lysine residues in histones leading to chromatin condensation and repression of 
gene transcription (Kuo and Allis 1998).
1.5 Previous work
Promoters of transferrin receptor, claudin 5, and p-glycoprotein-1 were 
investigated for common sequence motifs in the 2000 bp region 5’ to the initiation 
codon. Expression of these proteins is seen in brain endothelium and not in other 
endothelia. However, these proteins are not restricted to brain endothelium and
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found in other cell types such as the epithelial tissue.
Commonly expressed endothelial markers Duffy antigen receptor for chemokines, 
P-selectin and p-glycoprotein-3 were used as controls. None of these proteins 
overlap in function. Work by David Male identified repeated motifs - (GGGC; 
GCCCC) in these regions which are heavily over-represented in the genes 
restricted to brain endothelium, but were present at standard frequencies in a set of 
control genes. Presence of cluster of common motifs in the cis-5’ regions of 
diverse brain endothelial genes suggests these are under common transcriptional 
control. The GC content in the control gene promoters and the CNS gene 
promoters is similar and hence the high incidence of the motif only in the CNS 
genes rules out non-specificity.
Spl/3 (target site is -GGGCGG-) is a known transcription factor that could bind 
this motif partly due to the similarity to the -GGGGC- motif. Analysis of the 
claudin 5 gene yielded a second cluster of 8 -GGGGC- motifs at -750 to -1100 
bp which were regularly spaced at every sixth turn of the DNA helix (69bp), 
shown below, which suggests a target site for a zinc-finger transcription factor. 
Table 1.7 shows the number of iterations of this motif in a segment of 500bp 
located between -150bp and -650bp of the first exon of the three proteins and in a 
previously identified enhancer region of p-glycoprotein-1
The sequence below shows an example of an identified motif in the 5’ region 
of the human claudin 5 promoter.
caggcccagggccccagcctcaccccccatgccactcactgcctctctggagcctgagtctctggcaaaaagcggt
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ggcacaggggctttccccctgcctggcgacccccactctcccaagccgcagggjgcttcccagacctctcaatcttca
caggggctgctcctcttcctgcggtactgcccgcaccccatccttgggggcccagttcaggtgacaccacttcagga
agttcccagtgacccagcacactgggtgtagcacccaggggcagtggtggccccaggcctagcagcctgctctggc
cttcagacaggagagacaaagggacacggaggggctgtgccctgccctcccaccagtggcgatggtgtccctggc
accccagcccccaggccaccctccggaagccaacttgga
Table 1-7 GC-rich Motif in Enhancers of Brain Endothelial Specific Genes.
Protein Gene Expression Forward
(cis)
Reverse
Claudin 5 CLD5 CNS endothelium 6 1
Transferrin
receptor
TFR CNS endothelium & 
dividing cells
9 2
pgp-i MDR1 CNS endothelium 2 -
occludin OCCLD CNS endothelium 3 5
p-glyc.
enhancer
MDR1 CNS endothelium 3
Duffy ARC FY Endothelium & 
erythrocytes
1 2
P-selectin PSL Most endothelia & platelets - -
Pgp3 MDR3 Epithelia outside the CNS - -
1.6 Aims of the Project
Endothelial cells in different tissues vary widely in structural phenotypes and 
function and are highly specialised in order to meet the requirements of the local 
tissue environment. For example, some of the important characteristics that
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distinguish brain- from non-brain endothelium include the presence of continuous 
tight junctions, expression of specific receptors and transporters, high expression 
of heparan sulphate glycoproteins and sialic acid on the cell surface, high 
expression of the chemokine receptor CXCR2. Tight junction proteins like 
occludin and claudin 5 determine the integrity of tight junctions and hence the 
function of the brain endothelium. Occludin is an integral membrane protein at the 
tight junction and is restricted to endothelium in the CNS. It is however, present in 
other cell types such as gut epithelium where continuous tight junctions are seen. 
The molecular mechanisms regulating differential gene expression in brain and 
non-brain endothelia are not known. The constituents of the tissue environment 
such as astrocytes, pericytes and soluble mediators have been known to contribute 
to the development of the barrier function in the brain. Studies have identified 
growth factors, transcription factors and signalling pathways that are responsible 
for the initiation of the endothelial phenotype in various tissues. It is possible 
these factors could be expressed in the endothelial cells and maintaining the 
expression of these factors can be responsible for the terminal phenotype. The 
general aim of this work is to identify transcriptional mechanisms involved in the 
regulation of brain endothelial specific proteins which could shed light on 
terminal differentiation of endothelium. We have analysed the regulation of 
occludin in this present study. Unlike other studies which have examined cues 
from cells in the native tissue, this study will aim to investigate the possibility that 
terminal differentiation in the brain is undertaken by transcription factors which 
are either activated only in brain endothelium or interact in a specific manner 
absent in non-brain endothelium.
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The specific aims of the present study are:
1. Analyse activity of the occludin promoter in brain and non-brain 
endothelial cells
Full length and promoter fragments cloned upstream of GFP sequence in a 
promoter deficient vector on transient transfection in brain (hCMEC/D3) and non­
brain (lung) cells will provide data on any differences in promoter activity.
2. Analyse transcription factor binding profiles in vitro and in vivo
Labelled promoter fragments will be analysed for binding of transcription factors 
present in nuclear preparations of brain and non-brain endothelial cells. Any 
difference in profiles of transcription factors leads to possible candidates. 
Immunoprecipitation of endogenous promoter in the different endothelial cells 
with antibodies to the possible transcription factors will provide information of 
transcription factors bound in a ‘living’ state.
3. Analyse expression and localisation of relevant transcription factors in 
brain and non-brain endothelium and investigate for any possible 
interactions between the target transcription factors.
4. Generation of reporter vectors containing occludin promoter fragments 
with deletions in specific transcription factor binding motifs and determine 
activity in brain endothelium.
5. Inhibition of target transcription factor(s) and investigate changes in 
expression of the occludin protein in brain endothelium.
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Why is the study of transcriptional regulation in endothelia important?
1. Phenotype of endothelium is dictated in large part by space and time specific 
differences in gene expression
For e.g. glomerular endothelium in the kidney and endothelium of the blood brain 
barrier (BBB)
This provides important insights into the molecular basis o f vascular diversity
2. Transcriptional networks act as signal transducers in the endothelium coupling 
input to output. For example, ECs in the blood brain barrier receive input from 
surrounding astrocytes
This helps understand the link between microenvironment and cellular phenotype
3. Each Transcription Factor (TF) is coupled to multiple upstream signals and 
downstream target genes
Characterisation of these small ‘hubs’ of activity in the context of network 
topology will provide:
I. Important mechanistic information
II. Foundation for targeted therapy
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Chapter 2
General Materials and Methods
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2 General Materials and Methods
2.1 Primary Antibodies
Table 2-1 Primary Antibodies
Antibody Species 
of Ab
Immunogen Clone
/PAD*
Applica
tion
Dilution Company
Claudin 5 rabbit peptide from C- 
terminal region 
of claudin 5 
protein
Z43.JK WB, 
FACS, 
IHC, IF
1:500
1:50
Zymed / 
Invitrogen
Claudin 5 rabbit 167-218 aa’s of 
CLD5 protein
H-52 WB,
FACS,
IF
1:500
1:100
Santa Cruz
Occludin rabbit peptide from C- 
terminal region 
of occludin 
protein
ZMD.46
7
WB 
IF, IHC
1:500
1:100
Zymed/
Invitrogen
Occludin mouse fusion protein 
containing the 
C-terminal 
region of 
occludin
Z-T22 WB
IF, IHC, 
FACS
1:500
1:50
1:100
Zymed/
Invitrogen
ZOl rabbit recombinant 
ZOl containing 
a region that 
lies N-terminal 
to the a-m otif
Z-Rl IF 1:100 Zymed/
Invitrogen
TR
(Transfer
rin
receptor)
mouse Rec. human
transferrin
receptor
H68.4 WB
FACS
1:500
1:100
Zymed
Von
Willebran 
d factor 
(vWF)
rabbit aa’s 2514-281 
mapping at the 
C-terminus of 
vWF
H-300 FACS 1:100 Santa Cruz
YY1 rabbit aa’s 1-414 
representing 
full-length YY1
H-414 WB,
IF, IHC, 
IP
1:500
1:100
2^g
Santa Cruz
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* PAD: Polyclonal antibody designation
2.2 Cell Culture
All cell lines were human in origin. hCMEC/D3 (D3) (Weksler, Subileau et al. 
2005), a brain microvascular endothelial cell line, bone marrow endothelial cell 
line (BMEC), primary lung (LMVEC) and primary human brain endothelial cells 
(HBMEC) were used in all experiments.
hCMEC/D3 cells were grown on collagen (Sigma, Cat No: C8919) coated flasks 
or culture plates and maintained in EGM-2 MV medium (Cat No: CC-3202, 
Lonza Biologies, Cambridge, UK) supplemented with 2.5% foetal bovine serum, 
and a quarter of the supplied growth factors-vascular endothelial growth factor 
(VEGF), epidermal growth factor (EGF), insulin-like growth factor I (IGF-I), 
human fibroblastic growth factor (FGF) but fully complemented with the supplied 
quantities of hydrocortisone, ascorbic acid and gentamicin sulphate.
Lung (LMVEC) and dermal (DMVEC) endothelial cells were purchased from 
Clonetics/Biowhittaker (Wokingham, UK) and grown in fully supplemented 
EGM-2 MV medium according to the manufacturer’s recommendations.
The transformed human BMEC line was donated by Babette Weksler. Cells were 
maintained in DMEM (Cat No: 31885-023, Invitrogen) with low glucose 
(1 mg/ml), 2 mM glutamine, 100 U/ml penicillin, and 100 pg/ml streptomycin and 
2.5 pg/ml amphotericin-B and with 10% FCS.
hCMEC/D3 cells were used between passages 21 and 30; lung and dermal
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endothelial cells were used at passages between 3 and 7; bone marrow endothelial 
cells at passages 22-28 and primary human brain endothelial cells at passages 1-4. 
The different endothelial cells were passaged when cultures reached 60-70% 
confluency. The monolayers were washed with HBSS without Ca2+ and Mg2+ (Cat 
No: H6648, Sigma Aldrich) and subjected to 0.25% trypsin-EDTA (Cat No: 
25200-072, Invitrogen) solution for 5 min at 37°C after which the cells were 
centrifuged in excess medium and plated as required. For all the analyses 
described in the methods, confluent monolayers were rested in EGM-2 MV 
medium without growth factors but with serum, antibiotics and hydrocortisone for 
48 hours before assay.
2.3 Isolation of Primary Brain Endothelial Cells (HBEC) 
from Human Donor Tissue
Buffers
Buffer A: HBSS without Ca2+ and Mg2+ supplemented with 10 mM Hepes (Sigma 
Aldrich, Cat No: 4034)
Collagenase/Dispase (C/D) solution: lyophilised powder (obtained from Roche 
Diagnostics Ltd, Cat No: 10269638001) was reconstituted in HBSS without Ca2+ 
and Mg2+ to a final concentration of 1 mg/ml and filter sterilised through a 0.22 
pm (Schleicher & Schuell) membrane filter and 20 ml aliquots were stored at - 
20°C. The final concentration of the enzymes was, collagenase: 0.1 U/ml and 
dispase: 0.8 U/ml.
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DNase I solution: 2000 U of the lyophilised enzyme (obtained from Roche 
Diagnostics Ltd, Cat no: 11284932001) was dissolved in 1 ml of sterile HBSS
*74 - 9 +  •without Ca and Mg to achieve a final concentration of 20 U/ml. The solution 
was aliquoted into equal volumes of 200 pi and stored at -20°C. One aliquot was 
used to reconstitute 20 ml of collagenase/dispase solution.
TLCK (Na-Tosvl-L-lysine chloromethyl ketone hydrochloride) solution: (Sigma 
Aldrich, Cat No: T7254). Final concentration of 0.147 mg/ml was achieved by 
dissolving 2.94 mg of TLCK in 20 ml of sterile HBSS without Ca2+ and Mg2+ and 
filter sterilised through a 0.22 pm membrane filter and 1 ml aliquots were stored 
at -20°C. 20 pi was added to 20 ml of collagenase/dispase solution just before use.
24% BSA: 5 gm of bovine serum albumin powder (Sigma Aldrich, Cat no: 
A4161) was dissolved in 20 ml of buffer A and filter sterilised serially using a 0.8 
pm and then a 0.22 pm membrane filter and stored at 4°C.
Percoll® gradient: 4.5 ml of Percoll® (Sigma Aldrich, Cat no: P4937) was added 
to 500 pi of lOx HBSS without Ca2+ and Mg2+ and 5 ml of lx  HBSS without Ca2+ 
and Mg2+ in DuPont tubes and centrifuged at 16500 rpm for 1 hour at 4°C.
Post mortem tissue obtained from MS patients (MS society, Charing Cross 
Hospital, London, UK) or from tissue obtained from temporal lobectomy 
resections for epilepsy at the Kings College hospital (London, UK) was used for 
the isolation of primary brain endothelial cells. The work was approved by the 
ethics committee at KCH.
Primary HBEC were isolated according to the method developed by Hughes and
81
Lantos in 1986 with slight modifications. After removal of the meninges, the 
tissue was cut into smaller pieces with a scalpel and centrifuged at 1500 rpm for 5 
min in buffer A. The tissue was resuspended in 15 ml of the collagenase/dispase 
solution and incubated for 1 hour at 37°C with occasional shaking. The 
suspension was then triturated with a Pasteur pipette until all the grey matter was 
dispersed and centrifuged at 1500 rpm for 5 min and the supernatant discarded. 
The digested tissue was resuspended in 17 ml of 25% BSA, mixed gently and 
centrifuged at 2900 rpm for 15 min. After removal of the myelin and the top 
layers, the capillary pellet was washed in buffer A and incubated with 5 ml of the 
enzyme digest solution for 2 hours at 37°C with occasional shaking.
The digested capillary pellet was washed and resuspended in 2 ml of buffer A and 
gently layered over a pre-spun 50% isotonic percoll gradient and subjected to 
density gradient centrifugation at 2900 rpm for 10 min to separate capillary 
fragments from single cells surrounding vessels and erythrocytes. The middle 
fraction of the gradient containing endothelial cells was gently aspirated and 
added to excess of buffer A. After centrifugation to wash off the percoll, 
microvessel fragments were plated on collagen coated flasks or cover slips with 
EGM-2 MV medium supplemented with 2 pg/ml puromycin (Sigma, Cat No: 
P8833) and 100 U/ml of Penicillin G and 100 pg/ml Streptomycin. Puromycin 
selectively eliminates cells that do not express p-glycoprotein (Weksler, Subileau 
et al. 2005). In addition, it is also cytotoxic to cells like astrocytes that express the 
protein albeit at a lower level than seen in endothelial cells. Medium was changed 
every 48 hrs and cells were grown without puromycin after the first passage.
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2.4 Immunofluorescence
Cells were grown to confluence on collagen-coated cover slips and rested for 2 
days in medium complemented with serum but lacking growth factors. The 
monolayers were washed with PBS for 15 minutes with three changes of the 
buffer. For staining for tight junction proteins, methanol was added along the 
walls of the culture plate containing the cover slips and the plate was quickly 
transferred to -20°C for 10 min. Claudin 5 (Z43.JK), Occludin (ZMD.467) and 
ZOl (Z-Rl) were used in the immunostaining. Methanol was gently aspirated 
from the wells with chilled PBS being added simultaneously and this step was 
repeated three times to rid of residual methanol. The cover slips were then 
incubated with blocking buffer (0.5% BSA in PBS) for 15 min at RT. Cells were 
then incubated with the primary antibody for 2 hours at RT and washed in PBS 
for 15 min with three changes of the buffer. This was followed by incubation with 
rabbit anti-mouse or goat anti-rabbit IgG conjugated FITC (1:250, Vector Labs, 
Burlingame, CA) for 1 hour at RT. Cells were washed in PBS for 40 min with 
four changes of buffer and the cover slips were mounted on slides with 
DakoCytomation fluorescent medium (Carpinteria, CA) and analysed by 
fluorescent microscopy.
2.5 Characterisation of endothelial cells
The different endothelia were characterised for expression of the endothelial 
marker vWF by FACS analysis (Fig. 2.1). Expression of the TJ proteins occludin 
and claudin 5 were analysed by western blot (Fig. 2.2). In addition, expression of
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the transferrin receptor and pgp-1, markers that confirm the brain endothelial 
phenotype of hCMEC/D3 cells (Weksler, Subileau et al. 2005) were also 
investigated. Localisation of the TJ proteins occludin, claudin 5 and ZOl was 
observed by immunofluorescence microscopy in hCMEC/D3 cells (Fig. 2.3). 
Results shown are representative of three experiments.
The TJ protein occludin was detected migrating at 65 kDa and is strongly 
expressed by hCMEC/D3 cells, faintly expressed in lung endothelial cells and was 
absent in dermal endothelium (Fig. 2.2). The transferrin receptor was detected as a 
band migrating at 95 kDa; P-glycoprotein-1 was detected at 170 kDa, claudin-5 at 
20-22 kDa (Fig. 2.2).
Localisation of the TJ proteins occludin, claudin 5 and ZOl was observed by 
immunofluorescence microscopy in hCMEC/D3 cells (Fig. 2.3). The proteins 
were localised to the tight junctions. However, ZOl and occludin were also seen 
in the nucleus.
Localization of occludin at tight junctions is controlled by posttranslational 
modifications such as phosphorylation of the protein and also by the 
reorganization of the actin filaments during cell division (Sakakibara, Furuse et al. 
1997, Kojima, Sawada et al. 1998). Serine/threonine phosphorylated form of 
occludin is selectively concentrated at the TJ whereas phosphorylation on tyrosine 
residues leads to its disassociation from the TJ complex. In hepatocytes that 
localization of occludin and actin simultaneously changed upon cell proliferation 
and there was a decrease in immunoreactivity of occludin at cell-cell contacts and 
increased cytoplasmic and nuclear localization (Kojima, Sawada et al. 1998). In
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bovine aortic endothelial cells, occludin expression has been shown in the nucleus 
but when these cells are subjected to cyclic strain, the protein localizes to cell 
borders (Collins, Cummins et al. 2006). However, the function of occludin in the 
nucleus is not known. It has been suggested that occludin may interact with ZOl 
to modulate expression of other TJ proteins but there is no supporting evidence.
It has been documented that ZOl interacts with ZONAB, a TF homologous to Y- 
box proteins (Baida and Matter 2000). The two proteins functionally interact in 
the nucleus to modulate the expression of the erbB-2 proto-oncogene, indicating a 
role for regulation of gene expression for TJ proteins (Baida, Garrett et al. 2003).
All the endothelial cells expressed the vWF marker the expression of which is 
restricted to endothelial cells and cells of megakaryocytic origin. The von 
Willebrand factor mediates adhesion of platelets to endothelial cells at site of 
injury.
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Figure 2-1 Expression of the Endothelial Marker vWF in Different 
Endothelia
hCMEC/D3 LMVEC
If
i
m
mw
 , s ..
*Sr *1
DMVEC BMEC
W
hCMEC/D3, lung (LMVEC), dermal (DMVEC) and bone marrow (BMEC) cells 
were grown to confluence and immunostained for expression of the endothelial 
marker vWF (grey histograms). Black histograms indicate cells stained with the 
control antibody (RblgG)
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Figure 2-2 Expression of the TJ Protein occludin in Different Endothelia 
Analysed by WBA
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Whole cell lysates (20jag) from hCMEC/D3 (B), dermal (D) or lung (L) 
endothelial cells were separated on 10% SDS-PAGE gels. Blots were probed for 
transferrin receptor (TFR), p-glycoprotein-1 (pgp-1), occludin and claudin-5. 
Arrows indicate the expected Mr of each of these markers. Blots were stripped 
and reprobed for actin or Akt ascontrols for equal protein loading.
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Figure 2-3 Localisation of occludin, claudin 5 and ZO l at the TJ in
hCMEC/D3
RblgG-FITC claudin 5-FITC
occludin-FITC Z01-FITC
hCMEC/D3 cells were grown to confluence on coverslips and rested for 48 hours. 
Following fixation with methanol, the cells were immunostained for expression of 
the TJ proteins-occludin, claudin 5 and ZOl or control antibody (RblgG) and 
analysed by fluorescent microscopy.
Chapter 3
Activity of human occludin promoter
3 Activity of occludin promoter in vitro
3.1 Introduction
The activity of the occludin promoter has been determined in the human intestinal 
cell line, HT-29/B6 (Mankertz, Tavalali et al. 2000). The authors concluded that 
region of the promoter spanning nucleotides 1402-1853 (451 bp) is sufficient for 
the promoter activity. Further, the work also identified the minimal promoter 
which comprises of 208 bp and extends from 1573-1853. Inversion of these 
sequences abrogated activity of the promoter and hence luciferase activity leading 
to the conclusion that the promoter sequence is unidirectional.
We hypothesised that activity of the full length and specific regions of the 
occludin promoter may not be similar between cells of epithelial and endothelial 
origin. To investigate the regions of the promoter essential for function in brain 
endothelial cells, we constructed a series of constructs in which different lengths 
of the occludin promoter were ligated into the reporter vector, pGlowTOPO®, 
which is a promoter deficient GFP expression vector. This vector can be used to 
analyse in addition to other functions, cell-specific promoter function and 
deletions within a promoter. CMV promoter cloned similarly served as a control 
for transfection efficiency. The reporter vector with no added sequence was used 
as a negative control. The longest construct we examined was the full length 
promoter (occ-FL). The shortest construct was F8, which contained only 120 bp 
of the promoter. Promoter activity and strength of different promoter fragments 
can be determined by assaying GFP activity after ectopic expression in cells of
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interest.
This chapter presents data on the functional analysis of the human occludin gene 
promoter in brain and non-brain endothelium.
Aims:
1. To analyse the activity of the occludin promoter in brain and non­
brain endothelial cells
2. To determine the regulation of promoter activity in brain and non­
brain endothelium
3. To determine the smallest region of the promoter sufficient for
promoter activity (minimal promoter).
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3.2 Materials and Methods
3.2.1 Generation of reporter plasmids
The full length and specific fragments of the occludin promoter were PCR 
amplified using primers described before. PCR reactions were run on 1% agarose 
gels and fragments migrating at the appropriate size were excised from the gel, 
extracted and purified (SpinPrep Gel DNA kit, Novagen) The fragments were 
ligated into pCR2.1-pGlow-TOPO® reporter vector (Invitrogen, Paisley, UK) 
following manufacturers instructions. Colonies obtained after transformation of 
TOPI OF' E Coli cells were grown in LB medium with ampicillin and the DNA 
isolated (Wizard Plus SV Mini-Prep, Promega) was screened by double digestion 
with restriction enzymes to release the insert. The DNA was further subjected to 
PCR amplification using M l3 primers and specific primers for the insert.
FRAGMENT PRIMERS
FP-RP
OCCLUDIN Ch. 5 
NT_006713
SIZE (bp)
0 1-225 19380963-1938118 225
1 1 1 !!! S l l $ s | 202-338 19381165-1938130 136
312-619 19381275-19381582 307
11! 598-864 19381561-19381827 256
842-1091 19381805-19382054 249
5 1068-1238 19382031-19382201 170
6 1218-1524 19382181-19382487 306
7 1505-1754 19382468-19382717 249
8 1733-1853 19382696-19382816 120
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3.2.2 Transient transfections
hCMEC/D3, DMVEC and LMVEC cells were transfected with occludin DNA 
promoter fragments cloned in pGlow TOPO vector using the reagent 
Lipofectamine™ 2000 as per manufacturer’s instructions (Invitrogen, Paisley, 
UK).
Briefly, 2-6 x 105 cells were plated per well on 6 well plates in 2 ml of EGM2- 
MV medium and cultured until 60% confluent. For each transfection condition, 2 
pg or 5 pg of DNA was diluted in 250 pi of basic EGM-2 medium in a sterile 
eppendorf. Similarly, 10 pi of Lipofectamine™ 2000 was diluted in 250 pi 
medium for each transfection condition and incubated for 5 min at RT. 250 pi of 
the diluted Lipofectamine™ 2000 reagent was added to each tube containing the 
diluted DNA, mixed gently by rocking and incubated for 20 min at RT to allow 
DNA-Lipofectamine™ 2000 complexes to form. The medium was aspirated and
0 4 -  9 4 -cell monolayers were washed with HBSS with Ca and Mg for 10 min with two 
changes of the buffer. The DNA-Lipofectamine™ 2000 complexes (-500pi) was 
added directly to each well of the 6 well plates containing cells and swirled so the 
reagent covered the cell monolayer and were incubated at 37°C for 6 hrs. The 
DNA-Lipofectamine™ 2000 complexes were then removed from the wells and 
EGM2-MV medium without antibiotics but with reduced serum (1%) and growth 
factors was added and cells cultured for a further 48-96 hours before analysis for 
GFP expression by FACS analysis.
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3.2.3 FACS analysis
9 -4-  9 -!-Transfected cell monolayers were washed once in HBSS without Ca and Mg 
and then detached from the matrix by incubation with 0.25% trypsin-EDTA at 
37°C for 5 min. Cells were then centrifuged at 1500 rpm for 5 min and cell pellets 
resuspended gently in excess chilled PBS and centrifuged at 1500rpm for 5 min. 
After an additional wash, cell pellets were resuspended in chilled PBS for analysis 
by FACS.
Transfection of the brain and lung microvascular endothelial cells lead to the 
generation of heterogeneity in the cell population. The forward scatter and side 
scatter profiles of cell populations that have been successfully transfected showed 
two populations of cells readily distinguished by the differences in the forward 
scatter profiles (Fig. 3.1). These two distinct populations can also be differentiated 
in the expression of the transgene. Smaller cells corresponding to lower forward 
scatter profile and gated as region R2 represent the transfected population. The 
untransfected population has been gated into region 1. Gate 3 (R3) on the FACS 
profiles represent both the R1 and the R2 gates.
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Figure 3-1 FACS Profiles of Transfected Cells
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Figure 3-3 Schematic of the Occludin Promoter showing Fragments used in
Deletion Constructs 
4 FO
^TTATGCTAAGTGAAAGAAGACAGACACAAAGGGCACATATTGTATTATCCATTCATATAAAATGTCCAG -1853 
AATAGGCAAATTAATAGAGACAGAAAGTACATTAGTGGTTGCCGAGGGATGAGGGGAGAGGGGAAATGGG -1783
4F1
GAGTGACTATTAATGGGCATGGGGTTTCTTTTGGGGGCGATTAAAATGGAATTAGATGGT(EG7GA7GG7T -1713
G7'ACAATC7~GG7GAgTATACTAAAACCCATTGAATTGTACGTGCCCTTTAAAAGGGTGAATTTTATGGTA -1643
fF 2
T GTG A ACT CT CTTTTAT AA AGT G G AAA AAA ACTCCTAA GA TCTCTTCA GAA CA TG 7~£A A A AT AC ATT AT A -1473
AAATAATAGACATGTGTTTACAAATCTGAGAGTATTAGGAAATGTTCCCTTGTTTAATTATAAACCAAAT -1503
GGAATGTTTGGAGATTTCAGTAATCTGACAGGGAACATTAAGGGGATTAACCTGACTTCCCCAGTGTTAA -1433
C AATACCAATTTAAACT G CAT CATT CAAA AACT AC AT AGT CATATT AAAG C ATTT GT AG CAAT G ACTT CC -1363
4F3
ACG A AAA A A AT ACC A ATT AA ATTAATT ACCC ATT AAAG CTGCCATCATCTGAAA TA CC7TAT ATTT AT AT -1293
F 2 i
AGT G CTTTTACTT CCT CAAGTAT G AATT GT G CCTT AAG AT CT AAT GTATGGG AG AGT CACAT CT CTAACC -1223
ATTTAATTAAAGGTAGAGAAGTGGGTGGGATTGGATAGAAATTTATTAGCAATGCTGACATTCCAGATTG -1153 
G AAC ACAAAG ACAAG CAGG AT GT AAG AAACCT A AAAGTT CG CTTT CAAT G CAG ATAGTTAAAT G CCA AG A -1083
4F4
AdTAL4A7TGCCACATCCrGGAG^ACAATTAAAAAATATGTTGAAAAACAACCAACATACATAAAAATAT -1013
ACACAGTGTTAAGTGCAGACTATGAAATTTCCCTTGGAAACAGAATCCAGATCAAGAAATAGAATACAGC -943 
ACCCGG A ACTAAG GTG CTTTTT CGTTTT CTT AAAAA AAA AA AAGT A AACCAAGTTT ATTTT G CTTTTTAA -873
f 5GTAGT GTT GTT CTTAAAG aACTACAGGTTG GTAAA CAA CGljATAAGGTG CTTTTT CT CAG G CCAAAG AG C -803
CATAATAGTTTAAATTTCCCGGTCCTCAAGAGCGGACCGGGTGGGCAGGAGAGGACCCTGGGGTGGTGAT -733
tF6
GTGTAAACTGTATTATGCACTTTAGCCTGdTGGATGGCA4CT4ACACC[rACAGTAGTTCACCCTCATTTT -663
F5t
AACCCCT CT AAGTAATT GT CT CTTATT CT G AAT CTAG AG ATT CAG AA ACAG CG CCA AT GTTTACAC ACG A -593
CTTTTG AAATTTT CCCAGG AGT CTTT CGTTG G AG CAATAC AT CTAG AT G CCTTTTT CCAG C AACAGTTTA -523
ATCAAATTCTGGAAGCAGAAAAGTGTCCTGTGAGGACGTGCCTTTCCTATCAAAGTGCTGAGTGCCTGGA -453
AF7
CCCTCTTTCCGGAGGAAACAGTCCCCTCTGGACCTICG7TCGGCCrCrCTCC4r(TAGACACCCCAAGGTTC -383
F6 +
CATCCGAAGCAGGCGGAGCACCGAACGCACCCCGGGGTGGTCAGGGACCCCCATCCGTGCTGTCCCCTAG -313
GAGCCCGCGCCTCTCCTCTGCGCCCCGCCTCTCGGGCCGCAACATCGCGCGGTTCCTTTAACAGTGCGCT -243
4F8
GGCAGGGTGTGGGAAGCAGGACCGCGTCCTCCCGCCCCCTCCCATCCGAGTntAGGTGAATTGGTCACC -173
GAGGIGAGGAGGCCGACACACCACACCTACACTCCCGCGTCCACCTCTCCCTCCCTGCTTCCTCTGGCGGA -103
F f t
GGCGGCAGG AACCGAG AGCCAGGTCCAG AGCGCI -33l
3.3 Results
3.3.1 Activity of Full Length Human Occludin Promoter in 
Brain and Non-Brain Endothelium
The three constructs containing either no sequence (black histograms, empty 
vector) or the full length promoter (Figs. 3.4 and 3.5) or the CMV promoter (Figs. 
3.6 and 3.7) were transiently transfected into hCMEC/D3 (Figs. 3.4 and 3.6) and 
LMVEC cells (Figs. 3.5 and 3.7). Cells were assayed for GFP expression 56 hours 
(hCMEC/D3) or 72 hours (LMVEC) post transfection.
Results clearly indicate the expression of GFP driven by the CMV promoter in 
hCMEC/D3 and LMVEC cells is similar though seen at different time points 
(Figs. 3.6 and 3.7). Between experiments, we encountered different transfection 
efficiency rates between the transformed and the primary cells. It was easier to 
ectopically introduce foreign DNA into hCMEC/D3 cells but the primary 
LMVECs were resistant to transfection requiring higher amounts of DNA and 
longer culture durations post transfection.
We also encountered higher cell death in the primary cell line and poor 
transfection efficiency with increasing passage number. In addition, independent 
of the cells and conditions of culture, there was batch variation with the 
lipofectamine reagent leading to different ranges of transfection efficiencies.
However, when the transfection efficiencies were similar in the two cell types, the 
activity of the CMV promoter is comparable in both brain (Fig. 3.6) and non-brain 
endothelial cells (Fig. 3.7).
However, the GFP expression mediated by the full length occludin promoter in 
lung endothelial cells (Fig. 3.5) is similar to that driven by the reporter alone 
(empty vector). In contrast the occludin promoter is active in the brain 
endothelium (Fig. 3.4). These results indicate the differential activation of 
regulatory elements mediate expression from the occludin promoter in brain and 
non-brain endothelium.
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Figure 3-4 Activity of Occludin Promoter in Brain Endothelium
—> empty vector
empty vector
Colour histograms show GFP expression mediated by the human occludin 
promoter in the transfected (green histograms, R2) and the entire population (red 
histograms, R3) which includes the untransfected population represented in gate 
R1 (red histograms). Expression driven by the empty vector is represented in 
black histograms.
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Figure 3-5 Activity of Occludin Promoter in Non-Brain Endothelium
R3
FSC-H
empty vector
empty vector
—> FL occ (R3)
> FL occ 
(R2)
<3FP
Colour histograms show GFP expression mediated by the full length occludin 
promoter in the transfected (green histograms, R2) and the entire population (red 
histograms, R3) which includes the untransfected population represented in gate 
R1 (red histograms). Expression driven by the empty vector is represented in 
black histograms.
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Figure 3-6 Activity of CMV Promoter in Brain Endothelium
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Colour histograms show GFP expression mediated by the CMV promoter in the 
transfected (green histograms, R2) and the entire population (red histograms, R3) 
which includes the untransfected population represented in gate R1 (red 
histograms). Expression driven by the empty vector is represented in black 
histograms.
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Figure 3-7 Activity of CMV Promoter in Non-Brain Endothelium
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Colour histograms show GFP expression mediated by the CMV promoter in the 
transfected (green histograms, R2) and the entire population (red histograms, R3) 
which includes the untransfected population represented in gate R1 (red 
histograms). Expression driven by the empty vector is represented in black 
histograms.
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3.3.2 Activity of human occludin promoter fragments in
brain (hCMEC/D3) and lung (LMVEC) endothelium
We also tested a series of constructs with fragments of the human occludin 
promoter in brain and non-brain endothelium. The nine constructs (Fig. 3.1) 
containing different promoter sequences and/or the empty vector (black 
histogram, empty vector) were transiently transfected into hCMEC/D3 (Figs. 
3.10-3.18, panels A-C) and LMVEC (Figs. 3.10-3.18, panels D and E) cells. Cells 
were assayed for GFP expression 56 hours (hCMEC/D3) or 72 hours (LMVEC) 
post transfection.
Results clearly indicate in hCMEC/D3 cells, the expression of GFP is driven by 
all of the occludin promoter fragments that we have used in the experiments in 
hCMEC/D3. However, the intensity of the GFP generated was different with the 
various fragments leading to the conclusion that the promoter strengths vary 
between the fragments.
However, the GFP expression mediated by the occludin promoter fragments in 
lung endothelial cells (LMVEC) is similar to that driven by the reporter alone 
(empty vector). These results indicate the differential activation of regulatory 
elements mediate expression from the occludin promoter in brain and non-brain 
endothelium.
104
Figure 3-8 Activity of occludin promoter fragments in pGLOW-Topo in
hCMEC/D3 cells
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Relative GFP activity from occludin promoter fragments. hCMEC/D3 cells were 
transfected with the reporter plasmids (FO- F8) and cultured for 56 h. GFP 
activities were measured and the relative values of each reporter was calculated 
and normalized to that of the empty vector-transfected cells to derive the median 
fluorescence of transfected cells. The values represent the mean ± SD of the 
median fluorescence values from three independent experiments for each reporter. 
The data was analysed by ANOVA (p<0.001) followed by Tukey’s multiple 
comparison test. Promoter activity from fragments FI, F2, F3 and F4 is 
significantly lower than that from the minimal promoter F8 (p<0.01 in all cases), 
but the activity of FO, F5, F6 and F7 is not significantly different from that of F8 
(p>0.05).
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Figure 3-9 Activity of Occludin Promoter Fragments in pGlow-TOPO in 
Lung Endothelial Cells
Relative GFP activity from occludin promoter fragments. Lung endothelial cells 
cells were transfected with the reporter plasmids (FO- F8) and cultured for 72 h. 
GFP activities were measured and the relative values o f each reporter was 
calculated and normalized to that of the empty vector-transfected cells to derive 
the median fluorescence of transfected cells. The values represent the mean ± SD 
of the median fluorescence values from three independent experiments for each 
reporter.
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Figure 3-10 Activity of FO in hCMEC/D3 and LMVEC cells
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Figure 3-11 Activity of F I in hCMEC/D3 and LMVEC cells
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Figure 3-12 Activity of F2 in hCMEC/D3 and LMVEC cells
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Figure 3-13 Activity of F3 in hCMEC/D3 and LMVEC cells
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Figure 3-14 Activity of F4 in hCMEC/D3 and LMVEC cells
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Figure 3-15 Activity of F5 in hCMEC/D3 and LMVEC cells
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Figure 3-16 Activity of F6 in hCMEC/D3 and LMVEC cells
R3 R2
O a UJ — :
FSC-H
[->  empty vector
I e m p t y  vector
CD CD “
F6 occ promoter (R3>F6 occ promoter (R2)
GFP GFP
D
o  -
empty vector
■n
E3o -*CMV promoter
CD "
GFP
Histogram FACS 
plots o f  transiently 
transfected 
hCMEC/D3 (B and 
C) or LMVEC (E) 
showing GFP 
expression 
(coloured
histograms) driven 
by reporter vector 
containing occludin 
promoter fragment 
F6. Control (grey 
histograms) denotes 
empty vector.
Forward and Side 
scatter profiles are 
shown in A  
(hCMEC/D3) and D 
(LMVEC). R l: 
untransfected cells, 
R2: transfected
population, R3 
represents R1+R2.
The entire
population (R3) has 
been taken to 
represent GFP 
expression in
LMVEC.
113
Figure 3-17 Activity of F7 in hCMEC/D3 and LMVEC cells
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Figure 3-18 Activity of F8 in hCMEC/D3 and LMVEC cells
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3.4 Discussion
This chapter details the characterization of the human occludin gene promoter 
activity in brain and non brain endothelial cells. Analysis of promoter regulation 
is one among the many strategies available to study regulation of genes and 
evaluation of promoter activity of tissue specific genes helps to understand 
mechanisms behind development and maintenance of differentiated phenotypes.
Full length and various fragments of the promoter were cloned upstream of GFP 
in the pGlow TOPO reporter vector that lacks promoter and enhancer sequences. 
The activity of the full length promoter and the fragments were monitored by GFP 
expression in transfected cells, expression of GFP indicating the activity. The 
present work set out to determine the effect of promoter length on activity, isolate 
minimal region showing strong promoter activity and determine differences in 
promoter activity between brain and non-brain endothelium.
The full length promoter was active in brain endothelium but not in lung 
endothelium. In hCMEC/D3 cells, its activity was comparable to that of the CMV 
promoter although variability of GFP expression was high between experiments. 
Cells transfected with plasmid DNA containing CMV promoter expressed GFP 
24-36 hours post transfection but GFP expression driven by the occludin promoter 
was not visible until 56 hours post transfection. Surprisingly, occludin promoter 
fragments FO, F5, F6 and F8 displayed activity similar to that of the full length 
promoter leading to the conclusion that there isn’t a single defined minimal 
promoter region. It appears promoter fragments which are rich in GC residues
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display maximal promoter activity. These fragments exhibited binding sites for 
YY1 and the Sp family TFs (discussed in detail in Chapter 4). Other unidentified 
binding sites for factors that activate or repress occludin expression may also 
contribute to this result.
Occludin protein expression is differentially regulated in endothelium. It is highly 
expressed in brain endothelial cells and absent in lung endothelial cells. It is 
however expressed in epithelial cells where it participates in the formation of tight 
junctions. The activity of the promoter in epithelial cells has been analysed by 
Mankertz et al using a luciferase reporter vector system (Mankertz, Tavalali et al. 
2000). The data shows the region of 1400-1853 bp to be sufficient for 
transcription as maximum promoter activity was driven by deletion constructs 
containing this region. The data in the epithelial cells also identifies a minimal 
promoter which is the region extending from 1645-1853 bp. However, our data 
does not clearly define a region in the occludin promoter that exhibits maximal 
promoter activity. Nevertheless, the present data suggests that occludin promoter 
is actively repressed in non brain endothelium-there was no ‘leakage’ of promoter 
activity. Shorter versions of the promoter were also inactive. These results 
indicate differential regulation of the protein in endothelia that contributes to 
tissue specific expression of occludin.
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Chapter 4
Analysis of Transcription Factors 
Binding to Occludin Promoter in vitro
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4 Analysis of Transcription Factors Binding 
to Occludin Promoter in vitro
4.1 Introduction
The promoter region of the human occludin gene was identified by Mankertz et al 
in 2000 (Mankertz, Tavalali et al. 2000). In addition to promoter activity there are 
several studies that have reported the modulation of the protein expression by 
transcription factors via a direct interaction with the promoter.
Expression of occludin may be regulated at the transcriptional level by a number 
of different factors, including those in the Ras pathway. In the human intestinal 
cell line HT-29/B6, the inflammatory cytokines, tumour necrosis factor-a, and 
interferon-y regulate promoter activity (Mankertz, Tavalali et al. 2000).
In an elegant study, Wang et al (2007) demonstrated that expression of oncogenic 
Raf 1 in Pa4 epithelial cells increases expression of occludin by direct interaction 
with the occludin promoter. In addition, Raf 1 also upregulates the expression of 
the well documented transcriptional repressor, slug which also interacts with an E- 
box in the occludin promoter to repress transcription (Wang, Wade et al. 2007).
Dokladny et al have shown that Caco-2 cells upregulated occludin protein in 
response to stress induced by heat. HS-induced activation of heat shock factor-1 
(HSF-1) resulted in nuclear translocation of cytosolic HSF-1 and binding to its 
target motif in the occludin promoter (Dokladny, Ye et al. 2008). In 2003, the 
transcriptional repressor snail was shown to repress transcription from the
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occludin promoter. Snail along with the related slug belong to the Snail 
superfamily of transcriptional repressors. In 293T epithelial cells, snail interacts in 
vitro with the single E-box present in the occludin promoter (Ikenouchi, Matsuda 
et al. 2003; Forster, Silwedel et al. 2005).
Brain endothelial cells treated with glucocorticoids lead to an increase of occludin 
at protein and mRNA levels by activation of the glucocorticoid receptor (GR) and 
its binding to putative glucocorticoid responsive elements in the occludin 
promoter (Forster, Silwedel et al. 2005).
However, the analyses have been restricted mainly to epithelial cell systems and 
the present chapter represents the detailed investigation of the regulation of 
occludin promoter in endothelial cells and aims to identify important transcription 
factors regulating expression via a direct or indirect interaction with the promoter.
4.2 Analysis of the Occludin Promoter for Putative TF 
Binding Sites
One of the elements in studying the process of gene regulation is investigating the 
binding of TFs to cis-elements, short sequences of DNA which influence the 
expression from the gene. TFs each recognize a family of cis-regulatory DNA 
sequences usually about 4-10 bases long with varying degrees of conservation at 
each position. There are approximately 2000 known different TFs from about 100 
species. They regulate spatial and temporal gene expression by binding to DNA 
and either activating or repressing action of an RNA polymerase. Like other 
proteins, TFs are composed of evolutionary units called domains, which belong to
1 2 0
families that can occur in many different proteins and various domain 
combinations. The precise description of TFs in DNA-binding is useful in a wide 
variety of studies. Examples include ChlP-chip assays, protein chip or yeast one- 
hybrid. This information is also valuable for studies involving gene regulation 
comparing multiple genomes or gene regulation networks. Hence it is useful to 
have a program, which can predict putative transcription factor binding sites in a 
given sequence of DNA based on binding motifs.
Transcription Element Search Software- TESS is a web based software tool for 
predicting possible transcription factor binding sites in a given DNA sequence. It 
can identify binding sites using site or consensus strings and positional weight 
matrices from the TRANSFAC, JASPAR, IMD, and the CBIL-GibbsMat 
databases. One of the disadvantages of using bioinformatics is that motif 
searching eliminates useful data when gene regulation is complex. For instance, 
the expression pattern of a particular gene may be due to a combination of 
different regulatory elements conferring different effects at different times (Xu, 
Unseren et al. 2000). In addition, a TF may be constitutively expressed but 
regulated strictly post-transcriptionally. A transcription factor's function may 
require cofactors that vary in expression temporally or spatially in a way that is 
not correlated with the TF itself. The program would not be able to predict the 
binding sites of such TFs nor would the algorithm make successful predictions 
concerning TFs that do not vary in expression.
The occludin promoter was analysed using this web program and results 
summarised (Appendix-1). Literature from groups who have published target-
1 2 1
binding sites based on mutagenesis assays was also considered. For example 
Forster et al., 2005 investigated glucocorticoid receptor (GR) binding sites in the 
human occludin promoter. According to their study, the human occludin promoter 
contains several pentamer sequences located (332-336, 361-365, 399-403, 448- 
452, 781-785, 1073-1077, 1325-1329 and 1427-1431) bp upstream of the 5' 
flanking region, which may be glucocorticoid-responsive elements (GREs) and on 
which glucocorticoids can influence gene expression.
4.3 Organisation of the Occludin Promoter
For use in EMSAs, we generated 15 individual overlapping gene segments of 
<200bp. The double stranded occludin promoter probes were divided into three 
categories based on the presence/absence of target sites for Sp family or YY1 on 
each of the probes (Fig. 4.1, Table 4.1). Eight of the probes have potential target 
sites for Sp-family transcription factors and six probes respectively for YY1. Four 
of the probes have sites for both of the TFs (Table 4.1). To determine which 
regions of the occludin promoter may interact with DNA-binding proteins in 
different endothelia, each probe was analysed by EMSA using nuclear extracts 
from hCMEC/D3 and lung endothelium. Data for each individual fragment shown 
is a representative image of data that has been repeated at least three times.
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Figure 4-1 Schematic of the occludin promoter showing fragments used in
EMSA
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4.4 Materials and Methods
4.4.1 Preparation of nuclear and cytosolic extracts from 
endothelial cell cultures
Buffers
Solution A: 10 mM Hepes (pH 7.8), 10 mM KC1, 1 mM DTT*, 2 mM MgC^, 0.1 
mM EDTA, 0.4 mM PMSF, 0.2 mM NaF, 0.2 mM Na3VC>4, 0.3 mg/ml Leupeptin 
made up in water.
Solution B: 10 ml nonidet-40 in 100 ml distilled water (final concentration is 10% 
v/v).
Solution C: 50 mM Hepes, 50 mM KC1, O.lmM DTT, 300 mM NaCl, 0.1 mM 
EDTA, 0.2 mM PMSF, 0.2 mM NaF, 0.4 mM PMSF, 0.2 mM Na3VO4,10% v/v 
Glycerol, made fresh before assay and stored on ice or at 4°C.
Fully confluent and rested cell cultures of endothelial cells in 175 cm flasks were 
used for the assay. Medium was discarded and cell monolayers were washed twice 
in chilled PBS and drained thoroughly. 1 ml of fresh PBS was added and cells 
were scraped into this volume by using a cell scraper (Cat no: 541080, Greiner). 
Cells were pipetted from the flask into a clean and sterile eppendorf tube and 
centrifuged at 1200 rpm for 10 min at 4°C. The supernatant was discarded and 
pellet was gently resuspended in 400 pi of solution A and incubated on ice for 15 
min. 25 pi of solution B was added and mixed vigorously by vortexing for 15 sec 
followed by centrifugation at 14000 rpm for 1 min. The supernatant which is the 
cytosolic extract was quickly removed into another eppendorf and left on ice. The
pellet which is the nucleic fraction was resuspended in 50 pi of solution C and 
incubated for 40 min at 4°C on a cell mixer. The tube was then centrifuged at 
14000 rpm for 10 min at 4°C and supernatant collected, the protein concentration 
estimated and aliquots stored at -80°C.
4.4.2 Assay for estimation of protein concentration
The Bio-Rad DC protein assay, a modification of the Lowry method was 
employed to determine the protein concentration of the nuclear and cytosolic 
extracts. Serial dilutions of the BSA protein standard were prepared to generate a 
range of protein concentrations: 2, 1.5, 1, 0.75, 0.5 and 0.25 mg/ml. 5 pi of the 
standards and the sample were pipetted into a 96-well flat bottomed micro titre 
plate. 25 pi of reagent S/A (20 pi of reagent S + 1 ml of reagent A) was added to 
each well followed by addition of 200 pi reagent B. Plate was read in an ELISA 
reader at 640 nm and the protein concentration of the samples was determined 
using the standard curve.
4.4.3 Generation of occludin promoter fragments for use in
EMSA analysis
Primers were designed to amplify regions of 100-150 bp in the occludin promoter. 
Occludin promoter is 1853 bp in length and was obtained from Joachim 
Mankertz, whose work had earlier established and characterised the promoter 
(Mankertz, Tavalali et al. 2000).
Primers were designed using the Custom Primers-OligoPerfect™ Designer on the
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Invitrogen (http://www.i nvitrogen.com) website following the parameters below:
1. Length of the primer ranging from 17-28 bases.
2. GC composition restricted to 50-60%.
3. Primers preferably ending (3') in a G or C, or CG or GC.
4. Melting temperatures (Tm) ranging from 55-80°C and the primers
constituting the primer pair having similar melting temperatures.
5. No internal complementarity.
6 . Restrict runs of three or more C’s or G’s at the 3'-ends of primers. 
Desalted primers were synthesised at 50 nM scale using oligonucleotide synthesis 
services at Invitrogen. Appropriate amount of deionised water was added to 
achieve a final concentration of 100 pM. Primer pairs were generated by diluting 
individual forward and reverse primers together to a final concentration of 10 pM 
in water and were stored at -20°C. A PCR reaction contained 1 pi DNA template, 
2 pi primer pairs, 1.2 pi 25 mM MgCh, 2 pi 10 x Taq buffer, and 11.5 pi water 
and 0.5 units’ high fidelity Taq polymerase. PCR was carried out by 1 step at 
94°C for 10 min, followed by 30 cycles of: 72°C 1 min, 50°C 30 sec, 72°C 30 sec, 
and finally 1 step of 72°C for 7 min. PCR products were diluted in blue/orange 
loading dye (Cat no: G1881, Promega) and were run on 1% agarose gels with 
O.lpg/ml ethidium bromide. 1 kb and 100 bp DNA ladders were loaded and 
fragments migrating at the appropriate size were excised from the gel using a 
clean scalpel into autoclaved eppendorfs. The gel slices were weighed and DNA 
extracted and purified using the SpinPrep Gel DNA kit according to 
manufacturer’s instructions (SpinPrep Gel DNA kit, Novagen). Concentration of
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the DNA was maintained at 1 |ig/}il for use in EMSA analyses. 
Table 4-2 Forward Primers
5’ATT ATG CTA AGT GAA AGA AGA CAG ACA C 3’
FP 97 5’ATC CCT CGG CAA CCA CTA ATG TAC 3’
FP 202 5’GTA CAT TAG TGG TTG CCG AGG GAT 3’
FP 312 5’CTC CTA AGA TCT CTT CAG AAC ATG TC 3’
5’GAT TAA CCT GAC TTC CCC AGT GT 3’
5’GCT GAC ATT CCA GAT TGG AAC AC 3’
m m m m : 5’ CTA TAA TTG GCA CAT CCT GGA G 3’
m m r n m i 5 ’ GAA TAC AGC ACC CGG AAC TAA G 3 ’
FP 1068 5’GCA CTA CAG GTT GGT AAA CAA CG 3’
FP 1218 5’TGC TGG ATG GCA ACT AAC AC 3’
FP 1358 5’GTT GGA GCA ATA CAT CTA GAT GCC 3’
FP 1505 5’TCG TTC GGC CTC TCT CCA T 3’
FP 1668 5’TTA ACA GTG CGC TGG CAG 3’
FP 1733 5’TCA GGT GAA TTG GTC ACC GAG 3’
Table 4-3 Reverse Primers
RP 120 5’ ATC CCT CGG CAA CCA CTA ATG TAC 3’
59 TC A CCA GAT TGT ACT ACC ATC C A 39
RP 338 5’ GAC ATG TTC TGA AGA GAT CTT AGG AG 3’
5’ACA CTG GGG AAG TCA GGT TAA TC 3’
:IK1 I  '9$m m 5’GCT GCC ATC ATC TGA AAT ACC 3’
5’GGT ATT TCA GAT GAT GGC AGC 3’
5’GTG TTC CAA TCT GGA ATG TCA GC 3’
l i i i e i i i i ® - 5’CTC CAG GAT GTG CCA ATT ATA G 3’
RP 994 5’CTT AGT TCC GGG TGC TGT ATT C 3’
RP 1091 5’CGT TGT TTA CCA ACC TGT AGT GC 3’
5’GTG TTA GTT GCC ATC CAG CA 3’
5’GGC ATC TAG ATG TAT TGC TCC AAC 3’
RP 1524 5’ATG GAG AGA GGC CGA ACG A3’
RP 1686 5’CTG CCA GCG CAC TGT TAA 3’
RP 1754 5’CTC GGT GAC CAA TTC ACC TGA 3’
RP 1853 5’GCG CTC TGG ACC TGG CTC T 3’
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4.4.4 Electrophoretic Mobility Shift Assay
The electrophoretic mobility shift assay (EMSA) of DNA-protein interactions is a 
sensitive method for the detection of sequence-specific (transcription factors) or 
non-sequence specific (histones) proteins in cellular extracts that can bind a 
particular gene segment in vitro. It can also be used to study the binding activities 
of purified or recombinant sequence-specific DNA-binding proteins. Additionally, 
it can be used to determine the affinity, abundance, association and dissociation 
rates and binding specificities of DNA binding proteins.
The basis of the EMSA assay is based on the observation that protein: DNA 
complexes migrate slower than free DNA molecules when subjected to separation 
on non-denaturing polyacrylamide or agarose gel electrophoresis. In an EMSA, a 
32P-labelled DNA fragment is incubated with a candidate transcription factor 
present in a nuclear extract or as a pure protein. The protein-DNA complexes are 
separated from free (unbound) DNA by electrophoresis through a non-denaturing 
polyacrylamide gel. The protein retards the mobility of the DNA fragments to 
which it binds; thus, the free DNA migrates faster through the gel than does the 
DNA-protein complex. Appearance of more than one or more slowly migrating 
bands indicates the presence of more than one sequence specific DNA-binding 
protein in the extract.
Buffers and reagents
150 mM STE buffer pH 8.0: 0.438 g of NaCl was dissolved in 40 ml TE buffer 
(10 mM Tris-HCl, pH 8.0, and 1 mM EDTA) and the pH was adjusted to 8.0 and
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the volume made up to 50 ml with lx TE buffer, pH 8.0.
T4 Polynucleotide Kinase and lOx buffer (Cat no: M4101) - Promega 
Nuclease free water (Cat no: PI 193)-Promega 
[y-32P]ATP Amersham (discontinued from Dec 2007)
4.4.4.1 Phosphorylation reaction and purification
Phosphorylation was carried out using 2 pi (lpg/pl) consensus oligonucleotide, 1 
pi T4 Polynucleotide Kinase (5 U/pl), 1 pi 1 Ox Buffer, 2.5pl [y-32P] ATP and 3.5 
pi nuclease-free water in a sterile micro centrifuge tube. The reaction was 
incubated at 37°C for 30 min following which lp l of 0.5 M EDTA was added to 
stop the labelling reaction. The volume was made up to 50 pi with lx  STE buffer 
and advanced to the next step.
Illustra ProbeQuant G-50 Micro Columns containing Sephadex™ (Amersham) 
were used for the removal of incorporated labelled nucleotides from the DNA 
labelling reaction. Briefly, the Sephadex G-50 resin in the column was vortexed 
for a few seconds followed by centrifugation at 735*g for 1 min to resuspend the 
resin and remove the excess storage buffer. The column was inserted into a sterile 
eppendorf and the 50 pi volume from the labelling reaction was applied to the 
centre of the resin bed. The tube was centrifuged for 2 min at 735xg and the 
eluted volume containing the purified labelled oligonucleotide was used 
immediately or stored at -20°C for subsequent assays.
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4.4.4.2 Gel preparation
30% Acrylamide/Bis Solution, 29:1 (Bio-Rad, Cat no: 161-0157) 
lOx Tris-Borate-EDTA buffer-DNase and RNase free, (Cat no: T4415)
20% APS (Sigma, Cat no: A3678)
TEMED (Sigma, Cat no: T9281)
Gels were made up with 8 ml 30% Acrylamide/Bis Solution 29:1,1.5 ml lOx TBE 
buffer, and 0.4 ml 10% APS, 0.1 ml TEMED and 50 ml water. The gels were 
allowed to set in the plates for about 2 hours at room temperature before using 
them in the experiment. Gels were pre-run at 120 V for 30 min in chilled 0.25x 
TBE buffer for equilibration. Temperature of the running apparatus was 
maintained at less than 15°C.
4.4.4.3 DNA binding reaction
Binding buffer: 8% Ficoll® (Cat no: F2637, Sigma) in 40 mM Hepes (Cat no: 
H3375, Sigma) pH 7.5.
Poly (deoxyinosinic-deoxycytidylic) acid sodium salt (Poly dI:dC): (Cat no: 
P4929, Sigma) 1 mg/ml solution were generated in water and aliquots of 50 pi 
were frozen at -20°C.
10 mM MgCE: (Cat no: M8266, Sigma) and 10 mM DTT: (Cat no: D9779, 
Sigma).
Loading dye: 250 mM Tris-Cl, pH 7.8, 0.2% bromophenol blue, 40% glycerol.
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The DNA binding reation was carried out with 10 pi binding buffer, 1 pi poly-dl: 
dC, 0.2 pi 10 mM MgCE, 0.2 pi 10 mM DTT, 1 pi labelled probe, adjusted to 20 
pi with water and 5 pg nuclear protein extract. The reaction without the labelled 
oligo was assembled in sterile, U-bottomed 96 well plate for 20 min at room 
temperature on a shaker. For super shift and cold inhibitor assays, 2 pi of antibody 
(200 pg/O.lml) or 2 pi of the ds DNA oligonucleotide (35 pMol/pl) were added 
respectively after this incubation and further incubated for 30 min at 4°C with 
gentle rocking.
Following this incubation, 1 pi of the labelled oligonucleotide was added to each 
condition and further incubated at RT for 30 min. After addition of 1 pi of the 
loading dye (250 mM Tris-Cl, pH 7.8, 0.2% bromophenol blue, 40% glycerol) 
DNA-protein complexes were loaded in pre-cooled and pre-run 6% native 
polyacrylamide (29:1) gels in 0.25x TBE for 5 hours at 120V. The gel plates were 
opened and the gel placed on a sheet of Whatman® 3 MM filter paper and then 
covered with plastic film and dried under vacuum at 70°C on a gel dryer and then 
exposed to Kodak X-Omat film (Amersham) at -80°C.
Antibodies used in super shift EMSA were purchased from Santa Cruz 
Biotechnology and 2 pg was used per reaction.
Table 4-4 Antibodies used in EMSA
Antibody Species of Immunogen (human) Clone/P AD*
GATA-1
c-Myb
Pitl
Ab
Mouse
Rabbit
Goat
120-235 aa’s of Gata-2 CG2-96
500-640 aa’s of c-Myb H-141
Peptide mapping at the N-20 
N-terminus of Pitl
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Spl
Sp3
TFIID
YY1
Rabbit
Rabbit
Rabbit
Rabbit
528-548 aa’s within an PEP2 
internal region of Spl 
Peptide mapping at the D-20 
C-terminus of Sp3
1-300 aa’s representing Sl-1 
lull length TFIID p36
aa’s 1-414 representing H-414 
full-length YY1
Consensus and mutant oligonucleotides in EMSA analysis were purchased 
from Santa Cruz Biotechnology and 2 pi was used per reaction.
Table 4-5 Cold Block Oligonucleotides
ds DNA probe 
AP-1 consensus
AP-1 mutant
CBF consensus
CBF mutant
TFIID consensus
TFIID mutant
MEF-2 consensus
MEF-2 mutant
c/EBP consensus
c/EBP mutant
Spl
Consensus
Spl
mutant
AP-2a consensus
AP-2a
Mutant
YY1 consensus
Sequence
5’ CGCTTGATGACTCAGCCGGAA 3’
3’ GCGAACTACTGAGTCGGCCTT 5’
5’ CGC TTG ATG ACT TGGCCGGAA 3'
3’ GCGAACTACTGAACCGGCCTT 5'
5’ AGACCG TACGTGATTGGTTAATCTCTT 3’
3’ TCTGGCATGCACTAACCAATTAGAGAA 5’
5 ’ AG ACCGT ACG A A AT ACGGG A AT CTCTT 3 ’
3’ TCTGGCATGCTT TATGCCCTTAGAGAA 5'
5’ GCAGAGCATATAAAATGAGGTAGGA 3’
3’ CGTCTCGTATATTTTACTCCATCCT 5’
5’ GCGGAGCAGCTAAAATGAGGTAGGA 3'
3’ CGTCTCGTCGATTTTACTCCATCCT 5‘
5’ GATCGCTCTAAAAATAACCCT GTCG 3’
3’ CTAGCGAGATTTTTATTGGGACAGA 5’
5’ GATCGCTGTAAACATAACCCT GTCG 3'
3’ CTAGCGACATTTGTATTGGGACAG C 5’
5’ TGCAGATTGCGCAATCTGCA 3’
3’ ACGTCTAACGCG TTAGACGT 5’
5’ TGCAG AG ACTAGTCTCTGCA 3’
3’ ACGTCTCTGATCAGAGACGT 5’
5* ATTCGATCGGGGCGGGGCGAGC 3’
3’ TAAGCTAGCCCCGCCCCGCTCG 5'
5’ ATTCGATCGGTTCGGGGCGAGC 3'
3' TAAGCTAGCCAAGCCCCGCTCG 5’
5' GATCGAACTGACCGCCCGCGGCCCGT 3'
3' CTAGCTTGACTGGCGGGCGCCGGGCA 5’
5' GATCGAACTGACCGCTTGCGGCCCGT 3’
3' CTAGCTTGACTGGCGAACGCCGGGCA 5'
5’ CGC TCC CCG GCC ATC TTG GCG GCT GGT 3’ 
3’ GCG AGG GGC CGG TAG AAC CGC CGA CCA 5’
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YY1 mutant
GR consensus
GR mutant
Ets-1/PEA3
consensus
Ets-1/PEA3
mutant
c-Myb consensus
c-Myb
mutant
CDP
consensus 
GATA consensus
GATA
mutant
IRF-1 consensus
MEF-2
consensus
NF-1
consensus
NF-1
mutant
NFkB consensus
NFAT-c
consensus
5 ’ CGCTCCGCGATTATCTTGGCGGCTGGT 3 ’
3’ GCGAGGCGCTAATAGAACCGCCGACCA 5’
5 ’G ACCCTAG AGG ATCTGTAC AGG ATGTTCTAGAT35 
3 ’CTGGG ATCTCCTAG AC ATGTCCTAC A AG ATCTA 5 * 
5 ’ G ACCCTAG AGG ATCTC A AC AGG ATC ATCTAG AT3 ’ 
3’CTGGGATCTCCTAGAGTTGTCCTAGTAGATCTA 
5’ GATCTCGAGCAGGAAGTTCGA 3'
3’ CTAGAGCTCGTCCTTCAAGCT 5’
5’ GATCTCGAGCAAGAAGTTCGA 3’
3’ CTAGAGCTCGTTCTTCAAGCT 5’
5' T AC AGGC AT A ACGGTTCCGT AGTG A 3'
3' ATGTCCGTATTGCCAAGGCATCACT 5'
5' TACAGGCATATCGGTTCCGTAGTGA 3’
3' ATGTCCGTAT AGCCA AGGC AT C ACT 5'
5' ACCCAATGATTATTAGCCAAT TTCTGA 3'
3’ TGGGTTACTAATAATCGG TTA A AG ACT 5'
5’ CACTTGATAACAGAAAGTGATAACTCT 3'
3’ GTGAACTATTGTCT TTCACTATTGAGA 5’
5’ C ACTT GAT A AC AG A A AGTCTT A ACTCT 3’
3' GTGAACTATTGTCTTTCAGAATTGAGA 5’
5’ GGAAGCGAAAATGAAATTGAC T 3’
3' CCTTCGCTTTTACTT TAACTGA 5’
5' GATCGCTCTAAAAATAACCCTGTCG 3’
3' CTAGCGAGATTT TTATTGGGACAGC 5’
5, TTXXGGATTGAAGCCAATAXGAXAA 3- 
3’ A A A ACCT A ACTTCGGTT AT ACT ATT 5’
5' TTTTGGATTGAATAAAATATGATAA 3’
3’ A A A ACCT A ACTT ATTTTAT ACT ATT 5'
5’ AGTTGAGGGGACTTTCCCAGGC 3'
3’ TCAACTCCCCTGAAAGGGTCCG 5’
5* CGCCCAAAGAGGAAAATTTGTTTCATA 3’
3' GCGGGT TTCTCCTTTT A A ACA A AG TAT 5’
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4.5 Results
4.5.1 Promoter Probes with Sp Target Sites
In this section, I shall discuss the interaction of occludin promoter probes 
containing putative target sites for the Sp family with nuclear protein from brain 
endothelial cells (hCMEC/D3) and/or lung endothelial cells (LMVEC, non-brain 
endothelium).
Fragment Position on Chr5 
NT 006713
Size (bp) *Target sites for Spl
6.2 19382321-19382487 166 X
7.1 19382468-19382649 181 X
8 19382696-19382816 120 X
4.5.2 Fragment 6.2
1382 1398 1424 1442 1447 1475
NF-AT AP-1 GR N H  GATA1 NF 1
NF-AT
Fragment 6.2 spans the region 1358-1524 in the occludin promoter and includes 
binding sites for NF-AT (1382, 1442), AP-1 (1398), NF-1 (1442, 1475), GR 
(1424) GATA (1447) and Sp family (1491). There is an overlap of nineteen base 
pairs between probes F6.2 and F7.1 owing to the particular nature the fragments 
were amplified and includes the transcription start site as published by Van Itallie 
and Anderson (Van Itallie and Anderson 1997) but this short stretch does not 
exhibit any potential transcription factor sites.
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Activity of fragment 6.2 in brain endothelium (hCMEC/D3)
The probe interacted with nuclear protein from hCMEC/D3 cells to form four 
DNA-protein complexes (Fig 4.2). The highest mobility complex was specific for 
Sp family as it was blocked in the presence of 100 molar excess of unlabelled Spl 
competitor (lane 9) and the complex was shifted in the presence of an antibody to 
Sp3 (lane 4) but not Spl (lane 3) hence confirming the preferential binding of Sp3 
and not Spl to this probe in the brain endothelial cells.
Table 4-6 Summary of F6.2 Activity in Brain Endothelium (hCMEC/D3) 
Shifted band Spl Sp3 GATA NF-1
6.2.1
6.2.3 - ^
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Figure 4-2 Activity of Fragment 6.2 in Brain Endothelium
Labelled oHgoF6.2
hCMEC/D3
Nuclear Extract - ---------  - ---------------
GATA ab - - + - - ........................
Sp1 ab - - - + - - - - - - -
Sp3 ab - - - - + - ...................
GATAoligo ................. -
Sp oligo ................. -
NF1 oligo................. ................. - - - - + .
NF1 mut oligo ................. ..............................
1 2 3  4 5  6 7 8  9 1011
6 . 2.2 -»
Nuclear protein bound 
to 32P labelled probe 
F6.2 (lanes 2, 7) was 
challenged with 
antibodies or 
consensus 
oligonucleotides to 
GATA1 (lane 3 and 
8), Spl (lane 4 and 9), 
Sp3 (lane 5 and 9).
Sp3 antibody (lane 5) 
shifted the highest 
mobility complex and 
this was also blocked 
in the presence of a 
competitor (lane 9). 
Wild type (lane 10) 
and mutant 
competitors (lane 11) 
to the factor NF1 did 
not affect the DNA- 
protein complexes.
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4.5.3 Fragment 7.1
Fragment 7.1 spans the occludin promoter region between 1505 and 1686 
(including the first and last base). This region includes target binding sites for the 
TF, AP2 at 1590 and 1614; Sp family at 1551, 1572, 1632 and 1675; a single 
binding site for the TFs, GR, NF-AT, c-Ets and c-Myb site at 1601, 1610, 1663 
and 1669 respectively.
The transcriptional role of API has been well established for cytokine gene 
promoters. Functional association for the TFs, API and Spl has been reported 
from the characterisation of the human GMCF gene promoter (Ye, Zhang et al. 
1996). API is a nuclear localised transcription factor that comprises gene products 
of the Fos and Jun families and binds to 5 '-TGA (C/G) TCA-3' target sequence 
(Bohmann, Keller et al. 1987). API activity requires co-operation from the NF- 
AT or Elf group of TFs (Macian, Lopez-Rodriguez et al. 2001).
Ets transcription factors comprise about 20 members and are characterised by a 
conserved 85 amino acid ETS domain. Members bind to the consensus DNA 
sequence GGA (A/T) and binding is affected by presence of flanking sequences 
(Seth and Watson 2005).
c-Myb is a nuclear localised oncogenic TF that is mainly expressed in cells of 
hematopoietic origin. It recognises the target motif 5'-VHYAACYR-3’ (where V 
= A, C, or G, and H = A, C, or T). Ets-12 and CBF/PEBP2/AML1 are two 
examples of TFs associating with c-Myb to enhance transcription from target 
promoters (Gonda 1998).
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Activity of F7.1 in brain endothelium (hCMEC/D3)
Probe F7.1 interacted with nuclear proteins from hCMEC/D3 cells to generate one 
low mobility and one high mobility complex of which the latter was abolished by 
addition of competitor to Spl (Fig 4.3, lane 7). Unlike the other promoter probes 
where Sp3 successfully competed out Spl for the binding sites, the converse was 
true as the DNA-protein complex was retarded by addition of an antibody to Spl 
(lane 3) and not Sp3 (lane 4).
Lung endothelial nuclear extracts did not generate any nuclear protein-DNA 
complexes with probe 7.1.
Table 4-7 Summary of Probe 7.1 in Brain Endothelium (hCMEC/D3)
Shifted band Spl Sp3 c-Myb
7.1.1 - - -
7.1.2 ^ - -
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Figure 4-3 Activity of Fragment 7.1 in Brain Endothelium
labelled oligo F7.1
Nuclear Extract 
Sp1 ab 
Sp3 ab 
Sp cold 
c-Myb ab 
Ets ds oligo  
NF-1 ds oligo 
NF1 mut ds oligo  
GR
 hCMEC/D3
—  +  -  -  - .....................................
 + .................................
 + ...................
 +  -
  +
1 2 3 4 5 6 7 8 9101112
+** £ i r*' . A
F7.1.1 ->
F7.1.2
EMSA showing the 
characterisation of 
complexes (lanes 2, 6; 
indicated by arrows) 
formed between 32P 
labelled probe F7.1 
and hCMEC/D3 
nuclear extracts. 
Addition of an 
antibody directed 
towards Spl (lane 3) 
or an unlabelled Spl 
consensus probe (lane 
7) super shifted 
and/or retarded one of 
the complexes. 
Antibodies against 
Sp3 (lane 4), c-Myb 
(lane 8) or wild type 
(lane 10) and mutant 
competitors (lane 11) 
to the factor NF1 
have no effect on 
formation of the 
complexes.
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4.5.4 Fragment 8
173
^  oo oo oo
H ---- 1----0 -i—'8=3
AP-1 GR Sp1 Sp1 Sp1 NF-1 GR
Fragment 8 spans the nucleotide bases 1733-1853 in the occludin promoter. Using 
HT29/B6, a subclone of the human intestinal cell line HT-29, Mankertz et al 
(Mankertz, Tavalali et al. 2000) determined the minimal promoter activity of the 
occludin promoter resides in 208 bp upstream of the putative transcription start 
site at 1781 bp previously published by Ando-Akatsuka et al (Ando-Akatsuka, 
Saitou et al. 1996). Putative transcription factors with target binding sites on this 
fragment include the Sp family, GR and members of the CCAAT binding proteins 
as illustrated in the figure above. These transcription factors have been discussed 
in chapter 1.
Activity of fragment 8 in brain endothelium (HCMEC/D3)
Four nuclear protein-DNA complexes, 8.1, 8.2, 8.3 and 8.4 were seen in the 
presence of extracts from hCMEC/D3 (Fig. 4.4 and 4.5, lane 2). The subunit 
composition of the complexes was investigated using competitor probes and/or 
antibodies directed against transcription factors predicted to have binding sites on 
the probe.
In the presence of a cold competitor to Spl (Fig. 4.4, lane 18) which as previously 
described is also specific to Sp3 due to redundancy in binding targets between Sp
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family members, the formation of complexes, 8 .1, 8.2 and 8.3 was inhibited and 
in the presence of an antibody directed against Sp3 (Fig. 4.4, lane 4), the 
complexes, 8.1, 8.2, 8.4 were retarded. In an unexpected observation we have 
observed that protein binding to this region is blocked by 100-molar fold excess 
of competitor for NFkB and AP2-a (Fig. 4.5, lanes 26 and 30), in which 
formation of nuclear protein-DNA complexes 8.1 and 8.2 are blocked. Since 
NFkB consensus oligonucleotide blocks the same complexes as does the Spl 
competitor, it is likely that the transcription factor interacts with the Sp family. 
Whether this is a functional interaction is not known. Due to this observation we 
performed EMSA employing cold probes and antibodies against transcription 
factors that do not have putative target sites on the probe (lanes 5-9; 11-25; 27-29 
and 31). With the exception of the AP-2a transcription factor, none of the other 
antibodies and competitors inhibited the formation or retarded the nuclear protein- 
DNA complexes.
Activity o f fragment 8 in lung microvascular endothelium (LMVEC)
The F8 probe interacted with nuclear extracts from lung endothelial cells to form a 
single DNA-protein complex (Fig 4.6, lane 2) which was not super-shifted by 
antibodies to Spl (lane 3) or Sp3 (lane 4). Notably, the complexes formed by 
brain and non-brain endothelium are totally distinct, implying that lung 
endothelium lacks the active Sp3 complex, even though Sp3 is present in these 
cells, albeit at a lower level than in brain endothelium (Holloway, Sade et al. 
2007). Furthermore, this complex is blocked in the presence of all of the 
unlabelled cold competitors (lanes 5-8) leading to the observation that the DNA-
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protein complex is not sequence specific.
Table 4-8 Activity of F8 in Brain Endothelium (hCMEC/D3)
Shifted Band Spl Sp3 NFkB AP2-cx
F8.1 S S S
F8.2 ysi;iiiiiiBiisiiiSiBi: l!IIS !!!!|||illl
F8.3 - s -
F8.4
Table 4-9 Activity of F8 in Non-Brain Endothelium (LMVEC)
Shifted Band Spl Sp3 NFkB AP2-a
F8.I
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Figure 4-4 Activity of Fragment 8 in Brain Endothelium
Labelled Oligo F8
Nuclear Extract ------------------ hCMEC/D3------------------------
Sp1 ab  - .......................... -
Sp3 ab - - - + ---------     -
YY1 ab - - - - + .............................................................
TFIID ab  + ...........................................................
GATAab  + ......................................................
P itlab .................................................... + ..................................................
c-Myb ab  - - + .......................  - -
Ets ds oligo    +  - ...........................
NF1 ds oligo - - -   - + ............................
YY1 ds oligo----------- ------------------------------ ------------------------------
NFAT-c ds oligo - - .................. - ........................ + - ------------
NF1 ds oligo m ut  .................. - ................................+ - - - .
YY1 ds oligo m ut  .................. - .............................. -  - +  - -
Sp1 ds oligo - - - - - -  - - ..........................
CBF ds oligo     +
1 2 3 4 5 6 7  8 9 1011 1213141516171819
8.1
8 . 2*
8.3-
8 .4 -
A
i
144
)
Figure 4-5 Activity of Fragment 8 in Brain Endothelium
Labelled oligo F8
Li , n _  hCMEC/D3
Nuclear E xtract------------------------------
Pitl ds oligo + ..........................................................
SREds oligo - + ....................................................
Sp ds m u t oligo - - + .............................................
GATA ds oligo - - - + .......................................
C reb ds oligo - - - - + ...................................
TFIID ds o l i g o .........................+ ................................
NFkB oligo ...............................+ .........................
CDP ds oligo ......................................+  - -  - -
IR F d so ig o  ........................................... +  - - -
c-Myb ds o l i g o ....................................... - - +  - -
A P2-a ds o l i g o .............................  +  -
AP1 ds oligo .............................................................+
20 21 22 23 24 25 26 2728 29 30 31
Figs. 4.4 and 4.5: EMSA analyses of complexes (8.1, 8.2, 8.3 and 8^4) formed 
with hCMEC/D3 (lanes 2-9 and 11-31) nuclear extracts and the promoter probe 
F8. Lanes 1 and 10 represent mobility of the probe in the absence of nuclear 
protein. The composition of the complexes was investigated using antibodies 
directed against transcription factors predicted to bind to the F8 sequence. 
Addition of an antibody to Sp3 (lane 4) or a competitor to Spl (lane 18) blocked 
the formation of all the nuclear protein DNA complexes in hCMEC/D3 cells. 
Addition of a consensus mutant Sp oligonucleotide reversed the loss of the 
complexes. Competitors to the transcription factors NFkB (lane 26) and AP2-a 
(lane 30) also blocked the formation of the nuclear protein-DNA complexes.
Antibodies to Spl (lane 4), YY1 (lane 5), TFIID (lane 6), GATA (lane 7), Pitl 
(lane 8), c-Myb (lane 8) or presence of consensus or mutant competitors-YYl (13, 
16), TFIID (25), GATA (lane 23), Pitl (lane 20), c-Myb (lane 29), Ets (lane 11), 
NF1 (lanes 12 ,15), NFAT-c (lane 14), CBF (lane 19), SRE (lane 21), Creb (lane 
24), CDP (lane 27), IRF (28) and AP-1 (lane 31) did not affect the formation of 
the complexes.
Fig. 4.6: EMSA analysis of nuclear protein derived from LMVEC cells bound to 
32P labelled probe F8. Antibodies, wild type or mutated oligonucleotides to Spl 
and 3 (lanes 3 and 4, 5, 6), NFKB (lane 7), AP-2a (lane 8) were added to 
characterise the composition of the nuclear protein DNA complex (8.1).
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Figure 4-6 Activity of Fragment 8 in Lung
endothelium
Labelled oligo F8
Nuclear Extract - LMVEC
Sp1 ab -  -  +  -  -  -  - -
Sp3 a b -  
Sp1 oligo -  
Sp1 mut oligo -  - _ - . _ 4 . _ _  
NFkB oligo - - - - _ _ 4 - _  
AP2-a oligo - - _ _ _ _ _ 4_
1 2 3 4 5 6 7 8
8.1-
FP
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Fig. 4.5: DNA-protein complexes with lung nuclear lysates (8.1) and probe F8 
(lane 2) do not appear to be specific for any of the transcription factors (lane 3- 
Spl; 4-Sp3) as they were blocked by the addition of consensus (5-Spl; 7-AP1; 8- 
NFkB) or mutant (6-Spl) oligonucleotides.
148
4.5.5 Promoter Probes with YY1 Target Sites
Fragment Position on Chr5 NT_006713 Size (bp) *Target 
sites for 
YY1
1 19381165-19381301 136 X
2.1 19381275-19381450 175 X
2.1 19381428-19381582 154 X
4.1 19381805-19381957 152 X
4.2 19382031-19382201 119 X
6.1 19382181-19382362 181 X
4.5.6 Fragment 1
283
GR c-Myb c-Myb GR TFIID GR
YY1
FI of the occludin promoter exhibits putative binding sites for the TFs GR (210, 
283, 328), c-Myb (220, 239), YY1 (284) and TFIID (295). YY1 has been shown 
to interact with a complex containing the TFs Stat 5 and GR in the nucleus in the 
transcription of the Spi 2.1 gene (Bergad, Towle et al. 2000). c-Myb is capable of 
replacing GR in erythroid progenitors (Wessely, Deiner et al. 1997).
Activity o f FI in non-brain endothelium (LMVEC)
Two closely migrating nuclear protein-DNA complexes were seen when probe FI 
was incubated with nuclear protein from lung endothelial cells (Fig. 4.7). 
Formation of complexes was unaffected in the presence of antibodies to the TFs c- 
Myb, TFIID, Pitl andYYl.
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Figure 4-7 Activity of Fragment 1 in Lung Endothelium
Nuclear Extract 
c-Myb ab 
c-Myb ds oligo 
c-Myb ds mut oligo 
TFIID ab 
TFIID ds oligo  
YY ab
YY1 ds mut oligo 
Pit1 ab 
Pit1 ds oligo 
Pit1 ds mut oligo 
GR ds oligo  
c/EBP ds oligo
LMVEC
-  -  -  -  -  -  -  +  -
r  \ ........
F1.I
"■' ' i r V - ;/. 
y v 'h y y / : : , ; M,  y f c .
/
/  1 y,:; •'
.y.v, ; ■ ■  ■■■!;y:/.-.yy.;:; ..
... - y . y r ^ : ;/y y: 4\.;Ss
y^^ Syy
1 2 3 4 5 6 7 8 91011121314
Fig. 4.7 EMSA 
analysis o f nuclear 
protein derived 
from LMVEC cells 
bound to 32P 
labelled probe FI. 
Antibodies, wild 
type or mutated 
oligonucleotides to 
c-Myb (lane 3 and 
4, 5), TFIID (lane 6 
and 7), full-length 
YY1 (lane 8 and 9) 
or Pit 1 (lane 10 and 
1 1 ,12) were added 
to characterise the 
composition of the 
nuclear protein 
DNA complex 
( 1.1).
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4.5.7 Fragment 2.1
398
399
328 338 347 357 3 ^7  1 ? 4° 4 0 9  417 436 446 468 478 481    t  ChQ~D"""  S"(^T>0 f  > D i  CM87
GR YY1 TFIID YY1 P ltl YY1SRFTFYY1 c/EBP AP-1 c ^ y b  c-Myb YY1
c/EBPa Pit1 IID *  AP1
c/EBPa
F 2.1 probe of the occludin promoter spans nucleotides 312 to 487 and exhibits 
putative binding sites for the TFs GR (328), c-Myb (468, 478), YY1 (338, 357, 
417, 481) and TFIID (347, 409), SRF (405), API (446, 478), Pitl (387, 399), 
c/EBP-a (387,400,436).
Activity o f F2.1 in brain endothelium (hCMEC/D3)
Nuclear protein from brain and non-brain endothelium interacted with probe F2.1 
(Fig 4.8) to form a single nuclear protein-DNA complex which was not affected in 
the presence of consensus oligonucleotides or antibodies directed against any of 
the factors predicted to have binding sites on the probes.
Table 4-10 Summary of Activity of F2.1 in Brain Endothelium (hCMEC/D3) 
YY1 ] P  ©TMyb"~]['TFIID [ c/EBP Kj| A P I..Shifted
F2.1.1
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Figure 4-8 Activity of Fragment 2.1 in Brain Endothelium
Nuclear Extract -  H C M E C /D 3
YY1 ab - - + - . - - - - - - - -
TFIID ab - - . + . ...............................
c-Myb ab - - - - + - - - - - - - -
YY1 oligo - - - . . - - + .................
YY1 mut oligo - - ............................ + - - - -
c/EBP oligo ..................
TFIID oligo - - - - -
c-Myb oligo ..................  - ................... + -
AP1 oligo - - - - -  - - ...................+
F 2 .1 .1 i l l  d&tw Wr
n sp
FP -»
Fig. 4.8 Nuclear 
protein isolate 
from hCMEC/D3 
cells was
incubated with 32P 
labelled probe 
F2.1. The DNA- 
protein complex 
(2.1.1, lanes 2, 7) 
was challenged 
with antibodies, 
wild type or 
mutated 
consensus 
oligonucleotides 
to YY1 (lanes 3, 
8, 9), TFIID
(lanes 4, 11), c- 
Myb (lanes 5 and
12), API (lane
13) and c/EBP 
(lane 10).
910111213
152
4.5.8 Fragment 2.2
4 6 8  4 7 8 481 4 9 6
4 7 3
513
51 4
531 5 53  562 598
465
c - M y b  A P 1YY1 c-MyD bKh SRF YY1
AP2 TFIID
AP-1 YY1
0 619
YY1
F2.2 probe of the occludin promoter spans nucleotides 465 to 619 and exhibits 
putative binding sites for the TFs c-Myb (468, 487), YY1 (481, 531, 562, 598), 
TFIID (513), SRF (514), API (478, 553), AP2 (473).
Activity o f F2.2 in brain endothelium (ltCMEC/D3)
Nuclear protein from brain and non-brain endothelium interacted with probe F2.2 
(Fig 4.9) to form a single nuclear protein-DNA complex which was not affected in 
the presence of consensus oligonucleotides or antibodies directed against any of 
the factors predicted to have binding sites on the probes.
Table 4-11 Summary of Activity of F2.2 in Brain Endothelium (hCMEC/D3)
Shifted
band
YY1 c-Myb TFIID I SRF I API
i
AP2
F2.2.1
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Figure 4-9 Activity of Fragment 2.2 in Brain Endothelium
labelled F2.2
hCMEC/D3
Nuclear Extract - +
TFIID ab 
YY1 ab 
c-Myb ab 
TFIID ds oligo
YY1 ds oligo ....................+ ................
YY1 mut ds o l i g o ......................... +---------
c-Myb ds o l i g o ...............................+ ____
SRF ds oligo 
AP1 ds oligo 
AP2 ds oligo
 +  -
1 2 3 4 5 6 7 8 9101112131-4
F2 .2 .1-»
n sp
FP
f e - :v
Fig. 4.9 Nuclear 
protein isolate 
from hCMEC/D3 
cells was
incubated with 32P 
labelled probe 
F2.2. The DNA- 
protein complex 
(2.2.1, lanes 2, 7) 
was challenged 
with antibodies, 
wild type or 
mutated 
consensus 
oligonucleotides 
to YY1 (lanes 4, 
9, 10), TFIID
(lane 3), c-Myb 
(lane 77), SRF 
(lane 12), API 
(lane 13) and AP2 
(lane 14).
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4.5.9 Fragments 4.1 and 4.2
Probes 4.1 and 4.2 span the occludin promoter between the nucleotides 842-994 
and 972-1091 respectively. The region comprising nucleotides 876-1044 is 
conserved in human and mouse. The probes exhibit putative binding sites for the 
TFs Pitl, TFIID, YY1 andNFl.
Activity o f 4.1 and 4.2 in brain and non brain endothelium
In the presence of nuclear protein from hCMEC/D3 and lung endothelial cells the 
probes generated a single nuclear protein-DNA complex in each condition (Fig. 
4.10-F4.1.1 and F4.2.1). But, antibodies and/or competitor probes to the 
transcription factors predicted to bind to the sequence did not abrogate or restrict 
the migration of the complexes. Extensive smearing was seen in the lanes where 
nuclear extract from hCMEC/D3 cells was used. This smearing was also seen 
with nuclear protein from lung endothelial cells but it was less intense. There is a 
possibility that there could be a protein-DNA complex in the region of the 
smearing. Hence, poly dA: dT was employed instead of poly dl: dC which was 
effective in getting rid of the background. However, it also abrogated the 
formation of complex F4.1.1 (Fig. 4.11). This can be attributed to the fact the 
F4.1.1 is a low specificity complex. Nuclear protein-DNA F4.2.1 was seen but 
remained unaffected when challenged by antibodies and/or cold competitor probes 
to the TFs.
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Figure 4-10 Activity of Fragments 4.1 and 4.2 in Brain and Lung
Endothelium
labelled F4.1 labelled F4.2
Nuclear Extract hCMEc/D3 lm vec hCMEC/D3 lmvec 
YY1 ab 
TFIID 
Pit1 ab -  -  -  +  -  -  -  +
1 2 3 4  5 6 7 8 910111213141516
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Figure 4-11 Activity of Fragments 4.1 and 4.2 in Brain Endothelium
labelled  . , n . _ . _
 ^ labelled  F4.2
11 | _ „ * hCMEC/D3N uclear Extract ---------------  ---------------------------------
YY1 ab - - + ................... + .......................................
YY1 ds oligo ................................
TFIID ab - - - - + .....................+ - ..........................
TFIID ds oligo ................ + ....................... + ........................
Pit1 ab   + . . . .
Pit1 ds oligo ...................................................... + - - -
Pit1 m ut ds oligo ..............................................................+ - -
NF1 ds oligo  + -
NF1 m ut ds oligo ...................................................................... +
1 2 3 4 5 6 7 8 9  10 11121314 15161718
Q* -’ ’ -  \   .
Figure 4-11 Activity of Fragments 4.1 and 4.2 in Brain Endothelium
Nuclear Extract 
YY1 ab 
YY1 ds oligo 
TFIID ab 
TFIID ds oligo 
Pit1 ab 
Pit1 ds oligo 
Pit1 m ut ds oligo 
NF1 ds oligo 
NF1 m ut ds oligo
labelled
F4.1 labelled  F4.2
hCMEC/D3
-  -  -  -  +  + ..............................
-  +  -  -  -  -
 -  + -
 +
1 2 3 4 5 6 7 8 9  1011121314 15161718
m
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(lanes 5-7; 13-16) endothelial cells was incubated with 32P labelled probe F4.1 
(lanes 1-7) or F4.2 (lanes 8-16). The DNA-protein complexes (F4.1.1 and F4.2.1- 
lanes 2, 5, 9, 13) were challenged with antibodies to YY1 (lanes 3, 6, 10, 14), 
TFIID (lanes 4, 7, 11, 15) and Pitl (lanes 12, 16).
Fig. 4.11: Nuclear protein isolated from hCMEC/D3 endothelial cells was 
incubated with 32P labelled probe F4.1 (lanes 1-8) or F4.2 (lanes 9-18). The non­
specific inhibitor poly dA:dT was used instead of poly dI:dC. The DNA-protein 
complexes were challenged with antibodies, wild type or mutated consensus 
oligonucleotides to YY1 (lanes 3, 4, 9, 10), TFIID (lanes 5, 6, 11, 12) and Pitl 
(lanes 14,15, 16) andNF-1 (17, 18)
Table 4-12 Summary of Activity in Brain (hCMEC/D3) Endothelium 
Shifted band YY1 TFIID Pitl NF1
F4.1.1 
F4.2.1
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4.5.10 Fragment 6.1
1232 1260 1279
1313
1314
1338
13401342 1382
1218 c CTF
SRF
c/EBP-a AP‘2 
NF-AT
NF-AT
1382
c-Myb c-Myb c-Myb
F6.1 of the occludin promoter exhibits putative binding sites for the TFs c-Myb 
(1232, 1260, 1279), SRF (1314), NF-AT (1340, 1382), AP2 (1342) and c/EBP-a 
(1338).
Activity in brain endothelium (hCMEC/DS)
The promoter segment spanning nucleotide base pairs F6.1 interacted with the 
nuclear proteins from the hCMEC/D3 cells to generate six distinct migratory 
DNA-protein complexes (Fig. 4.12, lanes 2 and 6). Addition of an antibody to 
YY1 abrogated complex 6.1.5 in contrast to the competitor which proceeded to
j
block the formation of all the complexes but a mutant form of the competitor 
failed to inhibit or retard the complex confirming the sequence specificity of this 
interaction. From the data it is likely the YY1 sites are occupied by other 
transcription factors.
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Figure 4-12 Activity of Fragment 6.1 in Brain Endothelium
Labelled o ligo  F6.1
Nuclear extract -  !lCM EC/D3--------
YY1 ab - -  .....................................
c-Myb ab - - - + ......... .........................
YY1 oligo ................................... + - - -
YY1 mut o l i g o ........................................  - -
c-Myb oligo ..........................
c/EBP oligo .............................................. ....
F6.1.1-* 
F 6.1.2-?
F6.1.3-*
F6.1.4-*
F 6.1 .5- *
F6.1.6-*
■; . .'f t,,;... .
. ■"■■'; ■' ---
   :: :
: :
n sp ^  ‘
1 2 3 4  5 6 7 8 9  10
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Fig. 4.12: Nuclear protein isolated from hCMEC/D3 cells was incubated with 32P 
labelled probe F6.1. The DNA-protein complexes (6.1.1-6.1.6, lanes 2, 6) were 
challenged with antibodies, wild type or mutated consensus oligonucleotides to 
YY1 (lanes 3, 7, 8), c-Myb (lanes 4 and 9) and c/EBP (lane 10). Shifts 6.1.5 and 
6.1.6 were retarded in the presence of an antibody to YY1 (lane 3) and the 
complexes were restored in the presence of an YY1 mutated oligonucleotide (lane 
8) confirming the sequence specific interaction of YY1 with the probe. The 
consensus oligonucleotide however blocked the formation of all the complexes 
(lane 7) and it is possible these complexes are specific to transcription factors that 
are binding to the YY1 target site.
Table 4-13 Summary of Activity of F6.1 in Brain Endothelium (hCMEC/D3)
Shifted Band YY1 c-Myb c/EBP-a
6.11 -
■ . ■ • • ■ . . ?
-
6.12 [ -
6.13 - - -
6.14 ✓ - '
...........  .-1
6.15
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4.6 Promoter Probes with Sp and YY1 Sites
Fragment Position on Chr5 NT 006713 Size (bp) *Target 
sites for 
Spl
* Tar get 
sites for 
YY1
0.1 19380963-19381083 120 X X
0.2 19381054-19381188 128 X X
3.1 19381561-19381740 179 X X
5 19382031-19382201 170 X X
Fragment F 0.1
24 32,34 4546 51 57 100
  HH3D30----------□— 120
GR Sp1 NF-lPit1 TFIID YY1
F0.1 of the occludin promoter exhibits numerous binding sites for diverse 
transcription factors as predicted by the TESS program. The reverse primer for 
F0.1 is also the forward primer for F0.2 hence there is an overlap of twenty three 
base pairs and so the probes share the predicted YY1 binding site at position 100. 
In addition to the YY1 site, F0.1 has response elements for TFs: interferon 
regulatory factors IRF1 and IRF 2, GR, members of the Sp family, Pitl and 
TFIID.
IRF-1 and IRF-2 are highly homologous TFs that bind specifically to AAGTGA 
hexamer repeat motifs (Tamura, Yanai et al. 2008). IRF-1 recognizes this site to 
initiate transcription of downstream target genes in contrast to IRF-2 which binds 
competitively and represses transcription through its C-terminal repression 
domain. The IRF recognition DNA sequence is also found in the regulatory
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regions of IFN-ce and IFN-inducible genes so it is possible that occludin promoter 
region is a target for transcriptional modulation during inflammation and disease.
Activity o f F0.1 in brain endothelium (HCMEC/D3)
The single nuclear protein-DNA complex formed between probe F0.1 and nuclear 
proteins from brain endothelial cells (FO.1.1) is not specific for any of the 
transcription factors with binding sites in the segment (Fig. 4.13)
Activity of F0.1 in lung endothelium (LMVEC)
However, probe F0.1 formed three complexes-FO.l.I, F0.1.II, F0.1.III with 
nuclear proteins from lung endothelium (Fig. 4.14, lane 2). Complex 0.1.Ill was 
formed by YY1, since addition of a lull length antibody to YY1 (lane 7) super 
shifted the complex. Probes F0.1 and F0.2 share one common YY1 site but the 
nuclear protein-DNA complex formed with F0.2 is not specific for YY1 (Fig 
4.15), implying that the single YY1 site in F0.1 is a genuine target for YY1. 
Complex 0.1.II was blocked by a TFIID consensus oligonucleotide (lane 6), but 
was not supershifted by a TFIID antibody. There is a potential TFIID site in F0.1 
located between the Sp site and the YY1 site.
Hence these data imply that a DNA-binding protein occupies the TFIID site, but 
that it is not TFIID itself. Taken together the data suggests that the YY1 site in 
F0.1 is active in lung endothelium, but not brain endothelium and that two 
additional proteins from lung endothelium may bind to this region.
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Figure 4-13 Activity of Fragment 0.1 in Brain Endothelium
Labelled oligo FO. 1 
hCMEC/D3
Nuclear Extract 
Sp oligo
Sp mut oligo
Pitl oligo
Pitl mut oligo
TFIID ab
TFIID oligo
YY1 ab
GR oligo
NF1 oligo
NF1 mut oligo
i   ■mw
FO.1.1
#  is
Fig. 4.13: EMSA 
analysis showing the 
binding of nuclear 
extracts from brain 
endothelial cells to 
32P labelled probe 
F0.1 in the presence 
of consensus 
oligonucleotides to 
Spl (lane 3), Pitl 
(lane 5), TFIID (lane
8) orNFl (lane 10) 
or with antibodies to 
TFIID (lane 7), full- 
length YY1 (lane 9) 
or with mutated 
consensus probes- 
Spl (lane 4) and Pitl 
(lane 6).
1 2 3 4  5 6 7 8 9  10
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Figure 4-14 Activity of Fragment 0.1 in Lung Endothelium
Labelled oligo F0.1
^  u M c
Nuclear Extract -
Sp oligo - - + .............................
TFIID ab - - - - + ....................
TFIID oligo ......................... + - - - -
YY1 ab  + - - -
GR oligo  + - -
NF1 oligo    “
NF1 mut oligo " ~ “ " “ “ " " " +
.V
ss
F0.1.I
F0.1.II
FO. 1 .III
FP
1 2 3 4  5 6 7 8 9  10
Fig. 4.14: EMSA 
analysis of nuclear 
protein complexes 
formed between 
radiolabelled probe F0.1
(0.1.1,0.1.11, 0 .1 .m ,
lanes 2-10) in the 
absence (lane 1) or 
presence of nuclear 
proteins (lanes 2) 
isolated from lung 
endothelial cells. 
Consensus
oligonucleotides to Spl, 
Pitl, TFIID, GR, NF1 
(lanes 3,4, 6, 8, 9,10  
respectively) or 
antibodies to TFIID (lane 
5) and full length YY1 
(lane 7) were added to 
the binding reactions in 
order to investigate the 
composition of the 
complexes. Shift 0.1. Ill 
(ss, *) was super shifted 
in the presence of 
antibody to YY1, 
whereas shift 0.1 .II was 
retarded by an antibody 
to TFIID confirming the 
presence of functional 
YY1 and TFIID proteins 
within LMVEC cell 
nuclei, ss denotes super 
shifted band.
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Table 4-14 Summary of FO.l Activity in Brain Endothelium (hCMEC/D3)
Shifted Band [ .....~“Sp~ ;| Piti  F TfTdF  T  “ y y T
FO.1.1 - - - -
Table 4-15 Summary of FO.l Activity in non-brain endothelium (LMVEC)
•r w r ~ ..Shifted Band i Sp Piti
F0.1.I 
FO.l.Ill
TFIID
✓
Fragment F0.2
O Tf 00
°  £553: 155 210 220
,7-0—KHDM .225
>  o .£  2 o . § i  Sp1 GR c_Myb>- 1/1 >- D.
Fragment 0.2 shares an YY1 site at position 100 with FO.l in addition to a 
predicted site for YY1 at position 124. Other TFs with putative target binding 
sites in this region include Sp (121, 138, 155), AP2 (137), p300 (139), GR (210) 
and c-Myb (220).
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Figure 4-15 Activity of Fragment 0.2 in Brain Endothelium
labelled F0.2
Nuclear Extract -
Sp1 ab
Sp3 ab
Sp1 ds oligo
Sp ds mut oligo -
YY1 ab
AP-1 oligo
hCMEC/D3
•  r*. la
'  '  : '
FO.2.1 ->
.
Fig. 4.15 EMSA analysis 
of nuclear extracts from 
brain endothelial cells 
with 32P labelled probe 
F0.2 in the presence of 
antibodies to Spl (lane 3) 
or Sp3 (lane 4) or to full- 
length YY1 (lane 7) or 
with 30-molar excess of 
consensus
oligonucleotides to Spl 
(lane 5), mutated Spl 
probe (lane 6) or to API 
(lane 8).
1 2 3 4 5 6 7 8
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Figure 4-16 Activity of Fragment 0.2 in Lung Endothelium
labelled F0.2
Nuclear Extract - -------------------------
Sp1 ab 
Sp3 ab
Sp1 ds oligo - - + - -
YY1 ab
AP-1 oligo - . . .  . - +
Fig. 4.16 EMSA analysis of 
nuclear extracts from lung 
endothelial cells with 32P labelled 
probe F0.2 in the presence of 
antibodies to Spl (lane 3) or Sp3 
(lane 4) or to full-length YY1 
(lane 6) or with 30-molar excess 
of consensus oligonucleotides to 
Spl (lane 5) or to API (lane 7)
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4.6.1 Fragment 3.1
598 622 626 640 658
SRFTFIID YY1
683 696699 724 733 756 765
1 -0  •  Or—177
AP"1 c-Myb 
YY1
Sp1 GATA1 AP-1 GATA1
GR 
Activity o f F3.1 in brain endothelium (hCMEC/D3)
The probe F3.1 showed three distinctly migrating DNA-protein complexes in the 
presence of nuclear proteins from hCMEC/D3 cells-F3.1.1, F3.1.2 and F3.1.3 (Fig 
4.17). All of the complexes were competed out by the addition of 100-fold molar 
excess of non radio-labelled Spl consensus oligonucleotide (lane 8). However, 
different complexes were retarded in the presence of antibodies to Spl (lane 5, 
complex I) and Sp3 (lane 6, complex III). The DNA probe has in addition 
potential binding sites for other transcription factors including c-Myb, the 
antibody to this transcription factor affects the mobility of complex III (lane 7) but 
the binding is not specific as addition of an unlabelled competitor does not block 
the association (lane 9).
Table 4-18 Summary of F3.1 Activity in Brain Endothelium (hCMEC/D3)
[ Shifted '[ Y Y f - ’j TFIID " i f ”  Spl j~  Sp3 cJVIyb
1 i i | .  it II It
Figure 4-17 Activity of Fragment 3.1 in Brain Endothelium
Nuclear Extract 
YY1 ab 
TFIID ab 
Sp1 ab 
Sp3 ab 
c-Myb ab 
Sp1 ds oligo 
YY1 ds oligo 
c-Myb ds oligo
labelled oligo F3.1 
hCMEC/D3
+  -
1 2 3 4 5 6 7  8 9  10
F3.1.1 -» 
F3.1.2-*
F3.1.3-*
*
- I -
■%
' i  '
n sp-» pti. "tt* ■■' fp f
Fig. 4.17: DNA-protein 
complexes formed between 
32P labelled promoter probe 
F3.1 and nuclear extracts 
from hCMEC/D3 cells (lane 
2) were investigated in the 
presence of antibodies (3-7) 
or consensus oligonucleotides 
(lanes 8-10) against 
transcription factors predicted 
to bind to the probe. 
Antibodies to Spl (lane 5) 
and Sp3 (lane 6) retarded 
complexes II and III 
respectively whereas the 
competitor to Spl (lane 8) 
restricted the formation of all 
the complexes. Retardation of 
complex III by the antibody 
to c-Myb (lane 7) was not 
specific as the competitor did 
not affect the formation of the 
complex (lane 10).
Antibodies to YY1 (lane 3) 
and TFIID (lane 4) did not 
affect the mobility of the 
complexes.
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4.6.2 Fragment 5
1088
1091 1160
1201
1195 1206 1232
1068« 1 i — d — [ > 1238
SRF
TFIID
Sp1 YY1 Pit 1 Sp1 c-Myb
Fragment 5 spans the region 1068 to 1238 of the occludin promoter and includes 
target binding sites for the TFs SRF (1091), TFIID (1091), Spl (1160, 1206), 
YY1 (1195), Pitl (1201) and c-Myb (1232).
Activity ofpromoter probe F5 in brain endothelium (HCMEC/D3)
The double stranded probe F5 generates a high mobility DNA-protein complex 
(5.1) with brain endothelial nuclear proteins (Fig 4.18, lanes 2 and 8) and this 
interaction is retarded on incubation with an YY1 antibody (lane 6) and is also 
blocked by the addition of 100 molar excess of unlabelled competitor (lane 12). 
Addition of 100-fold excess of an unlabelled oligonucleotide containing a mutated 
YY1 binding site (lane 13) failed to inhibit or retard the complex confirming the 
sequence specificity of this interaction.
Activity o f promoter probe F5 in non-brain endothelium (LMVEC)
The probe interacts with nuclear extracts from lung endothelial cells and generates 
a single nuclear protein-DNA complex, F5.I (Fig. 4.19, lane 2) which was not 
affected in the presence of consensus oligonucleotides or antibodies directed 
against any of the factors predicted to have binding sites on the probe (lanes 3-15).
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Table 4-19 Summary of F5 Activity in Brain Endothelium (hCMEC/D3)
YY1 ' Spl Sp3 TFIID c-MybShifted
Band
F5.1 ✓
Table 4-20 Summary of F5 Activity in Non-Brain Endothelium (LMVEC)
Shifted YY1 Spl ; Sp3 : TFIID ; c-Myb
Band
F5.I
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Figure 4-18 Activity of Fragment 5 in Brain Endothelium
Nuclear Extract 
Pitl ab 
Sp1 ab 
c-Myb ab 
YY1 ab 
Pitl ds oligo 
Pitl ds mut oligo 
c-Myb ds oligo 
YY1 ds oligo 
YY1 mut ds oligo 
NF-1 ds oligo
labelled oligo F5 
HCMEC/D3
- -  + ...................................................................
- - - + ..................................................................
- - - - + ..........................................................
 + ..................................
...........................
  + ■
 +
1 2 3 4 5 6 7 8  9 1011121314
  • • - •  i,.-
• <•
F5.1 -»
Fig. 4.18:32P labelled 
probe F5 was 
incubated in the 
absence of (lanes 1, 7) 
or presence of nuclear 
extracts from 
hCMEC/D3 
endothelial cells 
(lanes 2-6; 8-15). 
DNA-protein 
complexes formed- 
F5.1 were 
characterised by 
incubating with 
antibodies, wild type 
or mutant 
oligonucleotides to 
transcription factors 
to Pitl (lanes 3, 9);
Spl (lanes 4 ,10); c- 
Myb (5 ,11); YY1 (6, 
12, 13) predicted to 
bind to the sequence.
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'Figure 4-19 Activity of Fragment 5 in Lung Endothelium
__________ labelled F5 oligo__________
Nuclear Extract ----------------- LMVEC-----------------------
Pit1 ab - - + .............................................
Pit 1 ds oligo - - - + ...................................................
Pit 1 mut ds oligo - - - - + ..............................................
Sp1 ab  + - - ................
Spt ds oligo  + .......................
Sp3 ab  + .................
Spt mut ds oligo .................................+ ..............................
c-Myb ab  + .
c-Myb ds oligo - - - - - -  - - - - - + - - - -
c-Myb mut ds o l i g o ....................................................+ - - -
YY1 ab ............................
YY1 ds oligo ..................................................... - + -
YY1 mut ds oligo ..................................................... - -  +
1 2 3 4  5 6 7 8 9  101112131415
M k.- A  Jfe. A  Aik. A
F5J -»
FP->
Fig. 4.19:32P 
labelled probe F5 
was incubated in 
the absence of 
(lane 1) or 
presence of 
nuclear extracts 
from LMVEC 
endothelial cells 
(lanes 2-15). 
DNA-protein 
complexes 
formed-F5.I were 
characterised by 
incubating with 
antibodies, wild 
type or mutant 
oligonucleotides 
to transcription 
factors to Pitl 
(lanes 3 ,4, 5);
Spl (lanes 6, 8,
9); Sp3 (7) c-Myb 
(10,77,12); YY1 
(13 ,1 4 ,15) 
predicted to bind 
to the sequence.
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4.7 Discussion
The occludin protein was identified as a major constituent o f  brain endothelial 
tight junctions (Furuse, Hirase et al. 1993; McCarthy, Skare et al. 1996). Apart 
from its restricted expression in brain endothelium, it is expressed in epithelia 
where it participates in tight junction formation and regulates paracellular 
permeability. The regulation o f  expression from the occludin promoter has been 
studied in epithelial cells (Mankertz, Tavalali et al. 2000). Information on the 
mechanism o f  occludin gene expression is useful in understanding the differential 
regulation o f  the protein in different endothelia. Additionally, occludin has been 
shown to play an important role in pathology o f several neurodegenerative 
disorders and inflammation processes. It is dephosphorylated in experimental 
autoimmune encephalitis (EAE) (Morgan, Shah et al. 2007). This event has been 
shown to coincide with inflammation and increased BBB permeability. These data 
imply occludin is a possible target in the pathological process in EAE. In 2007, 
(Romanitan, Popescu et al. 2007) showed an increase in occludin expression in 
Alzheimer's disease (AD), and vascular dementia (VD) brains in comparison to 
ageing controls. So understanding the regulation o f occludin gene expression in 
normal physiology is helpful to investigate possible alteration o f  transcriptional 
regulatory mechanisms in inflammatory or degenerative diseases o f the CNS.
In intestinal epithelium, TNF-a has been shown to affect transcription from the 
promoter. Specific transcription factors have not yet been attributed to the 
promoter in endothelial cells. We have used the program TESS to screen for 
potential TFs binding motifs in the promoter. The list o f the transcription factors
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has been summarised in a table (appendix). In this study, in addition to data from 
the TESS program, we have particularly focussed our attention on the Sp family 
and YY1 TFs. Previous work in our group on the regulation o f the human 
transferrin receptor which is also restricted to the brain endothelium has 
implicated Sp and YY1 TFs to be important for its expression in brain 
endothelium (Holloway, Sade et al. 2007). Data suggests two important events 
that lead to the initiation o f  gene expression from the HTR promoter in brain 
endothelium:
1. Requirement o f the transcription factors TFIID and Sp3.
2. TFIID successfully competes for YY1 binding sites on the HTR promoter DNA  
in the brain but not non-brain endothelium.
Additional data had shown differences in TF binding profiles between brain 
endothelial cells and lung, dermal and bone marrow endothelial cells as 
determined by EMSA. The TFs, Spl, Sp3, IRF1, CBF, NFAT, SRE, and CDP 
exhibited similarity in the formation o f  nuclear protein complexes between the 
different endothelia. P itl, GAT A, c-Myb were slightly different and YY1 was 
completely different (Holloway, Sade et al. 2007).
We have used the transformed cell line, hCMEC/D3 and primary lung 
microvascular endothelium cells (LMVEC) to elucidate the regulation o f  
transcription from the occludin promoter.
Our work identifies TFs Sp3 (Figs. 4.2, 4.3, 4.4, 4.5 and 4.17) and YY1 (Figs. 
4.12 and 4.18) present in brain endothelial nuclear lysates to bind their target
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elements on the occludin promoter. TFs c-Myb (Fig. 4.17), NFkB (Fig. 4.5) and 
AP2- a  (Fig. 4.5) present in the brain endothelial cells also bind the promoter in 
EMSA analyses. In the lung endothelium however, only the Y Y 1 TF occupies its 
target site in FO (Fig. 4.14) and though Spl and Sp3 are expressed in the lung 
endothelium, they do not appear to bind the target motifs on the occludin 
promoter probes (Fig. 4.6). Therefore, it would be reasonable to think that these 
transcription factors might be involved in the expression o f occludin in a cell- 
type-independent manner.
Figure 4-20 Summary of Identified TFs on the Occludin Promoter in Brain 
and Lung Endothelial Cells.
Brain Endothelial Cells
0.1 2.1
0.2
3.2
2.2 4.1
  3.1   4.2
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Lung Endothelial Cells
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0.2
-1600
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-1200
 I_
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2.2 4.1
  3.1   4.2
6.1
-800
6.2
-400
7.1
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YY1
The transcription factors Spl and Sp3 are ubiquitous and play important roles in 
normal tissue and organ development (Suske 1999). It is to be noted that despite 
the ubiquitous nature o f  expression o f  Spl and Sp3, these factors have been
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shown to regulate gene transcription in development and these mechanisms differ 
among cell types (Opitz and Rustgi 2000; Ghayor, Chadjichristos et al. 2001; 
Yoo, Jeong et al. 2002; Guo, Degnin et al. 2003; Reddy, Vuong et al. 2003; 
Nakamura, Kawachi et al. 2007). Changes in level o f expression and nuclear 
localisation in cells may occur during different stages o f development. And 
posttranslational modifications like acetylation and sumoylation have been known 
to affect the activity o f  these transcription factors whilst preserving their nuclear 
localisation (Sapetschnig, Rischitor et al. 2002; Stielow, Sapetschnig et al. 2008).
In endothelium, Sp family TFs have been implicated in the regulation o f  
endothelial specific genes, cadherin (Gory, Dalmon et al. 1998), human thrombin 
receptor (Wu, Ruef et al. 1998), integrin alphaV promoter (Czyz and Cierniewski 
1999) and fgl2 (Liu, Leibowitz et al. 2003). Spl functions mainly as a 
transcriptional activator in contrast to Sp3 which is capable o f  activation or 
repression depending on cellular context (Hagen, Muller et al. 1994). It is clear 
from the data obtained from the EMSA analyses that Sp3 competes successfully 
with Spl for the Sp target sites on the occludin promoter in brain endothelial cells. 
This maybe explained by the Sp3:Spl ratio in these cells where Sp3 protein levels 
are significantly higher than Spl (discussed in detail in Chapter 6). Considering 
that relatively high levels o f Sp3 expression are observed in brain endothelial 
cells, gene expression mediated by Sp3 may be controlled by the expression level 
o f Sp3 (Karantzoulis-Fegaras, Antoniou et al. 1999). And it is well known that 
promoters containing multiple adjacent Sp-sites form significantly more stable 
Sp3-DNA complexes than those with single Sp-binding sites. These Sp3-DNA  
complexes are also more stable than a corresponding Spl-D N A  complex (Yu,
180
Datta et al. 2003). This observation seems to be true in the case o f  promoter probe 
F8 (Figs. 4.4 and 4.5) which has two closely positioned Sp sites (1798 CCCTCCC 
1804 and 1820 AGGCGG 1825). Spl is excluded from this complex and it is 
probable that Sp3 occupies both the sites.
There are two possible reasons for the inability o f Sp factors present in lung 
endothelium to bind the occludin promoter fragments:
1. Inaccessibility o f  the TFs to the occludin promoter due to the presence o f  
other DNA binding proteins that promote chromatin condensation in the 
occludin promoter region (discussed in chapter 5)
2. Increased level o f splice variants o f Sp3 which repress Spl and Sp3 
mediated transcription (discussed in chapter 6)
In addition to Sp3, TF c-Myb binds the promoter probe F3.1 (4.17). However, the 
binding o f c-Myb is not specific because the association is not blocked in the 
presence o f a competitor. Two other proteins bind the occludin promoter on probe 
F8 and these associations are blocked in the presence o f a competitor to NFkB 
(Fig. 4.5) and A P2-a (Fig. 4.5). We haven’t been able to confirm the association 
o f  these TFs by super shift assays. Nevertheless, functional interaction between 
Sp family and AP2-a have been reported in the regulation o f  human pPro-al (I) 
collagen gene promoter (Vergeer, Sogo et al. 2000). Data from transmission 
electron microscopy shows Spl binding to target sites in an intron resulting in the 
looping out o f DNA. This leads to the interaction o f  the TF with AP2 bound in the 
proximal promoter region. Spl and AP2 associations have been shown to be
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required to drive transcription from the mouse GM3-synthase gene promoter in 
neuro 2a cells (Xia, Zeng et al. 2005) and from the human fragile-X mental 
retardation promoter in SK-N-SH neuronal cells (Carrillo, Cisneros et al. 1999). 
More importantly, associations between AP2 and Sp family have been shown for 
promoters o f  genes that are regulated temporally and spatially during 
development. Sp3, Spl and AP2 TFs have been shown to associate in the 
activation o f  transcription from the human MIP gene promoter (Ohtaka- 
Maruyama, Wang et al. 1998).
During neuronal differentiation, the NR1 gene that encodes for the N-methyl-D- 
aspartate (NMDA) receptor has been shown to be regulated by the binding o f Spl 
and Sp3 family members to an NFkB response element (Liu, Hoffman et al. 
2004). It is known that Sp family bind NFkB sites and can activate transcription 
from NFkB  sites as seen in the case o f  the P-selectin promoter (Hirano, Tanaka et 
al. 1998). Interestingly in the CNS, there appears to be a distinct neuronal-KB- 
binding factor that is found in a complex o f Spl and -3 and binds the NFkB 
consensus (Mao, Moerman et al. 2002). It is possible that this specific binding 
factor is recruited to the proximal promoter along with A P2-a by virtue o f  their 
associations with the Sp family members. Whether this is a functional interaction 
remains to be elucidated.
We have shown the regulation o f the transferrin receptor (Holloway, Sade et al. 
2007) by YY1 in brain endothelium. YY1 is multifunctional ZnF TF that can 
either activate or repress transcription from target promoters (Thomas and Seto 
1999). YY1 core consensus binding site is CGCCATnTT (n indicates any base at
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that position); other less stringent binding motifs include CCATnTT without the 
CpG dinucleotide or ACATnTT (Kim and Kim 2008). Since YY1 binding to its 
CpG-containing binding site (CGCCATnTT) is methylation sensitive it can be 
controlled by CpG methylation (Kim, Kollhoff et al. 2003) and since it has 
relatively flexible binding sites, EMSA results may not correspond with YY1- 
target sequences predicted by the program.
The occludin promoter sequence includes YY1 binding sites (Table 4.1) and we 
examined if  these sites are actively bound by the transcription factor in brain and 
non-brain endothelial nuclear extracts. YY1 from lung lysates interacted only with 
the binding motifs in the 5’ end o f the promoter region (Fig. 4.14). YY1 from 
brain endothelial lysates interacted with consensus binding sites in the probes 
from F5 (Fig. 4.18) and F6.1 (Fig. 4.12) though it is likely the YY1 sites in F6.1 
are occupied by other transcription factors.
Further analysis is required to reveal the cooperative mechanism between Sp3 and 
YY1. In vivo analysis o f transcription and translation level o f  occludin in normal 
brain endothelial cells and cells where the TFs have been silenced is required for 
further clarification o f the involvement o f  the TFs in regulation.
To conclude, EMSA data clearly indicates there is a difference in the association 
o f transcription factors with the occludin promoter between brain and non-brain 
endothelium. However, the biochemical technique investigates interaction o f  
transcription factors with naked DNA under in vitro conditions and results do not 
necessarily represent a functional target in vivo. It should be remembered that 
EMSA analyses do not demonstrate all possible interactions between TFs and
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binding motifs on target genes and hence we used chromatin immunoprecipitation 
analysis to look at protein: DNA interactions in vivo.
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Chapter 5
Interaction of TFs with Human 
Occludin Promoter
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5 Interaction of TFs with Human Occludin 
Promoter
5.1 Introduction
Protein-DNA interactions influences include DNA replication and repair, 
transcription and epigenetic silencing o f gene expression. Transcriptional 
regulation o f  gene expression is required for the maintenance o f  cellular 
homeostasis and disruption o f this regulation is directly linked to many human 
diseases, including cancer. The identification o f TFs, binding sites within the 
genome, and regulated genes is necessary to understand signalling in normal 
physiology and in disease. Hence, investigating interactions between transcription 
factors and targets in vivo is a very important aspect in the field o f transcriptional 
regulation. Techniques such as EMSA, DNase I footprinting, microarrays have 
been used to study protein-DNA interactions. However, the assays measure TF 
binding to naked DNA under in vitro conditions and results do not necessarily 
represent a functional target in vivo and observed gene expression changes may be 
due to direct or indirect regulation, making it challenging to detect primary gene 
targets. In addition, factors like chromatin structure, nucleosome positioning, 
associations and competitions between different TFs, modifications o f histones or 
DNA control the interaction o f a given factor to a target DNA sequence.
Chromatin immunoprecipitation (ChIP) is an experimental method used to 
determine whether proteins, such as certain transcription factors, are associated
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with a specific genomic region in living cells or tissues using specific antibodies 
that recognize a specific protein or a specific modification o f a protein. This cell 
based technique is often used together with non-cell-based assays to characterize 
protein: DNA purified and identified by PCR using specific primers to the 
suspected binding region. This technique is a valuable tool in identifying 
regulatory regions directly bound by a TF in the context o f the native chromatin 
structure.
Data in the present chapter investigates the role o f potential regulatory elements 
controlling transcription from the occludin promoter in brain and lung endothelial 
cells.
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5.2 Materials and Methods
5.2.1 Chromatin Immunoprecipitation (ChIP) assay
Kits: Active M otif Enzymatic shearing kit and Upstate Chromatin
immunoprecipitation kit were used for the assay.
Buffers and solutions
37% Formaldehyde: (Sigma, Cat No: F I635)
Glycine Stop-Fix solution: 3 ml o f lOx glycine (supplied in the Active M otif kit), 
3ml lOx PBS mixed in 24 ml o f  deionised water. Made just prior to use and stored 
at RT.
Treatment with formaldehyde
Cells were grown to confluence in a 175 cm flask and rested for 48 hours prior to
n
assay. 10 cells were used for one assay. 37% formaldehyde (Cat no: F I635, 
Sigma Aldrich) was directly added to the culture medium to achieve a final 
concentration o f 1% (3pl/cm ) and incubated for 10 min at 37°C. Medium was 
aspirated and the fixation reaction was stopped by adding 10 ml glycine stop-fix 
solution and swirling the culture flask to cover the cell monolayer and then 
rocking at room temperature for 5 minutes. The solution was then discarded and 
cells washed with ice cold PBS containing protease inhibitors (1 mM PMSF, 1 
pg/ml aprotinin and lpg/m l pepstatin A) for 10 min with two changes o f  buffer.
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Isolation of nuclei
Cells were scraped into a tube and centrifuged for 4 min at 2000 rpm at 4°C. The 
pellet was resuspended in 1ml chilled lysis buffer and incubated on ice for 40 min 
to release nuclei. The nuclei were collected by centrifugation at 5000 rpm for 10 
min at 4°C.
Shearing of chromatin
The nucleic pellet was resuspended in 1ml digestion buffer (supplemented with 5 
pi PIC and 5 pi o f 1 mM PMSF) and warmed at 37°C for 5 min. A  working 
enzymatic shearing cocktail solution was prepared by diluting 1:100 o f the 
supplied mixture (Active Motif) with 50% glycerol (in nuclease free water) to 
make a final stock at 200 U/ml. 50pl o f  the working stock o f  enzymatic shearing 
cocktail was added to the pre-warmed nuclei, vortexed to mix and incubated at 
37°C for 40 min. The tube was flicked and/or vortexed periodically during the 
incubation to ensure the chromatin is evenly sheared. The reaction was then 
stopped by addition o f  20 pi ice-cold 0.5 M EDTA and the tube chilled on ice for 
10 min followed by centrifugation at 15000 rpm in a 4°C micro centrifuge for 10 
min. The supernatant contains the sheared chromatin and was aliquoted into 
4x250 pi; each 250 pi aliquot to be used for one ChIP reaction.
Immunoprecipitation of the Chromatin
The 250 pi sheared chromatin lysate was pre-cleared with 40 pi o f  Salmon Sperm 
DNA/Protein A agarose-50% slurry (upstate Biotechnology) for lhr at 4°C. After 
a brief centrifugation to pellet agarose, the supernatant fraction was collected.
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4 jig o f  the immunoprecipitating antibody was added per each reaction and 
incubated overnight at 4°C with rotation. 60 pi o f Salmon Sperm DNA/Protein A  
agarose slurry was then added and further incubated for 60 min at 4°C with 
rotation to collect the antibody/histone complex. The agarose was pelleted by 
gentle centrifugation at 1000 rpm at 4°C, -lm in . The supernatant which contains
the unbound, non-specific DNA was carefully removed. The protein A
agarose/antibody/histone complex was washed for 3-5 min on a rotating platform 
with 1ml o f  each o f the buffers listed in the order as given below:
Low Salt Immune Complex Wash Buffer, one wash
High Salt Immune Complex Wash Buffer, one wash
LiCl Immune Complex Wash Buffer, one wash
lx  TE, two washes
250 pi o f  freshly prepared elution buffer ((1% SDS, 0.1 M NaHCOs) was added to 
the pelleted protein A  agarose/antibody/histone complex , vortexed briefly to mix 
and incubated at room temperature for 15 min with rotation. The tubes were 
centrifuged at 1000 rpm for lmin at RT and the supernatant fraction (eluate) 
carefully transferred to another tube. The elution step was repeated and the eluates 
were combined (total volume = -500  pi).
Reversal of cross links
20 pi o f 5 M NaCl was added to the combined eluates (500 pi) and histone-DNA  
crosslink’s reversed by heating at 65°C for 4 hours. Then, 10 pi o f  0.5M EDTA,
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20 pi 1M Tris-HCl, pH 6.5 and 2 pi o f 10 mg/ml Proteinase K(Sigma) was added 
to the combined eluates and incubated for 60 min at 45°C. After addition o f 3 pi 
o f a carrier molecule, glycogen (2 pg/pl), DNA was recovered by 
phenol/chloroform extraction and ethanol precipitation, resuspended in TE buffer 
for use in PCR analyses.
5.2.2 Antibodies used in ChIP
All antibodies were purchased from Santa Cruz Biotechnology and 2 pg was used 
per reaction.
Table 5-1 Antibodies used in ChIP Assays
Antibody Species of Ab Immunogen (human) Clone/PAD*
GATA-2 Mouse 120-235 aa’s o f  Gata-2 CG2-96
c-Myb
Pitl
Spl
Sp3
TFIID
YY1
Rabbit
Goat
Rabbit
Rabbit
Rabbit
Rabbit
500-640 aa’s o f  c-Myb H-141
Peptide mapping at the N- N-20
terminus o f Pitl
528-548 aa’s within an PEP2
internal region o f  Sp 1 
Peptide mapping at the C- D-20
terminus o f Sp3
1-300 aa's representing full SI-1
length TFIID p36
aa’s 1-414 representing H-414
full-length YY1
* PAD: Polyclonal antibody designation
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5.3 Results
5.3.1 Interaction of Spl, Sp3 and YY1 with the occludin 
promoter
This chapter presents a study addressing the promoter occupancy o f  occludin by 
the TFs SP1, Sp3 and YY1 in endothelial cells derived from brain, dermal and 
lung. EMSA data clearly indicates there is a difference in the association o f  
transcription factors with the occludin promoter between brain and non-brain 
endothelium. To determine if  the TFs Spl, Sp3 and YY1 are present in the 
regulatory protein complex on the chromatin o f occludin in different endothelia 
and to elucidate any differences between the cell types, chromatin 
immunoprecipitation (ChIP) was carried out using specific antibodies directed 
against the three TFs.
DNA isolated from immunoprecipitation with TF(s) and/or control antibody was 
subjected to a PCR analyses with primer pairs designed to amplify regions o f  the 
promoter DNA that have Sp or YY1 sites and the length o f the amplified 
fragments corresponding to <500 bp.
Chromatin isolated from hCMEC/D3 (Figs. 5.1, 5.4 and 5.8), primary human 
brain endothelial cells (Figs. 5.2, 5.5 and 5.9), non-brain (Figs. 5.3, 5.6 and 5.10; 
LMVEC, DMVEC) endothelial cells was immunoprecipitated with antibodies to 
Spl (Figs 5.1, 5.2 and 5.3), Sp3 (Figs. 5.4, 5.5, 5.6) or YY1 (Figs 5.8, 5.9 and 
5.10). Results show that varying association o f  the TFs with the endogenous 
occludin promoter. Results are summarised in tables 5.2 (Spl), 5.3 (Sp3) and 5.4 
(YY1).
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5.3.2 Association of the Sp family with the endogenous 
occludin promoter in brain and non brain endothelium
Spl occupied the endogeouns occludin promoter in the transformed brain 
endothelial cell line, hCMEC/D3 and in the primary brain endothelial cells 
(Tables 5.2, Figs. 5.3 and 5.4). Spl was also seen in association with the occludin 
promoter in dermal endothelial cells (Fig. 5.6) which do not express the protein 
(Chapter 2, Fig. 2.2). The TFs did not associate with the endogenous promoter in 
lung endothelial cells. (Fig. 5.5 ).
Data shows that Sp3 also occupies target motifs on the occludin promoter but only 
in brain endothelial cell (Figs. 5.7 and 5.8)s. It interacts with similar regions as the 
Spl TF except that the proximal region in hCMEC/D3 cells was also occupied 
(Figs. 5.7 and 5.8). Spl and Sp3 bind to GC and GT boxes, but with diferent 
affinities which is dependent on the ratio o f their expression in cells. Sp3 levels 
are higher in brain endothelial cells (Holloway, Sade et al. 2007) and it is possible 
Sp3 succesfully competes with Spl to interact with the consensus binding motifs. 
Our data clearly shows that Sp3 does not interact with the endogenous occludin 
promoter.
5.3.3 Association of the YY1 family with the endogenous 
occludin promoter in brain and non brain endothelium
YY1 interacted with the promoter regions in hCMEC/D3 cells, the primary brain 
endothelial cells and also in the lung endothelial cells. (Table 5.2, Figs. 5.11, 5.12 
and 5 .13).
In the lung endothelial cells, YY1 appears to interact at various points through the 
length o f the promoter (Fig. 5.13)
Results clearly demonstrate that the Spl, Sp3 and YY1 TFs actively associate 
with the occludin promoter in brain endothelial cells. However, in the lung ECs it 
appears that the Sp family is not associated with the endogenous occludin 
promoter. Experiments using higher cell number, increased amount o f  
immunoprecipitating antibody or PCR amplification cycles did not yield a 
positive PCR amplification. Nevertheless, the TF YY1 associated with the 
endogenous promoter in the lung endothelial cells.
To our knowledge, this is the first demonstration showing association o f  the Sp 
family and YY1 TFs with endogenous occludin promoter in human brain and lung 
endothelial cells. This is also the first study whereby occludin promoter regulation 
and hence activity is illustrated by the differential binding o f  TFs in brain and 
non-brain endothelium. It was not possible to repeat EMSA analysis undertaken 
with the transformed cell line in primary human brain endothelial cells as 
availability o f  tissue was a limiting factor. However, it was possible to scale down 
the ChIP protocol for primary human brain endothelial cell cultures and 
investigate any possible differences in TFs associated with the promoter in 
transformed and primary cell cultures. The ChIP assays confirm the in vitro 
interaction seen between the three transcription factors present in hCMEC/D3 
nuclear extracts and occludin promoter DNA as these complexes were active in 
cultured live cells. It is clearly apparent that the some o f the TF-DNA interactions 
are also seen in primary cell cultures.
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5.3.4 Discussion
Chromatin immunoprecipitation (ChIP) is a powerful technique for studying 
interactions o f  DNA with proteins including transcription factors and histones. 
Data in this chapter represents to the best o f  our knowledge, the first analyses 
carried out on transcription factor interactions with the endogenous occludin 
promoter in primary and transformed brain and lung endothelial cells.
The ChIP assays demonstrate that
1. Sp family and YY1 interact with target cis-elements in the endogenous 
human occludin promoter.
2. Spl and Sp3 are recruited to the occludin gene promoter in brain 
endothelial cells in contrast to the lung endothelium, where Sp family TFs 
are not associated with any o f the target sequences and only YY1 
association is observed.
3. The TF YY1 binds the promoter at different sites in the brain and lung 
endothelium raising the possibility that it differentially regulates chromatin 
structure across different endothelia.
We found that Sp3 in primary and transformed brain endothelium is associated 
with the proximal GC rich region which has been shown to be a part o f  the 
minimal promoter in epithelial cells. It is known that this binding is not exclusive 
to occludin as expression o f a number o f other genes involves Sp family binding 
to similar proximal GC motifs.
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5.3.4 Discussion
Chromatin immunoprecipitation (ChIP) is a powerful technique for studying 
interactions of DNA with proteins including transcription factors and histones. 
Data in this chapter represents to the best of our knowledge, the first analyses 
carried out on transcription factor interactions with the endogenous occludin 
promoter in primary and transformed brain and lung endothelial cells.
The ChIP assays demonstrate that
1. Sp family and YY1 interact with target cis-elements in the endogenous 
human occludin promoter.
2. Spl and Sp3 are recruited to the occludin gene promoter in brain 
endothelial cells in contrast to the lung endothelium, where Sp family TFs 
are not associated with any of the target sequences and only YY1 
association is observed.
3. The TF YY1 binds the promoter at different sites in the brain and lung 
endothelium raising the possibility that it differentially regulates chromatin 
structure across different endothelia.
We found that Sp3 in primary and transformed brain endothelium is associated 
with the proximal GC rich region which has been shown to be a part of the 
minimal promoter in epithelial cells. It is known that this binding is not exclusive 
to occludin as expression of a number of other genes involves Sp family binding 
to similar proximal GC motifs.
In the lung endothelium, YY1 binds to an upstream 5’ cis element (also confirmed 
by EMSA); this association has not been observed in the brain endothelium. It is 
possible, YY1 binding to the endogenous promoter may lead to different 
outcomes in brain and lung endothelia.
YY1 can function as a positive or negative regulator of transcription. The TF 
positively modulates transcription by inducing bends in DNA (Thomas and Seto 
1999) or forming synergistic associations with other proteins. Transcription 
factors are able to act as activators or repressors by using specific domains. 
However, certain regulatory proteins are able to exert their control on gene 
promoters indirectly. These proteins bend DNA resulting in the alteration of 
promoter structure which can either facilitate or abrogate interactions between co­
activators, TFs and other components of the basal transcription machinery (Maher 
1998). Examples of DNA-bending proteins include HMGB proteins (Grasser, 
Launholt et al. 2007), SRY (Harley 2002), YY1 etc. YY1 induced bending of 
DNA has been reported in the regulation of the c-fos (Natesan and Gilman 1993) 
and the c-Myc (Austen, Cerni et al. 1998) promoters.
Interactions with other regulatory proteins have been known to alter or modulate 
the ability of YY1 to interact with its recognition sequence on DNA. A large 
number of proteins have been reported to interact with YY1 and includes TATA 
binding protein, Spl (Seto, Lewis et al. 1993), c-Myc (Shrivastava, Saleque et al. 
1993), C/EBP (Bauknecht, See et al. 1996) etc. YY1 also associates with p300 
(Austen, Luscher et al. 1997) and CREB-binding protein (CBP) (Lee, Galvin et al. 
1995) which function as histone acetyltransferases. Acetylation of histones
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neutralises the charge on their N-terminal tails and reduces the affinity of histones 
for DNA. This leads to a decondensation of chromatin resulting in a relaxed 
structure that can be accessed by other TFs and co-activators. YY1 also interacts 
with histone deacetylases (HDACs) (Yang, Inouye et al. 1996; Yang, Yao et al. 
1997) which deacetylate the repressor domain(s) and hence determine the ability 
of YY1 to function as a transcriptional repressor. The binding of YY1 to the F0.1 
(Fig. 4.14) in the lung endothelium could lead to changes in chromatin structure 
that impairs the access of Sp family members to the occludin promoter.
In the brain endothelium, however, it is possible that synergistic association 
between the Sp family and YY1 transcription factors contribute to activating 
transcription from the occludin promoter. ChIP analysis from primary brain 
endothelium shows the association of YY1 in the region which has been identified 
to be a minimal promoter in epithelial cells. The Sp family also interact with the 
promoter in this region. Sp and YY1 TFs interactions have been observed in the 
activation of other gene promoters. This could be the case for occludin gene 
expression as well. Beyond directly regulating occludin basal promoter activity, 
they could also potentially contribute to remodelling the chromatin structure. 
Recent work identified the ability of Sp family to interact with p300 a histone 
acetyltransferase (Hung, Wang et al. 2006).
Further chromatin structure modifications could be undertaken by the recruitment 
of a TF that binds to a NFicB-like site in the proximal promoter (Fig. 4.5). As 
discussed before, there appears to be a distinct neuronal-KB-binding factor that is 
found in a complex of Spl and -3 and binds the NFkB consensus (Mao, Moerman
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et al. 2002). And if this factor, can like NFkB recruit histone acetyl transferases 
could result in increased acetylation of histones in the occludin promoter region 
leading to relaxation of the chromatin structure and allowing easy access for Sp3 
and YY1 TFs to the binding regions. It is likely that the chromatin structure of the 
occludin promoter is predominantly in the relaxed form in brain endothelial cells.
Detailed study of chromatin remodelling in the occludin promoter region in brain 
endothelial cells could thus potentially contribute to an understanding of how 
transcriptional regulation is differentially controlled in the brain and non brain 
endothelium.
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Chapter 6
Sp family and YY1 Transcription 
Factors in Endothelium
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6 Sp family and YY1 Transcription Factors 
in Endothelium
6.1 Introduction
Spl, Sp3 and YY1 are ubiquitously expressed ZnF transcription factors. Spl is a 
known activator and has been implicated in the activation of diverse genes 
regulating tissue specificity, cell-cycle and is required to prevent methylation of 
CpG islands (Suske 1999). Sp3 apart from its role as a transctivator is known to 
repress Spl activity (Hagen, Muller et al. 1994). Spl and Sp3 when expressed in 
the same cell compete for the binding sites on the DNA and hence the levels of 
expression of the individual proteins determine the binding of either Spl or Sp3 to 
bind target motifs (Sjottem, Anderssen et al. 1996). The structure and arrangement 
of the recognition sites and the ratio of the factors in a cell appear to determine 
activity or repression. It has been established that prompters containing a single 
binding site are activated, whereas promoters containing multiple binding sites 
often are not activated (Dennig, Beato et al. 1996).
YY1 is a bi-functional protein that serves as a repressor or activator (Thomas and 
Seto 1999). YY1 represses transcription from the adeno-associated virus promoter 
and activates transcription of the c-myc and ribosomal proteins L30 and L32 (Lee, 
Galvin et al. 1995; Yang, Inouye et al. 1995; Austen, Cemi et al. 1998). YY1 
activity is further complemented by its ability to induce DNA-bending which 
affects position and interaction of other proteins present on the promoter or
2 1 6
enhancer regions (Thomas and Seto 1999).
Aims
In the present study, the occludin promoter interacts with the Sp and YY1 family 
of transcription factors in brain endothelial cells. However, in lung endothelial 
cells, the association of occludin promoter fragments with Sp TFs is absent and 
YY1-DNA complexes are seen in different regions of the promoter.
1. To establish the expression and localisation of YY1 and Sp family 
in brain and lung endothelial cells
2. Investigate if the transcription factors interact at the level of the 
protein
3. To determine the effect of inhibition of transcription factor-DNA 
complexes on the expression of the occludin protein
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6.2 Material and Methods
6.2.1 Immunofluorescence
Cells were grown to confluence on collagen-coated cover slips and rested for 2 
days in EGM-2 medium with serum but lacking growth factors. The monolayers 
were washed with chilled PBS for 15 minutes with three changes of the buffer. 
For staining for transcription factors, cells were fixed with 4% paraformaldehyde 
(PFA) in PBS for 15 min at RT. Cells were then washed with PBS for 15 min with 
three changes of buffer were permeabilised with 0.2% Triton-X-100 in PBS for 10 
min. After 15 min incubation with blocking buffer (0.5% BSA in PBS), cells were 
incubated with the primary antibody for 2 hours at RT and washed in PBS for 15 
min with three changes of the buffer. This was followed by incubation with rabbit 
anti-mouse or goat anti-rabbit IgG conjugated FITC (1:250, Vector Labs, 
Burlingame, CA) for 1 hour at RT. Cells were washed for 40 min with four 
changes of buffer and the coverslips were mounted on slides with 
DakoCytomation fluorescent medium (Carpinteria, CA) and analysed by confocal 
or fluorescent microscopy.
6.2.2 Immunoprecipitation analysis
Buffers
RIPA buffer: 50mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% Na-deoxycholate, 150 
mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 pg/ml each of aprotinin, leupeptin, 
pepstatin, 1 mM Na3V04  and 1 mM NaF. 1 mg/ml aliquots of the protease 
inhibitors were stored at -20°C and were made up in water (leupeptin and
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aprotinin) or methanol (pepstatin). All other components were stored at 4°C
40 pi of Protein G slurry (Pierce, Chester, UK) was used per immunoprecipitation 
reaction. The slurry was spun down, washed once and then resuspended in 250 pi 
of chilled RIPA buffer and 2 pg of the specific antibody was added and incubated 
for 1 h at 4°C on a cell mixer. Isotype matched IgG was used to control for 
specificity in all immunoprecipitation assays.
106D3, DMVEC or LMVEC endothelial cell monolayers were washed twice with 
chilled PBS and then scraped into 1ml of ice-cold RIPA lysis buffer. The samples 
were incubated at 4°C for 15 min on a cell mixer. The lysates were then 
centrifuged at 14000 rpm for 15 min at 4°C to remove cell debris. The supernatant 
was carefully removed and immunoprecipitated overnight at 4°C with the protein 
G beads previously incubated for 1 h at 4°C with the specific antibody. After three 
washes with chilled RIPA buffer to remove non-specific protein, beads were 
resuspended in SDS lysis buffer and boiled at 100°C for lOmin and samples spun 
briefly at 14000 rpm. The supernatants containing the immune complexes were 
separated on 10% SDS-PAGE gels and subunit composition of the complexes was 
detected by western blotting as described in below.
6.2.3 Western blot analysis 
Buffers
Tris/EDTA: 6.057g Tris, 0.93g EDTA, pH adjusted to 7.4 with HC1
Lvsis Buffer: 1%TNE, 1% Triton-X-100, 1 mM PMSF and lpg/ml each of
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leupeptin, aprotinin, pepstatin and made up in water.
Laemelli’s reducing buffer: 62.5 mM Tris HC1 pH 6.8, 2% SDS, 10% (v/v) 
glycerol, 50 mM DTT, 0.5% bromophenol blue made up in distilled water.
lOx Running Buffer-lOx Tris/Glvcine/SDS: 0.25 M Tris, 1.92 M Glycine and 1% 
SDS (Cat No: EC-870, National Diagnostics)
lOx Transfer Buffer-lOx Tris/Glycine: 0.25 M Tris, 1.92 M Glycine (Cat No: EC- 
880, National Diagnostics)
Blocking buffer: 5% non-fat dry milk (Blotto®, Cat No: sc-2325, Santa Cruz 
Biotechnology) in 0.1% Tween 20 in PBS
ProtoGel 30%: (Cat No: EC890, National Diagnostics)
PBS-Tween 20 (PBS-D: lx  PBS (pH 7.4) with 0.1% Tween 20
Cells were harvested and washed twice by centrifugation in chilled PBS. Cells 
were lysed in 100 pi of lysis buffer, vortexed and then sonicated on ice for 10 sec 
to reduce sample viscosity. Protein concentration was measured using the DC 
Protein assay kit according to the manufacturer’s instructions (Cat no: 500-0116, 
Bio-Rad Laboratories). Samples were made up in 2x or 4x Laemelli’s buffer 
depending on the protein concentrations and boiled at 100°C for 5 min. Samples 
were centrifuged at -14000 rpm for a min before loading on 10-15% SDS-PAGE 
gels. 5 pi of pre-stained protein molecular weight marker (Cat No: P7708S, NEB) 
was loaded on the gels to visualise and determine the molecular weights of the 
target proteins. Proteins were transferred onto Hybond-ECL nitrocellulose
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membrane (Cat No: RPN303D, Amersham) for 2 hours at 0.45 mA using the wet 
transfer technique. Protein transfer was validated by using Ponceau Red (Cat No: 
09189, Sigma) staining. Membranes were washed in PBS constituted with 0.1% 
Tween-20 for 5 min to rid of excess dye and then incubated in blocking buffer for 
1 h at RT. The membrane was incubated overnight with primary antibody in 
blocking buffer at 4°C, with gentle rocking. Membranes were washed for 30 min 
with three changes of buffer and then incubated for 1 h at RT with goat anti-rabbit 
HRP or with rabbit anti-mouse HRP (1:5000, Pierce Biotechnology), diluted in 
blocking buffer. After another three washes, proteins were detected by 
chemiluminescence, according to the manufacturer’s instructions (Amersham)
6.2.4 Treatment with mithramycin
Mithramycin: cat no: M6891 (Sigma). Stock solutions were made up in DMSO 
and stored at -20°C.
' X lEMSA: Double stranded P-labeled fragment 8 containing two Sp sites was used 
as a probe. To block Spl/3 binding to DNA, DNA probes were preincubated for 1 
h at 4°C with mithramycin (50 nM, 100 nM, 200 nM) or DMSO (control) before 
being used in binding reactions with nuclear extracts derived from hCMEC/D3 
ECs.
Immunostaining: For analysis of tight junctions in mithramycin treated cells, 
confluent hCMEC/D3 cells were cultured with 100 nM and 200 nM mithramycin 
for 48 hours. Cell monolayers were washed in HBSS without Ca2+ and Mg2+ and 
then detached from the matrix by incubation with 0.25% Trypsin-EDTA at 37°C
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for 5 min. Cells were then centrifuged at 1500 rpm for 5 min and gently 
resuspended in PBS containing 0.4% paraformaldehyde and incubated for 20 min 
at room temperature followed by centrifugation. Supernatants were discarded and 
cell pellets were washed twice with PBS and then resuspended in PBS containing 
0.01% triton-X-100 (permeabilisation buffer, PB) and incubated on ice for 20 
min. Samples were microfuged at 4000 rpm for 5 min and pellets resuspended in 
lOOpl of primary or isotype antibody made up in the PB and incubated on ice for 
40 min. Samples were microfuged at 4000 rpm for 5 min and cell pellets washed 
twice with excess chilled PBS to rid of unbound antibody. 100 pi of secondary 
antibody (1:200, goat anti rabbit Alexa Fluor 488, Cat No: Al 1094) was added to 
the cell pellets and incubated on ice for 40 min following which samples were 
microfuged and cell pellets washed in excess chilled PBS. Finally, the cells were 
resuspended in chilled PBS for analysis on FACS.
Trypan blue exclusion assay: cells were incubated at RT for 10 min with 0.1% 
trypan blue and the cells were counted in a hematocytometer for dye uptake. At 
least 300 cells were counted for each data point.
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6.3 Results
6.3.1 Immunoreactivity and localisation of Sp family and YY1 in 
Brain and Non-brain Endothelium
hCMEC/D3 (Fig. 6.1), LMVEC (Fig 6.2), BMEC (Fig. 6.3) and primary human 
brain endothelial cells (Fig. 6.4) were assayed for the expression and localisation 
of the regulatory proteins. The transcription factors were detectable on all three 
endothelia and show a predominantly nuclear localisation, though cytosolic 
localisation is observed following Sp3 and YY1 immunostaining in lung and 
dermal endothelial cells respectively. Levels of the transcription factors were 
similar between cells in various stages of cell cycle. However, the levels and 
profiles of the transcription factors are dependent on the endothelial cell type.
6.3.1.1 Sp 1 and Sp3
The Sp3:Spl ratio is highest in brain endothelium, in both the primary as well as 
the transformed line (Figs. 6.1 and 6.4). Similar Sp3:Spl ratio was maintained in 
lung (Fig. 6.2) but not in dermal ECs (Fig. 6.3) where the expression of Spl was 
favoured over Sp3. Spl expression in hCMEC/D3 and lung endothelial cells was 
predominantly nuclear but speckled. In the primary brain and dermal endothelial 
cells, Spl expression was seen in the nucleus and excluded from the nucleolus. 
Additionally, in the primary endothelial cells, traces of Spl protein were also seen 
in the cytoplasm. Sp3 protein was predominantly nuclear localised in hCMEC/D3, 
dermal and primary brain endothelial cells.
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However, in lung endothelial cells, the Sp3 protein was also observed in the 
cytoplasm. It should be noted that the antibody to Sp3 recognises in addition to 
the full length protein, the shorter isoforms (N-terminal truncations) which are 
also nuclear localised.
6.3.1.2 YY1
The expression of YY1 was low in hCMEC/D3 cells and a distinctive punctuate 
nuclear localisation was observed (Fig. 6.1). Lung (Fig. 6.2) and dermal (Fig. 6.3) 
ECs expressed higher levels of YY1 though the cytosolic localisation was 
restricted to the latter cell line. YY1 expression was excluded from the nucleolus 
in cells of both the lines. It must be noted that YY1 expression and, especially, 
localisation in the primary endothelial cells is similar to that visualised in primary 
lung and dermal endothelium. It is indeed possible that some of the characteristics 
of the hCMEC/D3 cell line could be contributed by virtue of the SV-40 large T 
transformation. We investigated whether a bone marrow endothelial cell line 
which has been transformed by SV-40 large T showed similar pattern of staining 
to hCMEC/D3 cells (Fig. 6.5). Bone marrow endothelial cells showed strong 
expression of YY1 in the nucleus and did not show the nuclear punctate staining 
seen in the brain endothelial cell line. These data suggests that the YY1 
expression and localisation of YY1 in hCMEC/D3 is a characteristic of the cell 
line which is not dependent on the transformation.
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Figure 6-1 Expression of Sp Family and YY1 in hCMEC/D3 Cells by 
Immunofluorescence Confocal Microscopy
hCMEC/D3 
RblgG Sp1
Sp3 YY1
Cells were rested for two days after reaching confluence and were then stained 
with antibodies to Spl, Sp3 or full length YY1 (H414). Normal rabbit IgG served 
as a negative control. All TFs are predominantly nuclear localised. Spl and YY1
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exhibit a speckled nuclear profile. Data shown is representative of 3 independent 
experiments.
Figure 6-2 Expression of Sp Family and YY1 in Lung Endothelial (LMVEC) 
Cells by Immunofluorescence Confocal Microscopy.
LMVEC
RblgG Sp1
Sp3 YY1
Cells were rested for two days after reaching confluence and were then stained
with antibodies to Spl, Sp3 or full length YY1 (H414). Normal rabbit IgG served
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as a negative control. Spl expression in very low but is nuclear localised. Sp3 and 
YY1 are strongly expressed but expression also seen in the cytosol. Data shown is 
representative of 3 independent experiments.
Figure 6-3 Expression of Sp Family and YY1 in Dermal Endothelial 
(DMVEC) Cells by Immunofluorescence Confocal Microscopy
DMVEC 
RblsG
Sp3 YY1
Cells were rested for two days after reaching confluence and were then stained
with antibodies to Spl, Sp3 or full length YY1 (H414). Normal rabbit IgG served
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as a negative control. Spl and YY1 are strongly expressed; Sp3 levels are low 
with some localisation in the cytosol. YY1 levels in the cytosol are the highest in 
among the endothelia.
Figure 6-4 Expression of Sp family and YY1 in Primary Human Brain 
Endothelial Cells by Immunofluorescence Confocal Microscopy
P r im a r y  BEC 
RblgG Sp1
Sp3 YY1
Cells were rested for two days after reaching confluence and were then stained
with antibodies to Spl, Sp3 or full length YY1 (H414). Normal rabbit IgG served
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as a negative control. Sp family and YY1 are strongly expressed, the latter shows 
punctate cytoplasmic localisation.
Figure 6-5 Expression of Sp Family and YY1 in Bone Marrow Cells by 
Immunofluorescence Confocal Microscopy
RblgG Sp1
Sp3 YY1
Cells were rested for two days after reaching confluence and were then stained 
with antibodies to Spl, Sp3 or full length YY1 (H414). Normal rabbit IgG served 
as a negative control. Sp 3 family and YY1 are strongly expressed, Spl exhibits
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speckled localisation in the cytosol and nucleus.
Figure 6-6 Quantification of differences in Sp family and YY1 TFs in 
hCMEC/D3 (D3), LMVEC (LM) and DMVEC (DM) cells
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After correction for background intensity which was estimated from several 
intensity measurements in regions of the coverslip that did not contain any cells, 
boxes were drawn around the fluorescent structure in each cell and the pixel 
intensity was determined. This measurement was repeated for -40 cells each 
from three experiments done on different days.
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6.3.2 Interaction of Sp3 and YY1 in Brain Endothelium
Whole cell lysates from different endothelia were investigated by 
immunoprecipitation analyses to determine if the TFs interact in vitro (Fig. 6.6). 
Sp3 (top panel) or YY1 (lower panel) protein were immunoprecipitated with their 
respective antibodies and the immunoprecipitates from each condition were 
analysed by western blotting for the presence of the precipitated protein as well as 
for the other transcription factors as evidence of interaction.
The results show that in hCMEC/D3 cells, Sp3 immunoprecipitation causes the 
co-precipitation primarily of the smaller YY1 variants. We detected some co- 
immunoprecipitation of the full length YY1 (70 kDa) by anti-Sp3 in dermal 
endothelium, but not in lung endothelium. The result was confirmed when the 
analyses was carried out by immunoprecipitating YY1 and investigating for the 
presence of Spl and Sp3 in the complexes. YY1 interacts with the larger variant 
of Sp3 (116 kDa) in the brain endothelium, but not from lung endothelium. Co­
precipitation of Sp3 with anti-YYl from dermal lysates was barely detectable.
The results indicate a strong association of YY1 and Sp3 in brain endothelium 
which is absent in non-brain endothelium.
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Figure 6-7 Interaction of Sp3 and YY1 Proteins in Endothelium
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Cell lysates o f  hCMEC/D3 cells, lung (LMVEC) and dermal (DMVEC) 
endothelia were immunoprecipitated with protein-G beads in the presence o f  
antibodies to transcription factors (Sp3 or Y Y I) or RblgG as negative control. 
Whole cell lysates (WCL) were used as positive control to confirm the 
size/presence o f  the transcription factor in each cell type. The precipitates were 
examined by western blotting for the presence o f Sp3 or Y Y 1. The upper 6 blocks
232
show experiments in which immunoprecipitating antibody was Sp3, to detect co 
precipitation o f  YYI. The lower 6 blocks show an experiment in which 
immunoprecipitation was carried out with anti-YYI antibody to detect co 
precipitation o f  Sp3.
6.3.3 Promoter Activity of Fragment 8 with Sp Site Deletions
A  single Sp site has been shown to be sufficient to drive transcription in 
promoters o f diverse genes. Most promoters contain multiple GC boxes to which 
Sp family members can bind but it is possible that only one or two sites are 
important in driving transcription. The human H-ras promoter has six Spl sites o f  
which only the most proximal one located around -45 is required for expression 
(Pintzas and Spandidos 1991). DNase I footprinting experiments using a TATA- 
less promoter containing Spl binding sites have shown that binding o f Spl 
stabilizes interaction o f TFIID with the transcription start site region (Emami, 
Burke et al. 1998).
Hence we hypothesised that the two Sp sites on fragment 8 could be important for 
the regulation o f the occludin promoter by the Sp TFs. The two Sp sites on 
fragment 8 ; 1798 CCCTCCC 1804 and 1820 AGGCGG 1825 were targeted for 
deletion and two single deletion mutants were generated. EMSA were carried out 
with the wild type and the mutants but unfortunately the results were not clear as 
the mutant probes generated a lot o f  background (not shown). However, the 
double stranded DNA probes were cloned into promoter deficient vectors and 
transient transfections were carried out in hCMEC/D3 cells (Fig. 6.3)
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Results show strong mediation o f GFP expression in cells transfected with the 
wild type fragment 8 . In cells transfected with the promoter fragment lacking the 
first Spl binding sequence-CCCTCCC (1798-1804), the GFP expression was 
comparable to WT albeit slightly decreased. However, deletion o f  the second Sp 
site AGGCGG (1820-1825) dramatically decreased the ability o f  the promoter 
fragment to drive GFP expression. The results imply that the downstream Sp site 
is important for the expression o f the occludin protein in brain endothelium. 
Sp3/Spl interacts with two putative target binding sites close to the transcription 
start to initiate or maintain expression. However, these sites are inactive in lung 
endothelium.
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Figure 6-8 Contribution of Sp Sites to the Activity of Fragment 8
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Promoter activity implicated by GFP expression in hCMEC/D3 transfected with 
vector containing wild-type F8 (A), or F8 with deletion o f  Sp target sites (B and 
C) (filled histograms) compared with control vector (open histograms). (B) 
Mutant represents deletion o f  the Sp-site at position -34 and (C) denotes deletion 
o f  the Sp-site at position -56. (D) represents relative GFP fluorescence o f  the three
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vectors from 5 different experiments.
6.3.4 Inhibition of Sp Transcription Factors by Mithramycin
Mithramycin is an aureolic acid antibiotic that specifically binds to GC sequences 
on the DNA and selectively inhibits transcription. Mithramycin A is a potent 
inhibitor o f  Spl binding to GC boxes in DNA, and is capable o f  interfering with 
Spl-mediated gene transcription (Blume, Snyder et al. 1991). Mithramycin has 
been shown to block binding o f  Sp factors consensus sites in the human c-myc, 
the SV40 early promoter and in the human dhff promoter (Ray, Snyder et al. 
1989; Blume, Snyder et al. 1991; Snyder, Ray et al. 1991). Mithramycin has been 
used as a specific inhibitor o f Spl, although the inhibition o f the binding o f  other 
transcription factors that recognize GC-containing sequences in the minor groove 
o f the DNA cannot be excluded (Miller, Polansky et al. 1987). For example, other 
ZnF transcription factors, including Egr-1, bind to GC-rich sequences in DNA  
(Krikun, Schatz et al. 2000). A lack o f specificity would lead to primary 
mithramycin cytotoxicity. With this possibility in mind we used concentrations o f  
mithramycin that did not affect cell viability. Mithramycin used at 50, 100 and 
200 nM did not affect cell survival 72 hours post incubation as assayed by trypan 
blue exclusion (Fig. 6 .8).
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Figure 6-9 Cytotoxicity of Mithramycin in hCMEC/D3 Cells
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6.3.4.1 Inhibition of Spl/3 Binding to F8 Probe
We first tested the effectiveness o f  mithramycin in reducing the binding o f  
Spl/Sp3 to the occludin promoter in a gel-shift assay (Fig. 6.9). The DNA probe 
F8 was used as it functions as minimal promoter in hCMEC/D3 cells. Labelled ds 
DNA probe was incubated with three different concentrations o f  mithramycin 
before the binding reaction with brain endothelial nuclear extracts. In chapter 3 , 1 
discussed the activity o f  the promoter probe in brain endothelial cells and 
concluded that Sp3 binds to the probe and is responsible for nuclear protein-DNA 
complexes F8.1, F8.2 and F8.3. Nuclear protein-DNA complex F8.4 was not 
abrogated in the presence o f  an antibody to Sp3 but was inhibited in the presence 
o f  a Sp competitor. Spl did not bind to the probe as evident by supershift assays. 
In the present experiment, Mithramycin reduced the binding o f  Sp3 to its
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recognition sequence in a dose-dependent manner (Fig. 6.9, lanes 5, 6 and 7). In 
the presence o f  50 nM mithramycin, complex F8.1 was partially abrogated (lane 
5). Incubation with 100 nM concentration o f  the drug abrogated complexes F8.1 
and F8.2. Higher concentration (200 nM) o f the drug inhibited the same 
complexes as the condition in which Sp3 antibody was present (lanes 4 and 6).
Figure 6-10 Mithramycin Blocks Binding of Sp TFs to Target DNA Motifs
Labelled oligo F8 
hCMEC/D3
Nuclear extract 
Sp1 ab 
Sp3 ab
50nM Mithramycin - - - - + - -
200nM Mithramycin  + -
100nM Mithramycin ......................... +
M---- F8.1
<---- F8.2
« — F8.3
k
<— F8.4
-n sp
FP
1 2 3 4 5 6 7
238
Fig. 6.10: EMSA analysis o f complexes (8.1, 8.2, 8.3 and 8.4) formed with 
promoter probe F8 and hCMEC/D3 nuclear extracts cultured in the absence (lanes 
2) or presence o f  different concentrations o f  the drug, mithramycin (lanes 5, 6 and 
7). Lane 1 represents mobility o f the probe in the absence o f  nuclear protein. 
Presence o f  lOOnM (lane 7) or 200nM (lane 6) mithramycin inhibited the 
formation o f  nuclear protein complexes identical to those inhibited in the presence 
o f  Sp3 supershift antibody.
6.3.4.2 Occludin Protein in Mithramycin Treated hCMEC/D3 Cells
To further demonstrate the role o f Sp transcription factors in the expression o f  
occludin, cells treated in the presence or absence o f 100 nM or 200 nM 
mithramycin were immunostained with an antibody to occludin (Fig. 6.12). Total 
occludin protein levels were down regulated in the presence o f  the 
pharmacological inhibitor (Figs. 6.11 and 6.12). This appears to be specific as 
expression o f other tight junction proteins-claudin 5 and ZOl was unaffected.
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Figure 6-11 Expression of TJ Proteins in Mithramycin Treated Brain
Endothelial Cells
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Graph represents percentage o f hCMEC/D3 cells expressing claudin 5 or occludin 
when cultured in the presence or absence o f  mithramycin. Data is obtained from 3 
experiments. Each protein was analysed by ANOVA followed, i f  p<0.05, by 
Dunnett’s multiple comparison test. *** indicates expression is significantly 
different from untreated cells, p<0 .001 .
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Figure 6-12 Loss of Occludin Protein in Mithramycin Treated Brain
Endothelial Cells
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Fully confluent hCMEC/D3 cells were cultured in the presence o f  DMSO  
(control), 100 nM mithramycin or 200 nM Mithramycin for 48 hours following  
which the cells were immunostained for the tight junction proteins-claudin 5 (left 
hand panel) and occludin (right hand panel) and assayed on FACS. Isotype 
matched IgG was used as a control.
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6.4 Discussion
Data so far shows that nuclear factors belonging to the Sp family and YYI present 
in brain endothelial cells bind the occludin promoter in vitro and in vivo and the 
key question is investigating whether one or both o f these proteins are involved in 
tissue-specific expression o f occludin in CNS endothelium.
Occludin mRNA levels increase with increasing confluence in brain endothelial 
cells cultures. The levels o f  occludin protein at the tight junction increase as cell­
cell contacts and junctions are established in fully confluent and resting culture. In 
this study we found that one o f the two Sp elements namely the one located 
between 1820-1825 (AGGCGG) o f the occludin promoter is responsible for a 
major part o f  occludin promoter activity in hCMEC/D3 cells (Fig. 6 .8C) and Sp3 
bound to this element (Figs. 4.4 and 6.10). It was slightly unexpected that 
promoter activity could be determined by a single Sp element especially as the 
data with the reporter vector constructs indicated activity in regions o f the 
promoter which lack this site. A  single Sp site has been shown to be sufficient to 
drive transcription in promoters o f diverse genes. Most promoters contain 
multiple GC boxes to which Sp family members can bind but it is possible that 
only one or two sites are important in driving transcription. The TATA-less 
human H-ras promoter has six Spl sites o f  which only the most proximal one 
located around -45 is required for expression (Pintzas and Spandidos 1991). Based 
on these results, it was suggested that Spl is required for functional assembly o f  
the basal transcription machinery on the H-ras promoter. DNase I footprinting 
experiments using a TATA-less promoter containing Spl binding sites have
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shown that binding o f  Spl stabilizes interaction o f TFIID with the transcription 
start site region (Emami, Burke et al. 1998). Another reason could be the fact that 
occludin expression is restricted and its regulation is different from genes that are 
commonly expressed. One o f  the main differences in the regulation o f  promoters 
from housekeeping and tissue specific genes is the presence o f extensive 
redundancy in the house keeping gene promoters. Both kinds o f  promoters 
display numerous transcription factor binding sites but large deletions or removal 
o f TF binding sites have relatively little effect on promoter activity on the 
promoters o f  housekeeping genes. Examples o f  such housekeeping promoters are 
the mouse DHFR promoter, the mouse hprt promoter and several promoters o f 
ribosomal protein genes. It has been proposed that different cell types exhibit 
different sets o f transcription factors and hence multiple regulatory elements are 
required for gene expression in each cellular background. Another proposal 
contends that activity o f  housekeeping genes is not sensitive to singular or 
transient cues from the environment and altering promoter activity in these 
promoters requires manifold changes in the cell environment and recruitment o f  
multiple regulatory elements.
We also confirmed the importance o f  the Sp elements by using mithramycin, a 
drug that modifies GC-rich regions o f  the DNA and blocks Spl/Sp3 binding 
(Blume, Snyder et al. 1991). Mithramycin treatment inhibited Sp3 binding to the 
Sp element (Fig. 6.10) and the protein levels o f occludin also decreased in 
mithramycin treated cells (Fig. 6.12) which strongly suggests that Sp3 binding is 
essential for occludin expression. Other TJ proteins like claudin 5 and ZO 1 were 
not affected. All o f these results clearly suggest that induction o f  occludin gene
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expression is dependent on activity of Sp3.
It is unlikely that Sp3 acts alone to activate expression from the occludin 
promoter. Sp3 is not a strong transctivator like Spl (Hagen, Muller et al. 1994) 
and usually interacts with other co-activators to drive transcription. We have 
investigated if  the Sp and YYI family members interact in brain endothelium. Sp3 
interacts with YYI in the brain but not in lung endothelium (Fig. 6.7).
The lung and dermal endothelial cells express the full length form o f  YYl-70kDa. 
The full length form o f  YYI in the brain and non-brain endothelium is subject to 
posttranslational modification like phosphorylation and acetylation that regulate 
the DNA-binding affinity and the capacity to form complexes with other nuclear 
proteins (Thomas and Seto 1999). In the brain endothelium there is a shorter 
isoform o f  YYI that migrates at 45 kDa in addition to the full length form 
(Holloway, Sade et al. 2007). Ths shorter isoform lacks the C-terminus which 
contains the DNA binding region but retains the ability to interact with TFs. This 
isoform migrates at 45kDa and is only present in the brain endothelium and absent 
from lung and dermal endothelia. This isoform could in essential act like a 
dominant negative or constitutively active form o f Y Y 1 by being able to bind 
other TFs that if  were allowed to interact with full length YYI could result in 
activation or inhibition o f transcription from a responsive promoter. In the brain, 
this isoform is as strongly expressed as the full length form (Holloway, Sade et al.
2007).
In the brain, it is clear that the shorter isoform o f  YYI interacts specifically with 
functional form o f Sp3-118 kDa and not the shorter form o f 97 kDa that has been
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shown to negatively regulate Sp3 activity. Despite interaction o f  Sp3 and YY 1 
protein, data from the YYI antibody super shift (lane 5, Fig 4.4) indicates that 
Sp3 and YY 1 do not interact in this region. Could it be possible that YY 1 and Sp3 
interact only at the level o f proteins but not as a complex with the promoter DNA?
It is possible because the shorter isoform lacks the DNA binding region but is able 
to bind TFs. It has to be remembered that YYI has the dual nature o f  activating or 
inhibiting transcription. It is possible in the brain endothelium; the shorter isoform 
binds Sp3 and acts to initiate transcription. Sp3 is a weak transactivator but in the 
presence o f  YYI and Spl is able to initiate transcription.
Figure 6-13 YYI isoforms in Brain Endothelium
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However, it is also possible that yet another single or groups o f  transcription 
factors are involved. Promoter probe F8 forms four nuclear protein complexes 
with hCMEC/D3 nuclear extract. Formation o f all complexes is completely and 
partially abolished in the presence o f a Sp competitor and an antibody to Sp3
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respectively. In addition, Spl is not a component o f these complexes as presence 
o f an antibody to the protein does not affect the formation o f  these complexes. 
Hence, all the DNA-nuclear protein interactions in this probe are Sp3 dependent. 
There are however, only two Sp sites on this probe. Several possibilities can 
explain the mismatch between the number o f binding sites and number o f  nuclear 
protein-DNA complexes:
1. There is a low molecular weight isoforms o f Sp3 in addition to the 
full length protein. The faster migrating bands on the EMSA gel may be 
attributed to these variants which would migrate differently in EMSA but 
not in western blots.
2. Presence o f  post translational variants o f Sp3 generated via 
sumoylation, phosphorylation or acetylation. F8.3 appears to have a higher 
affnity than F8.1 or F8.2 as it is harder to block. Hence it is possible these 
two complexes are formed by a post translational variant o f  Sp3.
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Chapter 7
Conclusion and Future Work
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7 Conclusion
Understanding the mechanism o f tissue-specific gene expression remains a 
fundamental question in genome biology. Despite major advances in 
developmental biology and bioinformatics, unravelling the seemingly simple 
concept o f different tissue types being determined by the same DNA template still 
remains a major challenge. The human genome has more than 25000 genes which 
display remarkable diversity in patterns and levels o f expression in different 
tissues. However these vast changes in spatial and temporal gene expression are 
controlled by only ~1850 TFs. Computational approaches have provided 
important tools in understanding transcriptional regulation in being able to predict 
identification o f  TF binding sites, regulatory elements o f combinatorial pathways 
and identification o f  gene targets for TFs in addition to promoter regions, but 
these predictions remain to be validated in vitro. Research which incorporates 
ChIP and microarray analyses in concert with cis-regulatory element analysis is 
proving a popular choice for researchers in this field.
In the present study, we investigated the transcriptional regulation o f  the tight 
junction protein occludin whose expression is restricted to the brain endothelium. 
Endothelial cells from different tissues differ widely in the expression o f  
junctional proteins and transporters. The expression o f proteins like occludin, p- 
glycoprotein and transferrin receptor is restricted to brain endothelial cells in 
contrast to claudin-5 which is strongly expressed in the brain and to a lesser extent 
in dermal and lung endothelia (Holloway, Sade et al. 2007). The mechanism(s) 
responsible for the differential expression o f these proteins is not known.
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Previously, we have shown that human brain, dermal and lung endothelial cells 
have distinct expression profiles o f  transcription factors and have demonstrated 
that a select few play important roles in the regulation o f a brain endothelial 
specific protein, the transferrin receptor promoter. Our study represents the one o f  
but many investigations where prior knowledge o f TFs expression was used to 
understand tissue specific gene expression patterns.
A brief summary o f  key findings from the work in the regulation o f  occludin in 
brain and lung endothelial cells are as follows:
1. Analysis o f the in vitro activity o f  the promoter by using a reporter vector 
transfection assay system concluded that the promoter in brain endothelial cells is 
capable o f  driving gene expression in contrast to the lung endothelium where no 
activity was observed.
2. Sp l, Sp3 and YYI present in nuclear extracts o f hCMEC/D3 cells associate 
with the occludin promoter under in vitro and in vivo conditions.
3. Sp3 interacts with YYI protein in brain endothelium and this is absent in the 
lung endothelium. The association is absent in lung in the case o f the Sp family.
4. Blocking Sp3 binding to target sites by the antibiotic mithramycin lead to the 
down regulation o f the occludin protein but not other tight junction proteins such 
as claudin 5 and ZOl.
5. Deletion o f one o f the proximal Sp sites on the promoter lead to a decrease in 
its activity on transient over expression within a reporter vector in brain
249
endothelium.
From the data, it is clear that Sp family positively regulates the expression from 
the occludin promoter in brain endothelium and YY1 augments this function and 
these TFs have important roles in maintaining the phenotype o f the differentiated 
brain endothelial cells.
It has been established in literature that Sp and YY1 TFs regulate differentiation 
in various cell types. Spl has been shown to regulate promoters o f  genes 
associated with differentiation and is also involved in transactivation o f promoters 
o f  housekeeping genes. Spl interacts with MyoD to positively up regulate the 
expression o f  many muscle-specific genes during muscle cell differentiation (Guo, 
Degnin et al. 2003). In corneal epithelial cells, the promoter o f  keratin 4 which is 
important in maintaining the differentiated phenotype is transactivated by Spl 
(Okano, Opitz et al. 2000). In F9 cells the induction o f  tissue plasminogen 
activator (t-PA) in the presence o f retinoic acid is mediated by Spl binding to 
proximal GC boxes in the t-PA promoter (Darrow, Rickies et al. 1990). Spl binds 
to a proximal GC box in the promoter o f the DNA topoisomerase Ha gene 
promoter in proliferating rat cells and activates transcription o f the gene (Yoon, 
Kim et al. 1999). Other promoters include dihydrofolate reductase (DHFR) 
(Dynan, Sazer et al. 1986), thymidine kinase (Dou, Fridovich-Keil et al. 1991), 
p21wafl/cipl (Pardali, Kurisaki et al. 2000), GM-CSF (Brettingham-Moore, Rao 
et al. 2005), EGFR (Liu, Innocenti et al. 2005). Spl physically interacts with other 
DNA binding proteins like PU.l (Feng, Teitelbaum et al. 2000), E2F-1 (Lin, 
Black et al. 1996), and p53 (Schavinsky-Khrapunsky, Huleihel et al. 2003). Rb
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protein is known to stimulate Spl and Sp3 mediated transcription (Chen,
Nishinaka et al. 1994; Udvadia, Templeton et al. 1995).
Importantly, the Sp family have also been implicated in regulation o f genes that 
are specific to endothelial cells such as those coding for the platelet-derived 
growth factor B-chain, the platelet-derived growth factor A-chain, the endothelial 
nitric oxide synthase, the vascular cell adhesion molecule-1, and KDR/flk-1.
In Chapter 1, I have discussed the upregulation o f SSeCKS (Src-suppressed C 
kinase substrate) in response to oxygen tension in astrocytes. Supernatants from 
SSeCKS-expressing cells increase the protein levels o f  ZOl and claudin 1, 
constituents o f  the TJs o f the BBB (Lee, Kim et al. 2003). An interesting 
observation is the the presence o f  a GC box between -1 0 6  and -4 9  in the proximal 
promoter o f  SSeCKS which is bound by Spl/Sp3. In v-Srotransformed NIH3T3 
cells, this region is negatively regulated by HDAC1 which is recruited into this 
complex (Yahao Bu and Irwin H. Gelman 2007).
The proximal promoter o f  GDNF (Glial cell line-derived neurotrophic factor) 
which is also involved in the development o f  blood brain barrier properties 
exhibits binding sites for Sp, AP2 and NFkB TFs (Woodbury, et al., 1998). 
GDNF is a weak promoter which is thought to be due to the presence o f  an 
upstream YY1 binding site and target motifs for other repressors namely 
epidermal growth factor receptor (ETF) and GC factor (GCF) (Baecker, Walter et 
al., 1999).
Spl along with a member o f the Ets family o f TFs, GABP has been implicated in
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the transcription o f Robo4, which is expressed exclusively in endothelial cells 
(Okada, Yano et al. 2007). In this study, GABP and Spl associate with the 
endogenous promoter in endothelial cells and transfection o f these cells with small 
interfering RNA against GABP and Spl resulted in a significant decrease in 
endogenous Robo4 mRNA expression.
Vascular endothelial cadherin another junction protein that is specific to 
endothelial cells is also regulated by the Sp family (Gory, Dalmon et al. 1998). 
Spl and Sp3 have been shown to associate with two GT boxes at positions -4 8  
and-4 0  in the proximal VE cadherin promoter and in conjunction with Ets TFs 
drive transcription.
Sp3 was initially described to inhibit Spl mediated transcription (Hagen, Muller 
et al. 1994; Dennig, Hagen et al. 1995) but later studies have identified it as a 
transcriptional activator (Liang, Robinson et al. 1996; Ihn and Trojanowska 1997; 
Prowse, Bolgan et al. 1997). This property depends on cellular context, levels o f  
Spl protein, number o f Sp elements on the promoter (Yu, Datta et al. 2003) and 
levels o f the shorter isoforms o f Sp3 itself (Kennett, Udvadia et al. 1997). There 
are three isoforms o f  Sp3; the full length isoform acts as an activator and the two 
shorter isoforms retain DNA binding activity and associate with target sequences 
to repress transcriptional activation by full length Sp3 or Spl (Kennett, Udvadia et 
al. 1997). The full length form predominates in brain endothelial nuclei, whereas 
the short isoforms predominate in non-brain endothelium, which could partly 
explain the differential activity o f Sp3 in lung and brain endothelium.
Sp3 competes successfully with Spl for the Sp target sites on the occludin
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promoter. Data indicates that it is possible the Sp3 protein singularly or via 
associations with other TFs acts to initiate transcription as Sp3 has been reported 
to be a poor activator in certain cellular systems. Our data on protein interactions 
indicate that Sp3 interacts with the transcription factor YY1 in brain endothelial 
cells and this specific interaction is absent in lung endothelial cells.
The Sp proteins present in nuclear extracts derived from the lung endothelial cells 
do not bind to the endogenous promoter or to the naked DNA in EMSA. Since 
lung endothelial cells express Spl and Sp3 it is possible that the binding motifs 
are occupied by other DNA modifying proteins restricting access to the promoter 
as seen with F8 in lung endothelial cells or there is a transcription factor that 
represses activation o f occludin transcription in the lung endothelium. Data 
suggests the possible candidate is the TF YY1 which like the Sp family proteins is 
widely expressed and acts as a repressor or as an activator dependent on cellular 
contexts.
YY1, a member o f  the Polycomb Group protein family is a ubiquitous and 
multifunctional zinc-finger transcription that has critical roles in hematopoiesis 
and cell cycle control (Thomas and Seto 1999). Promoters that have been 
established to be under YY1 control include endothelial nitric-oxide synthase 
promoter (Karantzoulis-Fegaras, Antoniou et al. 1999), c-Myc (Austen, Cemi et 
al. 1998), c-Fos (Zhou, Gedrich et al. 1995), p53 (Sui, Affar el et al. 2004), a -  
actin (Wu and Lee 2001), E6 and E7 o f HPV (O'Connor, Tan et al. 1996) and a 
number o f other viral LTRs (Shrivastava and Calame 1994). YY1 present in the 
lung endothelial nuclear extracts associates with the promoter region up stream o f
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the transcription start site and this specific binding is not seen in the brain 
endothelial cells. However, YY1 in the brain endothelial nuclear extract binds to 
other target motifs on the occludin promoter namely F5 and F6.1 raising the 
possibility that the preferential binding on the F0.1 in the lung endothelium is 
important in repression o f transcription. We have shown the interaction o f YY1 
with Sp3 in the brain endothelium where it is likely that the association is 
synergistic.
Interestingly, the Sp and YY1 family have been shown to associate with pathways 
that modulate expression and localisation o f the occludin protein at the tight 
junctions. I have discussed the regulation o f occludin protein in section 1.4.1.1.6 
by cytokines, phosphatases, Rho, PI3K and MAPK signalling. It is possible the 
regulation is mediated at the transcriptional level i.e. the decrease in protein levels 
may be correlated to the disruption o f transcription factor(s) involved in occludin 
promoter regulation.
Glucocorticoids such as hydrocortisone and dexamethasone have been shown to 
upregulate protein levels o f  occludin and increase localisation at the tight junction 
in brain endothelial cells. In brain endothelial cells, the activated glucocorticoid 
receptor has been shown to bind glucocorticoid-responsive elements, GREs in the 
occludin promoter (Forster, Silwedel et al. 2005). It will be interesting to know  
whether YY1 or Sp family o f  TFs are recruited to the promoter in this context. 
YY1 functions as a repressor in the regulation o f (3 casein promoter and in mouse 
mammary epithelial cells activation o f the glucocorticoid receptor can lead to 
disassembly o f  YY1 at the P casein proximal promoter and enhancer elements
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thus allowing for transcription (Meier and Groner 1994). It would be interesting to 
investigate if  the converse is true in the brain endothelium. Does activation o f GR 
induce increasesd recruitment o f YY1 to the oclcudin promoter? ChIP analysis o f  
hCMEC/D3 cells treated with dexamethasone and investigated for YY1 
association with the endogenous promoter would provide information.
Treatment o f  a multiple myeloma cell line, LP1 with dexamethasone induced the 
proteasomal degradation o f c-maf (Mao, Zhu et al. 2008). Mao and colleagues 
investigated the mechanism by which GCs were able to upregulate ubiquitin 
mRNA without direct association with the promoter. The authors showed 
increased association o f  the TF Spl with the ubiquitin promoter in dexamethasone 
treated cells. Since the protein levels or localisation patterns o f  Spl were not 
modulated it is speculated the increased affinity o f Spl for the ubiquitin promoter 
may be due to increased phosphorylation. In rat muscle cells, increased binding o f  
Spl to the ubiquitin promoter has been attributed to MEK1 dependent Spl 
phosphorylation (Marinovic, Zheng et al. 2002). GR induced phosphorlatyion o f  
Spl is specific as other Spl regulated genes such as Glutl are not increased in 
these cells. The mechanism behind the selective activation o f Spl in the regulation 
o f  specific genes is is unknown. Again, treatment o f  hCMEC/D3 and lung 
endothelial cells with dexamethasone and investigating any possible effects on the 
phosphorylation status o f the Spl and Sp3 protein would provide additional 
insights.
Activation o f signalling through the protein kinase C pathway induces 
phosphorylation o f occludin and its redistribution at cellular contacts. Activation
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o f  the PKC pathway in primary human nasal epithelial cells induces transcription 
from the GATA-3 and -6 gene promoters and these TFs have been shown to be 
responsible for upregulating levels o f ZO-1 and-2 and claudin-1 in these cells 
(Koizumi, Kojima et al. 2008). In T cells, PKC isoforms transactivate the 
p21W AFl gene promoter by mediating the binding o f Spl-p53 complex to 
binding sites on the promoter (Schavinsky-Khrapunsky, Huleihel et al. 2003). 
Synergistic associations between PKC and Spl drive the transcription o f  the 
human serum paraoxonase 1 (PON1) in hepG2 cells (Osaki, Ikeda et al. 2004). It 
remains to be seen if  transfection o f  small interfering RNA to the respective PKC 
isoform in our system would disrupt occludin protein expression via decreased 
association o f Sp family with the occludin promoter.
However, the role o f  Sp family and YY1 is not restricted to signalling pathways 
that upregulate occludin protein. The Sp family have been shown to play an 
important role in signalling pathways that lead to the down regulation o f  occludin 
protein and increase permeability. The cytokine TNF-a, VEGF A, reactive 
oxygen species are known to activate signalling pathways that downregulate the 
occludin protein (discussed in chapter 1). Sp family have been implicated in the 
activation o f  transcription o f the VEGF A promoter in many systems (Hasegawa, 
Wakino et al. 2006; Bermudez, Yang et al. 2007; Pages 2007; Santra, Santra et al.
2008). In ovarian cancer cells, treatment with VEGF leads to an increase in 
telomerase activity which is highly dependent on Sp and the AP family o f  TFs 
(Bermudez, Yang et al. 2007). Some o f these mentioned pathways also synergise 
to mediate their effects. Presence o f  reactive oxygen species enhances VEGF A  
gene expression and analysis o f  the VEGF-A promoter mapped the
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oxidative stress response element to a minimal sequence that contains two target 
sequences for Spl and Sp3 (Schafer, Cramer et al. 2003).
When human brain microvascular endothelial cells are exposed to 
methamphetamine, depletion o f  glutathione and corresponding increase in reactive 
oxygen species have been shown (Lee, Hennig et al. 2001). Activation o f TFs, 
AP-1 and NFkB was central to these effects. These TFs are regulated by cellular 
redox status and are known activators o f  TNF-a the cytokine that downregulates 
occludin expression. It is interesting to note the proximal promoter in occludin 
contains two sites that are bound by TFs with similar motifs to AP2-oc and NFkB. 
Shono and collagues in a different study have also shown the activation o f AP-1 
and NFkB in brain endothelial cells and have further investigated the involvement 
o f Sp family. Data indicates the Sp family are not activated in response to 
oxidative stress (Shono, Ono et al. 1996).
The work identifies the importance o f  Sp family and YY1 in the regulation o f  
occludin promoter in brain and non-brain endothelium. The occludin gene is 
actively transcribed in brain endothelium which involves the association o f the Sp 
family, particularly Sp3 which occupies the Sp binding motif close to the 3 ’-end 
o f the promoter. In lung endothelium the Sp family o f TFs do not associate with 
their target motifs due to a possible change in chromatin structure induced by the 
binding o f  YY1 to an upstream cis-element and this is associated with the lack o f  
occludin gene transcription.
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7.1 Future Work
1. The data from reporter vector assays is not conclusive in the brain endothelium. 
We were not successful in identifying a minimal promoter region and in addition 
all the fragments exhibited fairly strong promoter abilities. Deletion analysis 
resulting in the differing lengths o f  the promoter from the proximal end o f the 
promoter would probably be more useful and provide data as to the region o f the 
promoter that is most indispensable for function.
2. Chromatin immunoprecipitations in healthy and pathological brain tissue where 
occludin expression is disrupted. If the decrease in expression o f occludin is 
regulated at the transcription level rather than posttranslational mechanisms, this 
work would provide valuable data on possible disruption in TF networks.
3. Deletion or mutation o f the upstream YY1 target motif (position 100 in F0.1) in 
the occludin promoter which is actively bound by the TF only in the lung 
endothelium. We hypothesise that YY1 interaction at this site is responsible for 
changing chromatin structure and impairing the accessibility o f  the Sp family to 
the target sites on the promoter region. Hence, deletion or mutation o f  this site 
should relieve the structural repression o f  YY1 and this occludin promoter 
construct in a reporter vector should be able to mediate GFP/luciferase expression.
4. Analysis o f  other gene promoters o f  other proteins similarly restricted in 
expression to the brain endothelium.
Chapter 8
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9 Appendix
Table 9-1 TESS analysis of the human occludin promoter
TF Beg
IRF-1,2 9
PRDI-BF1 9
GR 16
GR 24
Spl 32
GR 33
Spl 34
NF1 45
Pit-1 46
Pit-la 48
Pit-la 51
SRF 56
TFIID 57
TBP 57
YY1 100
Spl 121
Spl 124
YY1 124
Spl 125
YY1 134
AP-2a 137
Spl 138
p300 139
API 144
N-Oct-3 149
Spl 155
AP2 156
GR 171
N-Oct-3 180
F2F 182
YY1 184
Pit-la 185
GR 210
GR 210
GATA-1 214
Sense Length Sequence
N 6 AAGTGA
N 10 AAGTGAAAGt
R 6 AGAAGA
N 6 GACACA
N 5 GGGCA
R 6 GGCACA
R 5 GCACA
N 10 ATTWNNNATK
N 8 TTATCCAT
R 10 ATtCATTCAT
N 7 CATTCAT
R 5 ATATA
N 6 TATAAA
N 7 TATAAAA
N 6 AAATGG
R 11 GAGGGGAGgGG
N 10 GGGgGAGGGG
N 6 GGGgGA
N 10 GGgGAGGGGA
R 6 AAATGG
N 6 TGGGGA
N 10 GGGGAGTGgC
N 7 GGGAGTG
N 4 TGAC
R 7 ATTWATK
N 5 GGGCA
R 8 SSSNKGGG
R 9 TTGGGGGCG
R 9 ATTWNNATK
N 6 TAAAAT
R 6 AAATGG
R 8 AATGGAAT
N 6 TGTACA
R 6 TGTACA
R 6 CAATCT
276
c-Myb 220
c-Myb 239
Spl 252
F2F 270
GR 283
YY1 284
TBP 292
TFIID 295
NF-ATp 302
NF-ATc 303
NF-ATp 303
GR 328
GR 328
API 335
YY1 338
c/EBP-p 345
TFIID 346
TFIID 347
F2F 349
YY1 357
Pit-la 364
c/EBP 384
c/EBP-a 385
Pit-la 386
PEA3 387
YY1 398
C/EBP-P 399
Pit-la 400
TBP 404
SRF 405
SRF 405
TFIID 408
TBP 409
TFIID 409
YY1 417
Pit-la 418
H4TF-1 433
c/EBP-a 436
c/EBP-a 436
N 6 GGTGAG
N 6 ATTGAA
R 5 TGCCC
R 6 ATTTTA
N 6 TGAACT
N 5 GAACT
R 7 TATAAAA
N 6 TATAAA
R 8 TGGAAAAA
N 6 GGAAAA
R 6 GGAAAA
N 6 AGAACA
R 6 AGAACA
R 4 TGAC
N 11 CCWTNTTNNNW
R 10 ATTAcAAAAT
R 5 TTATA
N 6 TATAAA
N 6 TAAAAT
N 6 ANATGG
R 7 GTGTTTA
N 7 ATTAGGA
N 9 TTAGGAAAT
N 10 TAGGAAATcT
N 6 AGGAAA
N 11 CCWTNTTNNNW
N 10 CTTGTTTAAT
R 10 TTGaTTAATT
R 7 TTAATTA
N 8 TAWWWWTA
R 8 TAWWWWTA
R 5 TTATA
N 6 TATAAA
N 6 TATAAA
R 6 AAATGG
R 8 AATGGAAT
N 6 GATTTC
N 8 TTNNGTAA
R 9 TTNNGTAAT
277
API
c-Myb
API
c-Ets-2
AP-2-a
AP-2
YY1
c-Myb
SRF
TBP
SRF
TFIID
API
YY1
API
YY1
TBP
N-Oct-3
N-Oct-3
TBP
N-Oct-3
YY1
N-Oct-3
SRF
SRF
TBP
TBP
TFIID
TBP
TFIID
TFIID
YY1
GR
Spl
AP-1
AP-1
c-Myb
YY1
TBP
446 N 4
468 N 4
473 N 4
476 R 6
478 R 6
478 N 10
481 N 6
486 R 4
496 N 5
498 R 7
513 N 5
514 N 6
529 R 4
531 N 6
553 N 4
562 N 6
577 N 7
580 N 7
581 R 7
582 R 7
585 R 10
598 N 9
606 N 10
622 R 8
622 N 8
622 R 10
622 N 10
624 R 6
624 R 8
626 N 6
626 R 6
640 N 6
658 N 6
658 N 5
683 N 7
686 R 4
696 N 4
699 N 6
703 R 7
278
TGAC
TAAC
TGAC
CTTCCC
TCCCCA
TCCCCAGTGg
CATTT
GTTA
CCAAT
AATTTAA
CCAAT
TTCAAA
GTAC
CATTT
TGAC
CATTT
TTAAATT
MATWAAT
ATTWATK
TTAATTA
ATTWNNNATK
GCTGCCATC
MATNNNWAAT
TAWWWWTA
TAWWWWTA
TATATATATA
TATaTATATA
TTTATA
TTTATATA
TATATA
TATATA
CATTT
TGTGCC
TGTGC
AGAGTCA
GTAC
TAAC
CCATTT
TTAATTA
TBP
CACCC-binding factor 
Spl
GATA-1
Spl
CCAAT-binding factor 
SRF
GATA-1
GATA-1
N-Oct-3
API
IL-6 RE-BP 
GATA-1
CCAAT-binding factor
SRF
PEA3
c-Myb
c-Myb
GATA-1
GATA-1
GATA-1
c-Myb
NF-1
GR
TFIID
PEA3
c/EBP-p
TBP
SRF
c-Myb
Spl
NF-kB
NF-kB
YY1
TBP
TBP
TBP
GR
GR
N 7 TAATTAA
N 6 GGGTGG
R 6 GGGTGG
R 7 GGGTGGG
N 6 GGTGGG
N 6 GATTGG
R 5 ATTGG
N 6 GGATAG
R 6 GATAGA
R 7 ATTWATK
N 4 GTAC
R 6 TTCCAG
N 6 AGATTG
N 6 GATTGG
R 5 ATTGG
N 8 CAGGATGT
R 6 AAGTTC
R 6 TTCAAT
R 6 AGATAG
N 6 AGATAG
N 6 AGATAG
R 4 GTTA
R 6 TGCCAA
R 6 AGAACT
N 5 TATAA
R 8 ACATCCTG
R 10 ATTAcAAAAT
N 7 TAAAAAA
R 5 ATATA
R 4 GTTA
R 5 GTGCA
N 10 gGAAATTTCC
R 10 gGAAATTTCC
N 6 CATTT
R 7 TCTTAAA
N 7 TAAAAAA
R 7 TTTATTT
R 6 TGTTCT
N 6 TGTTCT
279
704
723
723
723
724
729
730
733
734
741
756
761
765
766
767
786
805
814
822
822
822
827
833
838
843
853
868
870
907
918
923
933
933
976
1008
1011
1034
1058
1058
GR 1058 R 6 TGTTCT
GR 1058 N 6 TGTTCT
TBP 1061 R 7 TCTTAAA
SRF 1088 R 10 cCGTATAAGG
TFIID 1091 N 5 TATAA
TBP 1130 N 7 TTAAATT
AP2 1158 R 8 SSSNKGGG
CACCC-binding
factor
1159 N 6 GGGTGG
Spl 1159 R 6 GGGTGG
GATA-1 1159 R 7 GGGTGGG
Spl 1160 N 6 GGTGGG
Spl 1163 N 6 GGGCAG
AP-2-a 1176 R 7 CCCTGGG
CACCC-binding
factor
1181 N 6 GGGTGG
Spl 1181 R 6 GGGTGG
YY1 1195 N 6 CATTT
Pit-la 1201 N 10 TATTATtCAC
Spl 1206 N 5 TGCAC
c-Myb 1232 N 4 TAAC
GR 1245 R 6 AGTTCA
F2F 1256 R 6 ATTTTA
AP-3 1257 R 10 TTTaAACCCC
c-Myb 1260 N 4 TAAC
c-Myc 1279 N 7 TCTCTTA
CBF 1313 N 6 GCCAAT
CTF 1313 N 7 GCCAATG
SRF 1314 N 5 CCAAT
TFIID 1333 R 6 TTTGAA
C/EBPoc 1338 N 9 AATTTTCCC
NF-ATp 1340 R 6 TTTTCC
NF-ATc 1340 N 6 TTTTCC
C/EBPp 1342 R 7 TTYCCAG
AP-2 1342 N 10 TcCCCAGGAG
IL-6 RE-BP 1343 R 6 TCCCAG
c/EBP-a 1360 R 9 TGGAGCAAT
Pit-la 1377 R 10 ATGCaTTTTT
NF-ATp 1382 N 8 TTTTTCCA
NF-ATc 1383 R 6
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TTTTCC
c/EBP-p 1384 R 7 TTYCCAG
IL-6 RE-BP 1385 R 6 TTCCAG
AP-1 1398 N 7 TTAATCA
GATA-1 1399 R 6 TAATCA
IL-6 RE-BP 1409 N 6 CTGGAA
GR 1424 N 6 TGTCCT
NF-1 1442 N 6 CTTTCC
NF-ATp 1442 N 7 CTTTCCT
PEA3 1443 R 6 TTTCCT
GATA-1 1447 R 6 CTATCA
GATA-1 1447 N 6 CTATCA
NF-1 1475 N 6 CTTTCC
NFAT-1 1482 R 7 GAGGAAA
PEA3 1483 N 6 AGGAAA
NF-ATp 1483 R 8 AGGAAACA
Spl 1491 N AGGCG
GR 1496 R 5 CTCTG
Spl 1550 R 10 gAGGCGGAGC
Spl 1551 N 6 AGGCGG
CAC-binding protein 1568 R 6 CACCCC
API 1570 R 4 GTCA
AP2 1570 R 8 SSSNKGGG
Spl 1572 N 10 tCGGGGTGGT
CAC-binding protein 1574 N 6 GGGGTG
CBF 1575 N 6 GGGTGG
Spl 1575 R 6 GGGTGG
API 1580 R 4 GTCA
AP2 1590 N 8 CCCMNSSS
GR 1601 N 6 TGTCCC
GR 1601 R 6 TGTCCC
NF-ATp 1610 N 6 GGAGCC
AP-2 1614 N 7 CCCGCGC
Spl 1614 R 10 tCCGCGCCTC
GR 1626 R 5 CTCTG
Spl 1627 R 10 TCTcCGCCCC
Spl 1632 N 10 GCCCCGCCcC
Spl 1632 R 15 GCCCCGCCcC
c-Ets-2 1663 R 6 TTCCTT
c-Ets-2 1663 N 6 TTCCTT
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c-Myb 1669 N 4 TAAC
Spl 1675 N 5 TGCGC
CBF 1683 R 10 CAGGGTGgGG
c-Ets-2 1691 N 6 GGGAAG
Spl 1709 N 10 CcCCCGCCCC
Spl 1711 R 8 CCCGCC
Spl 1711 N 9 CCCGCCCCC
EGR2 1712 N 10 CCGCCCCCgC
AP-1 1712 N 8 CCGCCCCC
Spl 1714 N 11 GCCCCCTCCCc
SRF 1714 R 5 ATTGG
AP2 1716 N 8 CCCMNSSS
AP-1 1729 N 7 AGTTTCA
AP-1 1745 R 4 GTAC
GR 1764 N 6 GACACA j
Spl 1767 R 7 ACACCAC |
NF-1 1767 R 7 ACACCAC * ]
p300 1779 R 7 CACTCCC
Spl 1790 R 15 CCACCNNNNCCaCCC
Spl 1798 N 7 CCCTCCC
PEA3 1806 R 8 RCWTCCKS j
EGR2 1816 R 10 GCGGgGGCGG ]
Spl 1820 N 6 AGGCGG ]
NF-1 1837 N 6 AGCCAG
GR 1846 N 5 CAGAG
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